# EDGAR Filing Document

**Accession Number:** 0001106861
**File Stem:** 0001214659-25-016770
**Filing Date:** 2025-11
**Character Count:** 540748
**Document Hash:** 449dcf2df89fbf01857f9b2c1243aea3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-016770.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0001214659-25-016770

**CONFORMED SUBMISSION TYPE**: 10-12G/A

**PUBLIC DOCUMENT COUNT**: 138

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CS DIAGNOSTICS CORP.
- **CENTRAL INDEX KEY:** 0001106861
- **STANDARD INDUSTRIAL CLASSIFICATION:** SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 201290331
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-12G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29611
- **FILM NUMBER:** 251489499

**BUSINESS ADDRESS:**
- **STREET 1:** STRESEMANNALLEE 4B
- **CITY:** NEUSS
- **STATE:** 2M
- **ZIP:** 41460
- **BUSINESS PHONE:** 49 21311510871

**MAIL ADDRESS:**
- **STREET 1:** STRESEMANNALLEE 4B
- **CITY:** NEUSS
- **STATE:** 2M
- **ZIP:** 41460

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLASHZERO CORP.
- **DATE OF NAME CHANGE:** 20221108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHILDRENS INTERNET INC
- **DATE OF NAME CHANGE:** 20030205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DWC INSTALLATIONS
- **DATE OF NAME CHANGE:** 20000214

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

 **Amendment No. 2**

**FORM 10**

**GENERAL FORM FOR REGISTRATION OF SECURITIES**

**Pursuant to Section 12(g) of The Securities Exchange Act of 1934**

![](cscorp_logo.jpg)

**CS DIAGNOSTICS CORP.**

(Exact name of registrant as specified in its charter)

Wyoming 20-1290331 <br> (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

1603 Capitol Avenue, Suite 413, Cheyenne, WY 82001, USA

(Address of principal executive offices)

+1 (307) 395 7333

(Issuer's telephone number)

Securities registered pursuant to Section 12(b) of the Act: Not Applicable

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.00001 per share

Indicate by check mark whether the registrant is a large accelerated ﬁler, an accelerated ﬁler, a non-accelerated ﬁler, a smaller reporting company, or an emerging growth company. See the deﬁnitions of "large accelerated ﬁler," "accelerated ﬁler," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer □ Accelerated filer □ <br> Non–Accelerated filer □ Small reporting company ⌧ <br> Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10**

Certain information required to be included herein is incorporated by reference to specifically-identified portions of the body of the information statement filed herewith as Exhibit 99.1. None of the information contained in the information statement shall be incorporated by reference herein or deemed to be a part hereof unless such information is specifically incorporated herein by reference.

**Item 1. Business.**

The information required under this item is contained under the sections of the information statement entitled "Business," "Risk Factors," "Security Ownership," and "Capitalization." Those sections are incorporated herein by reference.

**Item 1A. Risk Factors.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation ("MD&A")." Those sections are incorporated herein by reference.

**Item 2. Financial Information.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Description of Capital Stock," "Capitalization," "MD&A," and the financial statements referenced therein, of the Information Statement which sections are incorporated herein by reference.

**Item 3. Properties.**

The information required under this item is contained under the section of the information statement entitled "Business—Leased Offices." Those sections are incorporated herein by reference.

**Item 4. Security Ownership of Certain Beneficial Owners and Management.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Business," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," and "Capitalization." Those sections are incorporated herein by reference.

**Item 5. Directors, Executive Officers and Corporate Governance.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A" Those sections are incorporated herein by reference.

**Item 6. Executive Compensation.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Executive Compensation," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 7. Certain Relationships and Related Transactions, and Director Independence**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance—Stock and Stock Option Issuances in 2023 and 2024 and Related Party Transactions," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 8. Legal Proceedings.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors" and "Legal Proceedings." Those sections are incorporated herein by reference.

**Item 9. Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters.**

The information required under this item is contained under the section of the information statement entitled "Business," "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 10. Recent Sales of Unregistered Securities.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Related Party Transactions," "Description of Capital Stock—Recent Issuances of Securities," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 11. Description of Registrant's Securities to be Registered.**

The information required under this item is contained under the section of the information statement entitled "Business—Overview," "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 12. Indemnification of Directors and Officers.**

The information required under this item is contained under the section of the information statement entitled "Business," "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Limitation of Liability and Indemnification," and "MD&A." Those sections are incorporated herein by reference.

**Item 13. Financial Statements and Supplementary Data.**

The information required under this item is contained under the section of the information statement entitled "Index to Financial Statements." This section is incorporated herein by reference.

**Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

None.

**Item 15. Financial Statements and Exhibits.**

(a) Financial Statements. The information required under this item is contained under the section of the information statement entitled "Index to Financial Statements." This section is incorporated herein by reference.

(b) Exhibits. The following documents are filed as exhibits hereto:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Exhibit Description</u>** |
| 3.1 | [Articles of Amendment](ex3_1.htm) |
| 3.2 | [Amended and Restated Bylaws of CS Diagnostics Corp. (as currently in effect)](ex3_2.htm) |
| 10.1 | [Asset Purchase Agreement between CS Diagnostics Corp. and CS Group dated September 4, 2023](ex10_1.htm) |
| 10.2 | [License Agreement between DWI and CS Diagnostics Pharma dated March 21, 2024](ex10_2.htm) |
| 10.3 | [Exclusive License and Distribution Agreement between CS Interpharm General Trading Co. LLC and CS Diagnostics Corp. for MEDUSA Product dated January 2, 2025](ex10_3.htm) |
| 10.4 | [Waiver of All Rights for MEDUSA SDP and Fulﬁllment Of Sales Agreement](ex10_4.htm) |
| 23.1 | [Audited Financial Statements for the Years Ended December 31, 2024 and December 31, 2023](ex23_1.htm) |
| 23.2 | [Audited Financial Statements for the Years Ended December 31, 2023 and December 31, 2022](ex23_2.htm) |
| 99.1 | [Information Statement](ex99_1.htm) |
| 99.2 | [Hydrogel Valuation](ex99_2.htm) |
| 99.3 | [Hydrogel Studies Summary](ex99_3.htm) |
| 99.4 | [Hydrogel Confirmation](ex99_4.htm) |
| 99.5 | [MEDUSA Evaluation copy](ex99_5.htm) |
| 99.6 | [MEDUSA Alcohol Free Certificates](ex99_6.htm) |
| 99.7 | [MEDUSA Alcohol Based Certificates](ex99_7.htm) |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 14, 2025 | **CS Diagnostics Corp.** | **CS Diagnostics Corp.** |
|  | By: | /s/Mohammad EsSayed |
|  |  | Mohammad EsSayed |
|  |  | Group CFO, VP |

---

## Exhibit 3.1

**Exhibit 3.1**

---

| | | |
|:---|:---|:---|
| ![](wyoming_logo.jpg) | **Wyoming Secretary of State** <br> Herschler Building East, Suite 101 <br> 122 W 25th Street <br> Cheyenne, WY 82002-0020 <br> Ph. 307.777.7311 <br> Email: Business@wyo.gov | For Office Use Only |

---

 **Profit Corporation <br> Articles of Amendment** 

&nbsp;&nbsp;&nbsp;&nbsp;1. Corporation name:

 *(Name must match exactly to the Secretary of State's records.)*

 

CS DIAGNOSTICS CORP <br>

 

---

| | | |
|:---|:---|:---|
| 2. Article number(s) | IV <br>| is amended as follows: |

---

 ***\*See checklist below for article number information.***

The Corporation does hereby New Certificate of Designation of the Series C Preferred Stock and Amend and Restate the Certificate of Designation of the Series A from 5,000,000 shares to 1,000,000 shares. <br>

3. If the amendment provides for an exchange, reclassification, or cancellation of issued shares, provisions for implementing the amendment if not contained in the amendment itself which may be made upon facts objectively ascertainable outside the articles of amendment.

&nbsp;&nbsp;&nbsp;&nbsp; <br>

4. The amendment was adopted on 01/24/2025 <br> *(Date – mm/dd/yyyy)*

 

P-Amendment – Revised June 2021

&nbsp;&nbsp;&nbsp;&nbsp;5. Approval of the amendment: *(Please check  **<u>only one</u>** appropriate field to indicate the party approving the amendment.)* 

 

---

| | |
|:---|:---|
| **☐** | **<u>Shares were *not* issued</u>** and the board of directors or incorporators have adopted the amendment. |
|  | **<u>OR</u>** |
|  | <u>**Shares were issued**</u> and the board of directors have adopted the amendment *without shareholder approval*, in compliance with W.S. 17-16-1005. |
|  | **<u>OR</u>** |
|  | **<u>Shares were issued</u>** and the board of directors have adopted the amendment *with shareholder approval*, in compliance with W.S. 17-16-1003. |

---

---

| | | |
|:---|:---|:---|
| **Signature:** | **Date:** | 01/24/2025 |
| *(May be executed by Chairman of Board, President or another of its officers.)* |  | *(mm/dd/yyyy)* |

---

Print Name: Mohammad EsSayed Contact Person: Mohammad EsSayed

Title: Chief Financial Officer Daytime Phone Number: +971 52 861 1930

---

| | |
|:---|:---|
| Email: | Email: mohammad.essayed@csinterpharm.ae |
| *(**An email address is required.** Email(s) provided will receive important reminders, notices and filing evidence.)*  | *(**An email address is required.** Email(s) provided will receive important reminders, notices and filing evidence.)*  |

---

 

---

| |
|:---|
| <u>Checklist</u> |
| ***<u>Filing Fee: $60.00</u>*** Make check or money order payable to Wyoming Secretary of State. |
| Processing time is up to 15 business days following the date of receipt in our office. |
| \*Refer to original articles of incorporation to determine the specific article number being amended or use the next number in |
| sequence if you are adding an article. *Article number(s) is not the same as the filing ID number.* |
| Please mail with payment to the address at the top of this form. **This form cannot be accepted via email.** |
| Please review the form prior to submission. **The Secretary of State's Office is unable to process incomplete forms.** |

---

 

 

 

 

 

P-Amendment – Revised June 2021

## Exhibit 3.2

**Exhibit 3.2**

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **ARTICLE I <br> OFFICES** 

 **Principal Office .** The principal office for the transaction of business of the Corporation is hereby fixed and located at Stresemannallee 4c, Neuss, Germany 41460. The location may be changed by approval of a majority of the authorized directors, and additional offices may be established and maintained at such other place or places, either within or outside of Wyoming, as the Board of Directors may from time to time designate.

 **Other Offices.** Branch or subordinate offices may at any time be established by the Board of Directors at any place or places where the Corporation is qualified to do business.

 **ARTICLE II DIRECTORS – MANAGEMENT** 

 **Powers :** Subject to the provisions of the Wyoming Revised Statutes (hereinafter the "Code"), and subject to any limitations in the Articles of Incorporation of the Corporation relating to action required to be approved by the Shareholders, as that term is defined in the Code, or by the outstanding shares, as that term is defined in the Code, the business and affairs of the Corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board of Directors. The Board of Directors may delegate the management of the day-to-day operation of the business of the Corporation to a management company or other persons, provided that the business and affairs of the Corporation shall be managed, and all corporate powers shall be exercised, under the ultimate direction of the Board.

 **Standard of Care; Liability**: Each Director shall exercise such powers and otherwise perform such duties, in good faith, in the matters such Director believes to be in the best interests of the Corporation, and with such care, including reasonable inquiry, using ordinary prudence, as a person in a like position would use under similar circumstances.

In performing the duties of a Director, a Director shall be entitled to rely on information, opinions, reports, or statements, including financial statements and other financial data, in which case prepared or presented by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) One or more officers or employees of the Corporation whom the Director believes to be reliable and competent in the matters presented,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) Counsel, independent accountants or other persons as to which the Director believes to be within such person's professional or expert competence, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) A Committee of the Board upon which the Director does not serve, as to matters within its designated authority, which committee the Director believes to merit confidence, so long as in any such case the Director acts in good faith, after reasonable inquiry when the need therefore is indicated by the circumstances and without knowledge that would cause such reliance to be unwarranted.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Number and Qualification of Directors .** The authorized number of Directors of the Corporation shall be not less than one (1) nor more than five (5) until changed by a duly adopted amendment to the Articles of Incorporation or by an amendment to this Section 2 of Article II of these Bylaws or, without amendment of these Bylaws, the number of directors may be fixed or changed by resolution adopted by the vote of the majority of directors in office or by the vote of holders of shares representing a majority of the voting power at any annual meeting, or any special meeting called for such purpose; but no reduction of the number of directors shall have the effect of removing any director prior to the expiration of his term.

 **Election and Term of Office of Directors . Directors shall be elected at each annual meeting of the Shareholders to hold office until the next annual meeting. If any such annual meeting of Shareholders is not held or the Directors are not elected thereat, the Directors may be elected at any special meeting of Shareholders held for that purpose. Each Director, including a Director elected to fill a vacancy, shall hold office until the expiration of the term for which elected and until a successor has been elected and qualified. Except as may otherwise be provided herein, or in the Articles of Incorporation by way of cumulative voting rights, the members of the Board of Directors of this Corporation, who need not be shareholders, shall be elected by a majority of the votes cast at a meeting of shareholders, by the holders of shares of stock present in person or by proxy, entitled to vote in the election.** 

 **Vacancies . A vacancy or vacancies on the Board of Directors shall be deemed to exist in the event of the death, resignation or removal of any Director, or if the Board of Directors by resolution declares vacant the office of a Director who has been declared of unsound mind by an order of court or convicted of a felony, or if the authorized number of directors be increased, or if the shareholders fail, at any annual or special meeting of shareholders at which any director or directors are elected, to elect the full authorized number of directors to be voted for at the meeting.** 

Any Director may resign, effective on giving written notice to the Chairman of the Board, the President, the Secretary, or the Board of Directors, unless the notice specifies a later time for that resignation to become effective. When one or more directors give notice of his or her or their resignation from the Board of Directors, effective at a future date, the Board may fill the vacancy or vacancies to take effect when the resignation or resignations become effective, each Director so appointed to hold office during the remainder of the term of office of the resigning Director(s)." No reduction of the authorized number of Directors shall have the effect of removing any Director before that Director's term of office expires.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Removal of Directors . The entire Board of Directors, or any individual Director, may be removed from office at any special meeting of stockholders called for such purpose by vote of the holders of two-thirds of the voting power entitling them to elect directors in place of those to be removed. No Director may be removed (unless the entire Board is removed) when the votes cast against removal or not consenting in writing to such removal would be sufficient to elect such Director if voted cumulatively at an election at which the same total number of votes were cast (or, if such action is taken by written consent, all shares entitled to vote, were voted) and the entire number of Directors authorized at the time of the Directors most recent election were then being elected; and when by the provisions of the Articles of Incorporation the holders of the shares of any class or series voting as a class or series are entitled to elect one or more Directors, any Director so elected may be removed only by the applicable vote of the holders of the shares of that class or series.** 

 **Place of Meetings** . Regular meetings of the Board of Directors shall be held at any place within or outside the state that has been designated from time to time by resolution of the Board. In the absence of such resolution, regular meetings shall be held at the principal executive office of the Corporation. Special meetings of the Board shall be held at any place within or outside the state that has been designated in the notice of the meeting, or, if not stated in the notice or there is no notice, at the principal executive office of the Corporation. Any meeting, regular or special, may be held by conference telephone or other digital communication equipment, so long as all Directors participating in such meetings can hear one another, and all such Directors shall be deemed to have been present in person at such meeting.

 **Annual Meetings.** Immediately following each annual meeting of Shareholders, the Board of Directors shall hold a regular meeting for the purpose of organization, the election of officers and the transaction of other business. Notice of this meeting shall not be required.

Minutes of any meeting of the Board, or any committee thereof, shall be maintained as required by the Code by the Secretary or other officer designated for that purpose.

 **Other Regular Meetings. Other regular meetings of the Board of Directors shall be held without call at such time as shall from time to time be fixed by the Board of Directors. Such regular meetings may be held without notice, provided the time and place of such meetings has been fixed by the Board of Directors, and further provided the notice of any change in the time of such meeting shall be given to all the Directors. Notice of a change in the determination of the time shall be given to each Director in the same manner as notice for such special meetings of the Board of Directors. If said day falls upon a holiday, such meetings shall be held on the next succeeding day thereafter.** 

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Special Meetings/Notices. Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the Chairman of the Board or the President or any Vice President or the Secretary or any two Directors. Notice of the time and place for special meetings shall be delivered personally or by telephone to each Director or sent by first class mail or telegram, charges prepaid, addressed to each Director at his or her address as it is shown in the records of the Corporation. In case such notice is mailed, it shall be deposited in the United States mail at least four days prior to the time of holding the meeting. In case such notice is delivered personally, or by telephone or telegram, it shall be delivered personally or be telephone or to the telegram company at least 48 hours prior to the time of the holding of the meeting. Any oral notice given personally or by telephone may be communicated to either the Director or to a person at the office of the Director who the person giving the notice has reason to believe will promptly communicate same to the Director. The notice need not specify the purpose of the meeting, nor the place, if the meeting is to be held at the principal executive office of the Corporation.** 

 **Waiver of Notice . The transactions of any meeting of the Board of Directors, however called, noticed, or wherever held, shall be as valid as though had at a meeting duly held after the regular call and notice if a quorum is present and if, either before or after the meeting, each of the Directors not present signs a written waiver of notice, a consent to holding the meeting or an approval of the minutes thereof. Waivers of notice or consent need not specify the purposes of the meeting. All such waivers, consents and approvals shall be filed with the corporate records or made part of the minutes of the meeting. Notice of a meeting shall also be deemed given to any Director who attends the meeting without protesting, prior thereto or at its commencement, the lack of notice to such Director.** 

 **Quorums.** Presence of a majority of the authorized number of Directors shall constitute a quorum for the transaction of business, except to adjourn as provided in Section 12 of this Article II. Members of the Board may participate in a meeting through use of conference telephone or similar communications equipment, so long as all members participating in such meeting can hear one another. Participation in a meeting as permitted by the preceding sentence constitutes presence in person at such meeting. Every act or decision done or made by a majority of the Directors present at a meeting duly held at which a quorum was present shall be regarded as the act of the Board of Directors, unless a greater number is required by law or the Articles of Incorporation. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of Directors, if any action taken is approved by at least a majority of the required quorum for that meeting.

 **Adjournment.** A majority of the directors present, whether or not constituting a quorum, may adjourn any meeting to another time and place.

 **Notice of Adjournment.** Notice of the time and place of the holding of an adjourned meeting need not be given, unless the meeting is adjourned for more than 24 hours, in which case notice of such time and place shall be given prior to the time of the adjourned meeting to the Directors who were not present at the time of the adjournment.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Sole Director Provided by Articles or Bylaws.** In the event only one Director is required by the Bylaws or the Articles of Incorporation, then any reference herein to notices, waivers, consents, meetings or other actions by a majority or quorum of the Board of Directors shall be deemed or referred as such notice, waiver, etc., by the sole Director, who shall have all rights and duties and shall be entitled to exercise all of the powers and shall assume all the responsibilities otherwise herein described, as given to the Board of Directors.

 **Directors Action by Unanimous Written Consent**. Any action required or permitted to be taken by the Board of Directors may be taken without a meeting and with the same force and effect as if taken by a unanimous vote of Directors, if authorized by a writing signed individually or collectively by all members of the Board of Directors. Such consent shall be filed with the regular minutes of the Board of Directors.

 **Compensation of Directors.** Directors, and members as such, shall not receive any stated salary for their services, but by resolution of the Board of Directors, a fixed sum and/or expenses, if any, may be allowed for their attendance at each regular and special meeting of the Board of Directors or for their services contributed to the Board of Directors; provided, however, that nothing contained herein shall be construed to preclude any Director from serving the Corporation in any other capacity as an officer, employee or otherwise receiving compensation for such services.

 **Committees.** Committees of the Board of Directors may be appointed by resolution passed by a majority of the whole Board. Committees shall be composed of two or more members of the Board of Directors. The Board may designate one or more Directors as alternate members of any committee, who may replace any absent member at any meeting of the committee. Committees shall have such powers as those held by the Board of Directors as may be expressly delegated to it by resolution of the Board of Directors, except those powers expressly made non-delegable by the Code.

 **Meetings and Action of Committees.** Meetings and action of committees shall be governed by, and held and taken in accordance with, the provisions contained herein, with such changes as are necessary to substitute the committee and its members for the Board of Directors and its members, except that the time of the regular meetings of the committees may be determined by resolution of the Board of Directors as well as the committee, and special meetings of committees may also be

given to all alternate members, who shall have the right to attend all meetings of the committee. The Board of Directors may adopt rules for the government of any committee not inconsistent with the provisions of these Bylaws.

 **Advisors.** The Board of Directors from time to time may request and/or hire for a fee one or more persons to be Advisors to the Board of Directors, but such persons shall not by such appointment be members of the Board of Directors. Advisors shall be available from time to time to perform special assignments specified by the President, to attend meetings of the Board of Directors upon invitation, and to furnish consultation to the Board of Directors. The period during which the title shall be held may be prescribed by the Board of Directors. If no period is prescribed, the title shall be held at the pleasure of the Board of Directors.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **ARTICLE III <br> OFFICERS** 

 **Officers.** The principal officers of the Corporation shall be a President, a Chief Operations Officer, a Secretary, and a Treasurer who may also be called Chief Financial Officer. The Corporation may also have, at the discretion of the Board of Directors, a Chairman of the Board, one or more Vice Presidents, one or more Assistant Secretaries, one or more Assistant Treasurers, and such other officers as may be appointed in accordance with the provisions of Section 3 of this Article III. Any number of offices may be held by the same person.

 **Election of Officers.** The principal officers of the Corporation, except such officers as may be appointed in accordance with the provisions of this Article, shall be chosen by the Board of Directors, and each shall serve at the pleasure of the Board of Directors, subject to the rights, if any, of an officer under any contract of employment. Each officer shall hold office until his successor shall be duly elected and qualified, or until his death, resignation, or removal in the manner hereinafter provided.

 **Subordinate Officers, Etc.** The Board of Directors may appoint such other officers as the business of the Corporation may require, each of whom shall hold office for such period, have such authority and perform such duties as are provided in the Bylaws or as the Board of Directors may from time to time determine.

 **Removal and Resignation of Officers.** Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by a majority of the Directors at that time in office, at any regular or special meeting of the Board of Directors, or, except in the case of an officer chosen by the Board of Directors, by any officer upon whom such power of removal may be conferred by the Board of Directors. Any officer may resign at any time by giving written notice to the Board of Directors. Any resignation shall take effect on the date of the receipt of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.

 **Vacancies.** A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed in the Bylaws for regular appointments to that office.

 **Chairman of the Board.** The Chairman of the Board, if such an officer be elected, shall, if present, preside at the meetings of the Board of Directors and exercise and perform such other powers and duties as may, from time to time, be assigned by the Board of Directors or prescribed by the Bylaws. If there is no President, the Chairman of the Board shall, in addition, be the Chief Executive Officer of the Corporation and shall have the powers and duties prescribed in Section 7 of this Article III.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **President.** Subject to such supervisory powers, if any, as may be given by the Board of Directors to the Chairman of the Board, if there is such an officer, the President shall be the Chief Executive Officer of the Corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the Corporation. The President shall preside at all meetings of the Shareholders and, in the absence of the Chairman of the Board, or if there be none, at all meetings of the Board of Directors. The President shall have the general powers and duties of management usually vested in the office of President of a corporation, shall be ex officio a member of all the standing committees, including the Executive Committee, if any, and shall have such other powers and duties as may be prescribed by the Board of Directors or the Bylaws.

 **Vice President.** In the absence or disability of the President, the Vice Presidents, if any, in order of their rank as fixed by the Board of Directors, or if not ranked, the Vice President designated by the Board of Directors, shall perform all the duties of the President, and when so acting, shall have all the powers of, and be subject to all the restrictions upon, the President. The Vice Presidents shall have such other powers and perform such other duties as from time to time may be prescribed for them, respectively, by the Board of Directors or the Bylaws, the President, or the Chairman of the Board.

 **Secretary.** The Secretary shall keep, or cause to be kept, a book of minutes of all meetings of the Board of Directors and Shareholders at the principal office of the Corporation or such other place as the Board of Directors may order. The minutes shall include the time and place of holding the meeting, whether regular or special, and if a special meeting, how authorized, the notice thereof given, and the names of those present at Directors' and committee meetings, the number of shares present or represented at Shareholders' meetings and the proceedings thereof. The Secretary shall keep, or cause to be kept, at the principal office of the Corporation or at the office of the Corporation's transfer agent, a share register, or duplicate share register, showing the names of the Shareholders and their addresses; the number and classes or shares held by each; the number and date of certificates issued for the same; and the number and date of cancellation of every certificate surrendered for cancellation.

The Secretary shall give, or cause to be given, notice of all the meetings of the Shareholders and of the Board of Directors required by the Bylaws or by law to be given. The Secretary shall keep the seal of the Corporation in safe custody, and shall have such other powers and perform such other duties as may be prescribed by the Board of Directors or by the Bylaws.

 **Treasurer.** The Treasurer shall keep and maintain, or cause to be kept and maintained, in accordance with generally accepted accounting principles, adequate and correct accounts of the properties and business transactions of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, earnings (or surplus) and shares issued. The books of account shall, at all reasonable times, be open to inspection by any Director. The Treasurer shall deposit all monies and other valuables in the name and to the credit of the Corporation with such depositaries as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, shall render to the President and Directors, whenever they request it, an account of all of the transactions of the Treasurer and of the financial condition of the Corporation, and shall have such other powers and perform such other duties as may be prescribed by the Board of Directors or the Bylaws.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **ARTICLE IV <br> SHAREHOLDERS' MEETINGS** 

 **Place of Meetings.** Meetings of the Shareholders shall be held at any place within or outside the state of Wyoming designated by the Board of Directors. In the absence of any such designation, Shareholders' meetings shall be held at the principal executive office of the Corporation.

 **Annual Meeting.** The annual meeting of the Shareholders shall be held, each year, as follows:

Time of Meeting: 10:00 A.M. Date of Meeting: September 15

If this day shall be a legal holiday, then the meeting shall be held on the next succeeding business day, at the same time. At the annual meeting, the Shareholders shall elect a Board of Directors, consider reports of the affairs of the Corporation and transact such other business as may be properly brought before the meeting. If the above date is inconvenient, the annual meeting of Shareholders shall be held each year on a date and at a time designated by the Board of Directors within a reasonable date of the above date upon proper notice to all Shareholders.

 **Special Meetings.** Special meetings of the Shareholders for any purpose or purposes whatsoever, may be called at any time by the Board of Directors, the Chairman of the Board, the President, or by one or more Shareholders holding shares in the aggregate entitled to cast not less than 50% of the votes at any such meeting. If a special meeting is called by any person or persons other than the Board of Directors, the request shall be in writing, specifying the time of such meeting and the general nature of the business proposed to be transacted, and shall be delivered personally or sent by registered mail or by electronic digital mail or other digital transmission to the Chairman of the Board, the President, any Vice President or the Secretary of the Corporation. The officer receiving

such request shall forthwith cause notice to be given to the Shareholders entitled to vote, in accordance with the provisions of Sections 4 and 5 of this Article, that a meeting will be held at the time requested by the person or persons calling the meeting, not less than 35 nor more than 60 days after the receipt of the request. If the notice is not given within 20 days after receipt of the request, the person or persons requesting the meeting may give the notice in the manner provided in these Bylaws or upon application to the Superior Court. Nothing contained in this paragraph of this Section shall be construed as limiting, fixing or affecting the time when a meeting of Shareholders called by action of the Board of Directors may be held.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Notice of Meetings – Reports.** Notice of any Shareholders meetings, annual or special, shall be given in writing not less than 10 days nor more than 60 days before the date of the meeting to Shareholders entitled to vote thereat by the Secretary or the Assistant Secretary, or if there be no such officer, or in the case of said Secretary or Assistant Secretary's neglect or refusal, by any Director or Stockholder. Such notices or any reports shall be given personally or by mail or other means of written communication as provided in the Code and shall be sent to the Stockholder's address appearing on the books of the Corporation, or supplied by the Stockholder to the Corporation for the purpose of notice, and in the absence thereof, as provided in the Code by posting notice at a place where the principal executive office of the Corporation is located or by publication at least once in a newspaper of general circulation in the county in which the principal executive office is located. Notice of any meeting of Shareholders shall specify the place, the day and the hour of meeting, and (i) in case of a special meeting, the general nature of the business to be transacted and that no other business may be transacted, or (ii) in the case of an annual meeting, those matters which the Board of Directors, at the date of mailing of notice, intends to present for action by the Shareholders. At any meetings where Directors are elected, notice shall include the names of the nominees, if any, intended at the date of notice to be presented for election.

Notice shall be deemed given at the time it is delivered personally or deposited in the mail or via electronic digital mail or posted on OTC Markets website, https://www.otcmarkets.com, a Form 8K, or sent by other means of verifiable communication. The officer giving such notice or report shall prepare and file in the minute book of the Corporation an affidavit or declaration thereof.

If action is proposed to be taken at any meeting for approval of (i) contracts or transactions in which a Director has a direct or indirect financial interest, pursuant to Section 310 of the Code, (ii) an amendment to the Articles of Incorporation, pursuant to Section 902 of the Code, (iii) a reorganization of the Corporation, pursuant to Section 1201 of the Code, (iv) dissolution of the Corporation, pursuant to the Code, or (v) a distribution to preferred Shareholders, pursuant to the Code, the notice shall also state the general nature of such proposal.

 **Quorum.** The holders of a majority of the shares entitled to vote at a Shareholders' meeting, present in person, or represented by proxy, shall constitute a quorum at all meetings of the Shareholders for the transaction of business except as otherwise provided by the Code or by these Bylaws. The Shareholders present at a duly called or held meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough Shareholders to leave less than a quorum, if any action taken (other than adjournment) is approved by a majority of the shares required to constitute a quorum.

 **Adjourned Meeting and Notice Thereof.** Any Shareholders' meeting, annual or special, whether or not a quorum is present, may be adjourned from time to time by the vote of the majority of the shares represented at such meeting, either in person or by proxy, but in the absence of a quorum, no other business may be transacted at such meeting. When any meeting of Shareholders, either annual or special, is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are announced at a meeting at which the adjournment is taken, unless a new record date for the adjourned meeting is fixed, or unless the adjournment is for more than 45 days from the date set for the original meeting, in which case the Board of

Directors shall set a new record date. Notice of any adjourned meeting shall be given to each Stockholder of record entitled to vote at the adjourned meeting in accordance with the provisions of Section 4 of this Article. At any adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Waiver or Consent by Absent Shareholders** The transactions of any meeting of Shareholders, either annual or special, however called and noticed, shall be valid as though had at a meeting duly held after regular call and notice, if a quorum be present either in person or by proxy, and if, either before or after the meeting, each of the Shareholders entitled to vote, not present in person or by proxy, sign a written waiver of notice, or a consent to the holding of such meeting or an approval of the minutes thereof. The waiver of notice or consent need not specify either the business to be transacted or the purpose of any regular or special meeting of Shareholders, except that if action is taken or proposed to be taken for approval of any of those matters specified in this Article, the waiver of notice or consent shall state the general nature of such proposal. All such waivers, consents or approvals shall be filed with the corporate records or made a part of the minutes of the meeting.

Attendance of a person at a meeting shall also constitute a waiver of notice of such meeting, except when the person objects, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened, and except that attendance at a meeting is not a waiver of any right to object to the consideration of matters not included in the notice. A Shareholder or Shareholders of the Corporation holding at least 5% in the aggregate of the outstanding voting shares of the Corporation may (i) inspect, and copy the records of Shareholders' names and addresses and shareholdings during usual business hours upon five days prior written demand upon the Corporation, and/or (ii) obtain from the transfer agent by paying such transfer agent's usual charges for such a list, a list of the Shareholders' names and addresses who are entitled to vote for the election of Directors, and their shareholdings, as of the most recent record date for which such list has been compiled or as of a date specified by the Shareholders subsequent to the day of demand. Such list shall be made available by the transfer agent on or before the later of five days after the demand is received or the date specified therein as the date as of which the list is to be compiled.

The record of Shareholders shall also be open to inspection upon the written demand of any Shareholder or holder of a voting trust certificate, at any time during usual business hours, for a purpose reasonably related to such holder's interest as a Shareholder or as a holder of a voting trust certificate. Any inspection and copying under this Section may be made in person or by an agent or attorney of such Shareholder or holder of a voting trust certificate making such demand.

Section .Maintenance and Inspection of Bylaws . The Corporation shall keep at its principal executive office, or if not in this state, at its principal business office in this state, the original or a copy of the Bylaws amended to date, which shall be open to inspection by the Shareholders at all reasonable times during office hours. If the principal executive office of the Corporation is outside the state and the Corporation has no principal business office in this state, the Secretary shall, upon written request of any Shareholder, furnish to such Shareholder a copy of the Bylaws as amended to date.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Annual Report to Shareholders** The Corporation shall post its Annual Reports to its portal on OTC Markets, https://www.otcmarkets.com. The posting of the Annual Report on OTC Markets Public Portal is sufficient notice. The Annual Report to Shareholders shall contain a Balance Sheet as of the end of the fiscal year and an Income Statement and Statement of Changes in Financial Position for the fiscal year, accompanied by any report of independent accountants or, if there is no such report, the certificate of an authorized officer of the Corporation that the statements were prepared without audit from the books and records of the Corporation.

 **Financial Statements.** A copy of any annual financial statement and any Income Statement of the Corporation for each quarterly period of each fiscal year, and any accompanying Balance Sheet of the Corporation as of the end of each such period, that has been prepared by the Corporation

shall be kept on file at the principal executive office of the Corporation for 12 months from the date of its execution, and each such statement shall be exhibited at all reasonable times to any Shareholder demanding an examination of such statement or a copy shall be made for any such Shareholder. The Corporation shall post its Financial Statements and Quarterly Financial Repots on the OTC Markets Portal, https://www.otcmarkets.com, which is adequate notice.

 **Annual Statement of General Information.** The Corporation shall, in a timely manner, in each year, file with the Secretary of State of Wyoming , on the prescribed form, the statement setting forth the authorized number of Directors, the names and complete business address of all incumbent Directors, the names and complete business address of the Chief Executive Officer, Secretary and Chief Financial Officer, the street address of its principal executive office or principal business office in this state and the general type of business constituting the principal business activity of the Corporation, together with a designation of the agent of the Corporation for the purpose of the service of process, all in compliance with the Code.

 **ARTICLE V <br> AMENDMENTS TO BYLAWS** 

 **Amendment by Shareholders.** All Bylaws of the Corporation shall be subject to alteration or repeal, and new Bylaws may be made by the affirmative vote of shareholders holding of record in the aggregate at least a majority of the outstanding shares of stock entitled to vote in the election of directors at any annual or special meeting of shareholders, provided that the notice or waiver of notice of such meeting shall have summarized or set forth in full therein, the proposed amendment.

 **Amendment by Directors.** The Board of Directors shall have power to make, adopt, alter, amend and repeal, from time to time, Bylaws of the Corporation, provided, however, that the shareholders entitled to vote with respect thereto as in this Article V above-provided may alter, amend or repeal

Bylaws made by the Board of Directors, except that the Board of Directors shall have no power to change the quorum for meetings of shareholders or of the Board of Directors or to change any provisions of the Bylaws with respect to the removal of directors or the filling of vacancies in the Board resulting from the removal by the shareholders. If any bylaw regulating an impending election of directors is adopted, amended or repealed by the Board of Directors, there shall be set forth in the notice of the next meeting of shareholders for the election of directors, the Bylaws so adopted, amended or repealed, together with a concise statement of the changes made.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Record of Amendments.** Whenever an amendment or new Bylaw is adopted, it shall be copied in the corporate book of Bylaws with the original Bylaws, in the appropriate place. If any Bylaw is repealed, the fact of repeal with the date of the meeting at which the repeal was enacted or written assent was filed shall be stated in the corporate book of Bylaws.

 **ARTICLE VI <br> SHARES OF STOCK** 

 **Certificate of Stock.** Shares of the capital stock of the Corporation may be certificated or uncertificated. Owners of shares of the capital stock of the Corporation shall be recorded in the share transfer records of the Corporation and ownership of such shares shall be evidenced by a certificate or book entry notation in the share transfer records of the Corporation. Any certificates shall be signed by the President or a Vice President and either the Secretary or any Assistant Secretary or such other officer or officers as the Board of Directors shall designate, and shall bear the seal of the Corporation or a facsimile thereof. The signatures of such officers upon a certificate may be facsimiles. In case any officer who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the date of its issuance. Shareholders of Record. The Board of Directors of the Corporation may appoint one or more transfer agents or registrars of any class of stock of the Corporation. The Corporation may be its own transfer agent if so appointed by the Board of Directors. The names and addresses of shareholders as they appear on the stock transfer book shall be the official list of shareholders of record of the Corporation for all purposes. The Corporation shall be entitled to treat the holder of record of any shares of the Corporation as the owner thereof for all purposes and shall not be bound to recognize any equitable or other claim to, or interest in, such shares or any rights deriving from such shares, on the part of any other person, including (but without limitation) a purchaser, assignee or transferee, unless and until such other person becomes the holder of record of such shares, whether or not the Corporation shall have either actual or constructive notice of the interest of such other person.

 **Lost or Destroyed Certificates.** The holder of any certificate representing shares of stock of the Corporation shall immediately notify the Corporation of any loss or destruction of the certificate representing the same. The Corporation may issue a new certificate in the place of any certificate theretofore issued by it, alleged to have been lost or destroyed. On production of such evidence of loss or destruction as the Board of Directors in its discretion may require, the Board of Directors may, in its discretion, require the owner of the lost or destroyed certificate, or his legal representatives, to give the Corporation a bond in such sum as the Board may direct, and with such surety or sureties as may be satisfactory to the Board, to indemnify the Corporation against any claims, loss, liability or damage it may suffer on account of the issuance of the new certificate. A new certificate may be issued without requiring any such evidence or bond when, in the judgment of the Board of directors, it is proper to do so.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **Transfer of Shares.** The shares of the Corporation shall be transferable on the stock transfer books of the Corporation by the holder of record thereof, or his duly authorized attorney or legal representative, upon endorsement and surrender for cancellation of the certificates for such shares if such shares are represented by certificates. All certificates surrendered for transfer shall be canceled, and no new certificate shall be issued until a former certificate or certificates for a like number of shares shall have been surrendered and canceled, except that in the case of a lost, destroyed or mutilated certificate, a new certificate may be issued therefor upon such conditions for the protection of the Corporation and any transfer agent or registrar as the Board of Directors or the Secretary or any other officer may prescribe. Uncertificated shares shall be transferred in the share transfer records of the Corporation upon the written instruction originated by the appropriate person to transfer the shares.

 **Record Date.** In lieu of closing the stock ledger of the Corporation, the Board of Directors may fix, in advance, a date not exceeding sixty (60) days, nor less than ten (10) days, as the record date for the determination of shareholders entitled to receive notice of, or to vote at, any meeting of shareholders, or to consent to any proposal without a meeting, or for the purpose of determining shareholders entitled to receive payment of any dividends or allotment of any rights, or for the purpose of any other action. If no record date is fixed, the record date for the determination of shareholders entitled to notice of, or to vote at, a meeting of shareholders shall be at the close of business on the day next preceding the day on which the notice is given, or, if no notice is given, the day preceding the day on which the meeting is held. The record date for determining shareholders for any other purpose shall be at the close of business on the day on which the resolution of the directors relating thereto is adopted. When a determination of shareholders of record entitled to notice of, or to vote at, any meeting of shareholders has been made, as provided for herein, such determination shall apply to any adjournment thereof, unless the directors fix a new record date for the adjourned meeting.

 **ARTICLE VII <br> DIVIDENDS** 

Subject to applicable law, dividends may be declared and paid out of any funds available therefore, as often, in such amount, and at such time or times as the Board of Directors may determine.

 **ARTICLE VIII <br> FISCAL YEAR** 

The fiscal year of the Corporation shall be December 31, and may be changed by the Board of Directors from time to time subject to applicable law.

 **ARTICLE IX <br> CORPORATE SEAL** 

The corporate seal shall be circular in form, and shall have inscribed thereon the name of the Corporation, the date of its incorporation, and the word "Wyoming " to indicate the Corporation was incorporated pursuant to the laws of the State of Wyoming . The Corporate is not required to maintain a physical Corporate Seal and instead may utilize a digital Corporate Seal.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **ARTICLE X <br> INDEMNITY** 

Every person who was or is a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or a person of whom he is the legal representative is or was a director or officer of the corporation or is or was serving at the request of the corporation or for its benefit as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust, or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible under the general corporation law of the State of Wyoming from time to time against all expenses, liability and loss (including attorneys' fees, judgments, fines, and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. The Board of Directors may, in its discretion, cause the expense of officers and directors incurred in defending a civil or criminal action, suit or proceeding to be paid by the corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the corporation. No such person shall be indemnified against, or be reimbursed for, any expense or payments incurred in connection with any claim or liability established to have arisen out of his own willful misconduct or gross negligence. Any right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire and, which such directors, officers, or representatives may have or hereafter acquire and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under any bylaw, agreement, vote of shareholders, provision of law or otherwise, as well as their rights under this Article.

The Board of Directors may cause the corporation to purchase and maintain insurance on behalf of any person who is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred in any such capacity or arising out of such status, whether or not the corporation would have the power to indemnify such person.

The Board of Directors may from time to time adopt further Bylaws with respect to indemnification and may amend these and such Bylaws to the full extent permitted by the Code.

 **AMENDED AND RESTATED <br> BYLAWS**

 **OF**

 **CS DIAGNOSTICS CORP.**

 **a Wyoming corporation**

 **ARTICLE XI <br> MISCELLANEOUS** 

Shareholders' Agreements . Notwithstanding anything contained in this Article X to the contrary, in the event the Corporation elects to become a close corporation, an agreement between two or more Shareholders thereof, if in writing and signed by the parties thereto, may provide that in exercising any voting rights, the shares held by them shall be voted as provided therein, and may otherwise modify the provisions contained in Article Iv, herein as to shareholders' meetings and actions.

 **Effect of Shareholders' Agreements.** Any Shareholders' Agreement authorized by the Code, shall only be effective to modify the terms of these Bylaws if the Corporation elects to become a close corporation with the appropriate filing of an amendment to its Articles of Incorporation as required by the Code and shall terminate when the Corporation ceases to be a close corporation. Such an agreement cannot waive or alter the Sections of the Code. Any other provisions of the Code or these Bylaws may be altered or waived thereby, but to the extent they are not so altered or waived, these Bylaws shall be applicable.

 **Subsidiary Corporations.** Shares of the Corporation owned by a subsidiary shall not be entitled to vote on any matter. For the purpose of this Section, a subsidiary of the Corporation as defined the Code is defined as another corporation of which shares thereof possessing more than 25% of the voting power are owned directly or indirectly through one or more other corporations of which the Corporation owns, directly or indirectly, more than 50% of the voting power.

## Exhibit 10.1

**Exhibit 10.1**

 **CS DIAGNOSTICS CORP.** 

 **Buyer**

 **And**

 **CS DIAGNOSTICS GROUP**

 **Seller**

 **ASSET PURCHASE AGREEMENT**

This Asset Purchase Agreement is by and between CS Diagnostics Corp., a Wyoming Corp., CS Diagnostics Pharma GmbH, an German registered Company; CS fnterphann LLC, a Duba i, UAE limited liability partnership (collectively referred to "CS Diagnostics Corp"), is entered into this 4th day of September 2023.

On June 14, 2022, a binding agreement was executed with Lapharm G mbH <sup>1</sup> and the issuer whereas La Pharm agreed to provide to CS an exclusive distributorship for a period of five years of Hydrogel.

On September 4, 2023, CS Diagnostics Group agreed to sell and transfer the tangibJe, intangible and patents for the CS Protect-Hydroge l, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation, to CS Diagnostics Corp.

The CS Diagnostics Group have obtained a valuation for the CS Protect-Hydrogel in amount greater that 960,000,000 Euro based on its discounted present commercial value . The valuation is supported , as contained in the final valuatio n, see Exhibit A, by the October 16, 2018 purchase of the similar product by Boston Scientific for $500,000,000 USD and further compensation based on the distribution revenues See Exhibit "B" .CS Diagnostics Corp., based on this valuation has agreed and has instructed its transfer agent, Transfer Online, to issue 110,000,000 shares of its common stock to represent a payment of $500,000,000 USD for the rights , patents and intellectual property of the CS Protect-Hydrogel product to the CS Diagnostics Group, its successor or assigns.

<u> </u>

<sup>1</sup>Lapharm GmbH was subsequen tly merged into CS Diagnos t ics Pharma GmbH and the entity no longer exis ts.

Page 1 of 4

Seller has aU requisite legal and corporate power to enter into, execute, deliver and perform this Agreement of even date herewith between Seller and Buyer. This Agreement has been duly executed by the Seller and constitute the legal, valid and binding obligations of Seller, enforceable in accordance with their terms, except as the same may be limited by (i) bank ru ptcy , ins ol vency , moratorium, and other laws of general application affecting the enforcement of creditors' rights and (ii) limitations on the enforceability of the indemnification provisions of the Registration Rights Agreement as limited by applicable securities laws.

All corporate and legal action on the part of Seller, its officers, directors and Sellers necessary for the execution and delivery of this Agreement, the Shares, and the performance of Seller's obligations hereunder have been taken.

The Shares, when issued in compliance with the provisions of this Agreement, will be duly and validly issued, fully paid and nonassessable free and clear of all liens and enc umbrances· provided, however , that the Note, and any securities into which it may be converted, may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein, and as may be required by future changes in such laws.

Government Consent, Etc. No consent, approva l, order or authorization of, or designation, registrati on, declaration or filing with, any federal, state, local or other governmental authority on the part of Seller is required in connection with the valid execution and delivery of this Agreement. The execution, delivery and performance of the Agreement by the Seller and the consummation by the Seller of the transactions contemplated thereby do not and will not conflict wit h, or constitute a default (or an event that with notice or lapse oftime or both would become a default) under, or give to others any rights of termination, amendment acceleration or cancellation (with or without notice, lapse oftime or both) of, any agreement of the Corporation.

Private Placement. Assuming the accuracy of the Buyer's representations and warranties set forth herein, no registration under the 1933 Act is required for the offer, issuance and sale of the Shares by the Seller to Buyer as contemplated hereby.

Representations and Warranties by Buyer. Buyer represents and warrants to Seller as of the Closing Date as follows:

Investment Intent: Authority. This Agreement is made with Buyer in rel ianc e upon Buyer's representation to Seller, evidenced by Buyer's execution of this Agreement, that Buyer is acquiring the Shares for investment for Buyer's own account, not as nominee or agent, for investment and no t with a view to or for resale in connection with, any distribution or public offering thereof within the meaning of the 1933 Act; provided , however, that by making the representations herein, Buyer does not agree to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. Buyer has the requisite right, power , authority and capacity to enter into and perforn, this Agreement and the Agreement will constitute a valid and binding obligation upon Buyer, except as the same may be limited by bank ruptc y, insolvency , moratorium, and other laws of general application affecting the enforcement of credito rs' rights.

Page 2 of 4

Knowledge and Expe rience. Buyer (i) has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of Buyer's prospective investment in the Shares (ii) has the ability to bear the economic risks of Buyer's prospective investment; (iii) has had all questions which have been asked by Buyer satisfactorily answered by Seller; and (iv) has not been offered the Shares by any form of advertisement, article, notice or other communication published in any newspaper , magazine, or similar media or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by any such media. Buyer represents and warrants that it is an "accredited investor" within the meaning of Rule 50 I of Regulation D of the Securities Act.

The provisions of this Agreement may only be amended or modified in a writing executed by each of Seller and Buyer. A waiver shall not be effective unless in a writing by the party against whom such waiver is to be enforced.

This Agreement and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of the United States without regard to the conflicts of law provisions thereof. Any action arising out of this Agreement shall be heard in any court of general jurisdiction in the State of Wyoming. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.

The repre sentations, warranties , covenants and agreements made herein shall survive the execut io n and delivery of this Agreement.

If any provision of this Agreement shall be judicially determ.ined to be i nval id, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

This Agreement may be executed in any number of counterparts, each of which shal I be an original but all of whi.ch together shall be deemed to constitute one instrument.

The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or imp l ie d, is intended to confer upon any pa1ty other than the parties hereto or their respective successors and assigns any rights, remedies, obli gations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

Buyer shall have al I rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any law. Any person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law .

Page 3 of 4

IN WITNESS WHEREOF, the Parties hereto have executed this ASSET PURCHASE AGREEMENT.

![](ex10_1stamp.jpg)

Page 4 of 4

## Exhibit 10.2

**Exhibit 10.2**

 **License Agreement**

 **Status:** 21 March 2024<br> **Innovation Ref.:** 01187V1<br> **Page 1 of 16**

 **License Agreement**

between

 **The DWI Leibniz Institute for Interactive Materials**<br> for the Department *Advanced Materials for Biomedicine*<br> – hereinafter "Licensor" or "DWI" –

represented at the conclusion of the contract by **RWTH Innovation GmbH**, represented by its management, Campus Boulevard 57, 52074 Aachen,

and

 **CS Diagnostics Pharma GmbH**, Müller-zu-Bruck-Straße 12, 83052 Bruckmühl<br> – hereinafter "Licensee" or "CS" –

The DWI and the Licensee are hereinafter also jointly referred to as the "Party/Parties."

 **Contents**

· Preamble 3

· § 1 Subject Matter of the Agreement 3

· § 2 Contractual Products 3

· § 3 Granting of License 3

· § 4 License Fee 4

· § 5 Accounting and Payment of the License Fee 5

· § 6 Obligation to Exercise 6

· § 7 Approval 6

· § 8 Modification and Further Development of
 the Subject Matter of the Contract 7

· § 9 Application and Maintenance
 of Contractual Protective Rights / Waiver / Opt-out and/or Opt-in 7

· § 10 Warranty and Liability of the Licensor 8

· § 11 Joint Enforcement and Defense 9

· § 12 Confidentiality 10

· § 13 Term of the Contract 11

· § 14 Prohibition of Assignment 13

· § 15 Collateral Agreements, Written Form, Export
 Control, and Applicable Law 13

· § 16 Place of Performance and Jurisdiction 13

· § 17 Final Provisions 14

· **Annex 1** List of Contractual Protective Rights 16

 **Preamble**

DWI, within the framework of its research and development work at the Department *Advanced Materials for Biomedicine*, has developed the invention entitled **"Space-Gel; Spacer Hydrogel for Organ Shielding During Radiation Treatment of Prostate Carcinoma"**, through the inventors **Mr. Andreas Krüger** (inventor share: 34%), **Prof. Dr.-Ing. Laura de Laporte** (inventor share: 33%), and **Dr. rer. nat. Jens Köhler** (inventor share: 33%) (DWI file reference: DW-LD015; hereinafter the "INVENTION").

The INVENTION was reported to DWI on **11 January 2023** and claimed by DWI on **13 January 2023**.

DWI is interested in commercial exploitation of the INVENTION and of any resulting or derived **applications for intellectual property rights and intellectual property rights themselves** (hereinafter collectively referred to as "TECHNOLOGY") by way of a license grant.

CS, as a company engaged in consulting services, manufacturing, and distribution of medical devices, is interested in the **commercial utilization** of the TECHNOLOGY.

The terms and conditions of the future use of the TECHNOLOGY shall be governed by the following agreements between the Parties:

 **§ 1 Subject Matter of the Agreement**

The subject matter of this Agreement consists of the **contractual protective rights** as set forth in **Annex 1** of this License Agreement.

The subject matter further consists of any **additional protective rights** that arise from those listed in Annex 1 through **nationalization, regionalization, or validation**.

 **§ 2 Contractual Products**

Contractual products within the meaning of this Agreement are all **hydrogel spacers** manufactured by the Licensee **using the license to the subject matter of the contract**.

 **§ 3 Granting of License**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Licensor grants to the Licensee an **exclusive**, **non-transferable** license,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o materially limited to the **field of application of prostate cancer**,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o temporally limited to the **duration of this Agreement**,
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o territorially limited to the **territorial scope of the contractual protective rights**,<br>
 to **manufacture and have manufactured**, to **offer**, to **place on the market**,
 and to **use** the contractual products, and to **possess** them for these stated purposes,
 and to offer **services relating to the contractual products** subject to the aforementioned
 material, temporal, and territorial restrictions.

In the event that one or more contractual protective rights lapse in one or more of the countries included in the territorial scope, **the exclusivity shall remain in effect** until the last contractual protective right in that country expires or becomes invalid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Licensor retains the right, alongside the Licensee, to use
 the contractual protective rights **for teaching purposes and for internal as well as publicly funded research**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Licensee is entitled, **with the consent of the Licensor**,
 to grant sublicenses. The Licensee shall inform the Licensor of intended sublicenses.<br>
 If the Licensor does not object within **two weeks** of receipt of the relevant notification,
 consent to the granting of the sublicense shall be deemed given.<br>
 The Licensor may refuse consent **only for important cause**.

 **§ 4 License Fee**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Licensee shall pay to the Licensor, as remuneration for the
 grant of license, **ongoing sales-based license fees** in accordance with the following
 scale.<br>
 The term *sales* refers to **net sales prices**.<br>
 The *net sales price* is the amount invoiced by the Licensee to its customers for each
 contractual product, **less** freight, packaging, insurance, taxes, and customs duties
 (**commissions, discounts, risk surcharges, etc. shall not be deductible**).

The claim arises upon **delivery of the contractual products** by the Licensee.<br> If the Licensee takes back contractual products already delivered, it remains obligated to pay the license fee already accrued.<br> Upon redelivery of such products, no additional license fee shall arise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The **sales-based license fees** amount to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o **3% of the net sales price** (as defined in paragraph 1)
 until the cumulative sales-based license fees paid reach **EUR 400,000.00**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Once the cumulative sales-based license fees exceed EUR 400,000.00,
 the rate shall be **2.5%** for the portion of sales exceeding EUR 400,000.00.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o When the cumulative sales-based license fees exceed **EUR 700,000.00**,
 the rate shall further reduce to **2%** for the portion exceeding EUR 700,000.00.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. A. In the case of **granted sublicenses**, the Licensee shall
 pay to the Licensor **sales-based license fees equal to 50% of the revenues** received
 from sublicensing.

B. For sublicenses granted to **affiliated companies** (within the meaning of §15 of the German Stock Corporation Act — *Aktiengesetz*), the license fees under § 4(1) and (2) shall be calculated **on the basis of the revenues generated by the sublicensee**.<br> License fees paid to the Licensor shall be **credited** toward the Licensee's total sales-based license fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Licensee shall pay to the Licensor, as compensation for the **development work performed**, a **one-time lump-sum payment independent of sales** in the amount of **EUR 15,000.00 (fifteen thousand euros)**.<br>
 This amount shall become **due upon execution of the Agreement**.<br>
 It shall **not be refundable**, even in the event of early termination of the Agreement.<br>
 It shall **not be credited** against ongoing license fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The Licensee additionally undertakes, for the duration of this
 Agreement, to pay an **annual minimum license fee** in the amount of **EUR 2,500.00 (two thousand five hundred euros)**.<br>
 The minimum license fee shall be **due on February 1 of each year** for the preceding
 year.<br>
 Payments already made under § 4(1)–(3) shall **not be credited** against the
 minimum fee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. All payments under § 4 shall be **denominated in euros**,
 and shall be **exclusive of applicable taxes and duties**.<br>
 Should payments under this Agreement become subject to **value-added tax (VAT)** pursuant
 to § 2b of the German VAT Act (*Umsatzsteuergesetz*), the Licensee shall pay the
 applicable VAT **in addition** to the agreed remuneration.<br>
 Invoices issued in foreign currency shall be converted to euros at the **buying rate** valid at the Frankfurt Stock Exchange on the date of invoicing.<br>
 Any **(bank) charges for payments from abroad** shall be borne by the Licensee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Should a third party assert **prior user rights** in respect
 of one or more contractual protective rights, the Licensee's obligation to pay the
 license fee shall remain **unaffected**.

 **§ 5 Accounting and Payment of the License Fee**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The **accounting period** shall be the **calendar year**.<br>
 The accounting statement shall include **complete information** on sales achieved in the
 calendar year pursuant to § 4(1) and (2), as well as all **quantities of contractual products delivered to customers** during that calendar year, and the **names and addresses of customers**.<br>
 The Licensee shall submit the accounting statement **in text form** at the **end of January each year** for the preceding calendar year.<br>
 If no sales were made during an accounting period, the Licensee shall notify the Licensor **in text form** accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The license fee resulting from the accounting statement shall
 be **paid within 30 days** of receipt of the corresponding invoice issued by the Licensor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. In the event of **late payment**, the outstanding amounts shall
 bear **interest at 9 percentage points above the base interest rate**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. If the Licensor has given consent to the granting of sublicenses,
 the Licensee shall provide the Licensor with an accounting of the **sublicensees' sales** as described in paragraph 1, and shall pay the resulting license fees to the Licensor **in accordance with § 4(3)**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The Licensee shall maintain **books and records** of the sales
 of contractual products and revenues, keeping such documentation **separate from other company records**.<br>
 The same shall apply to the sublicensees' revenue data.<br>
 The Licensor shall be entitled, at reasonable intervals, and up to **one year after termination** of the Agreement, to **inspect all books, accounts, invoices, and other documents** directly
 or indirectly relating to license fee accounting, and to have them **audited by an independent tax advisor or auditor** bound to confidentiality toward the Licensee.<br>
 These rights shall also extend to the sublicensees.<br>
 The costs of such audits shall be borne by the Licensee.

 **§ 6 Obligation to Exercise**

The Licensee shall **exercise the license right** and use **best efforts** to commercialize the contractual products.<br> Commencement of production is targeted by **December 31, 2030**.<br> The Licensee shall provide the Licensor with **proof in text form** of the commencement of production no later than **four weeks after production begins**.<br> If production has not commenced by the specified date, the Licensor shall have the right under **§ 13(3)(c)** of this Agreement.

 **7 Approval**

The Licensee is hereby informed that, in certain countries belonging to the **territorial scope of the contractual protective rights**, the contractual products **may not be placed on the market without approval** from the relevant authorities.

Such approvals **do not currently exist**.<br> It shall be the **responsibility of the Licensee** to initiate and obtain such approvals from the competent authorities in the respective countries and to **only place the contractual products on the market in each respective country** once the required approvals have been granted.

The Licensee shall notify the Licensor of the submission of an approval application by **sending a copy of the application**.

The Licensor shall support the Licensee within the framework of the approval procedure.<br> However, the Licensor **assumes no liability** for obtaining such approvals in any of the countries included in the contractual territory.

 **§ 8 Publications**

The Licensor alone shall be entitled to **scientific publication**.<br> **No prior coordination or agreement with the Licensee** shall be required.

 **§ 9 Application and Maintenance of the Contractual Protective Rights / Waiver / Opt-out and/or Opt-in**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **A.** The Licensor shall, during the term of this Agreement, **maintain the contractual protective rights** in consultation with the Licensee and,
 upon the Licensee's request, shall undertake **subsequent filings** and **nationalizations, regionalizations, or validations**.<br>
 All costs associated with the **application and maintenance** of the contractual protective
 rights and any **subsequent filings, nationalizations, regionalizations, or validations** shall be borne by the Licensee.

The Licensor shall issue the corresponding invoices in order to obtain reimbursement of costs from the Licensee.<br> The Licensee shall **settle the invoice within 30 days** from the date of issue by the Licensor.

 **B.** The Licensee shall have **control over the proceedings** and may decide, in this connection, **whether and to what extent the contractual protective rights are to be continued and/or whether limitations of the scope of protection are to be made**.

Subsequent filings or validations that the Licensee does **not wish to undertake** shall **not be considered contractual protective rights** and may be executed **independently and at the Licensor's own expense**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Licensee may have the application and maintenance of the contractual
 protective rights handled by a **law firm of its choice**.<br>
 The Licensor shall, upon request of the Licensee, **engage such law firm**.<br>
 Should the Licensor intend to **waive** one or more of the contractual protective rights,
 whether in whole or in part, it shall **first offer** such rights to the Licensee for **assumption**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Licensor shall be entitled to **sell or transfer** the
 contractual protective rights to third parties.<br>
 In such a case, the Licensor shall ensure that **all rights and obligations arising from this License Agreement are assumed by the third party**.<br>
 Furthermore, the Licensor shall be obliged to **notify the Licensee** of the **name and address** of the purchaser of the contractual protective rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The declaration of an **Opt-out** pursuant to Article 83(3)
 of the *Agreement on a Unified Patent Court* shall be **exclusively reserved for the Licensor**.<br>
 The same shall apply for the declaration of an **Opt-in** pursuant to Article 83(4) of
 the same Agreement.

 **§ 10 Warranty and Liability of the Licensor**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Licensor declares that it has the **sole right of disposal** over the contractual protective rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Licensee is aware of the **technical characteristics** of the contractual protective rights.<br>
 The Licensor provides **no warranty** for possible **material or legal defects** of
 the products resulting from the contractual protective rights.<br>
 Corresponding **warranty or rescission rights** of the Licensee are excluded.<br>
 The Licensor further makes **no assurance** that the contractual protective rights are **free of defects**, **technically useful**, or **commercially exploitable**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Licensor **accepts no liability** for the **legal validity** of the contractual protective rights and any resulting **applications or intellectual property rights**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Licensor is **not aware** of any **third-party rights** conflicting with the contractual protective rights.<br>
 However, the Licensor gives **no guarantee** that the use of the contractual protective
 rights will not **infringe upon third-party rights**, and therefore **assumes no liability** that the use of the contractual protective rights does not **interfere with third-party intellectual property**.<br>
 The Licensor is likewise unaware of any **prior user rights** of third parties, for the
 absence of which it **accepts no liability**.

Nevertheless, the Licensor assures that it is **not aware of any circumstances** that could **jeopardize the existence or exploitation** of the contractual protective rights, particularly that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o no **prior art detrimental to novelty** is known to it, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o no **prior user rights** of third parties or other **dependencies** preventing unrestricted use are known.

The Licensor also confirms that, up to the time of signing this Agreement, it is **not aware of any third party** having applied for or announced or threatened **revocation or cancellation** of the contractual protective rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The Licensor has **not conducted** any **search for prior rights** (*Schutzrechtsrecherche*) or **Freedom-to-Operate (FTO)** analysis.<br>
 The Licensor is **under no obligation** to conduct such searches.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. The Licensor **assumes no liability** for the **technical usability or performance** of the contractual products.<br>
 The Licensee alone shall be **responsible for the proper manufacture** of the contractual
 products, as well as for the accuracy of **assembly and operating instructions**.<br>
 The Licensee is obligated to **indemnify and hold harmless** the Licensor against any **claims arising from product liability or manufacturer liability**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Apart from the foregoing, **liability for minor negligent breaches of duty** is excluded.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Liability for grossly negligent breaches of duty** shall
 be **limited in amount** to the **contractually typical and foreseeable damages** at
 the time of contract conclusion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Liability for **indirect damages**, in particular **consequential damages** and **lost profits**, is excluded.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. The **liability exclusions and limitations** stated above
 shall **not apply** to damages resulting from **injury to life, body, or health**,
 or to **claims under the Product Liability Act**, nor to **essential contractual obligations** (cardinal obligations).

The Parties agree that the **cardinal obligations** of this Agreement are **exhaustively set forth in §§ 1–5**.<br> In the event of a breach of cardinal obligations due to **slight negligence**, liability shall be limited to the **contractually typical and foreseeable damages** at the time of contract conclusion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. The above **limitations or exclusions of liability** shall
 not apply where they concern **damages resulting from injury to life, body, or health**,
 or **claims under the Product Liability Act**, nor shall they apply to **breaches by vicarious agents** (*Erfüllungsgehilfen*).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Unless DWI is liable for **intentional misconduct**, any claims
 by the Licensee arising from **breach of duty or tort** shall **expire within one (1) year** from the statutory commencement of the limitation period.

 **§ 11 Joint Enforcement and Defense**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. In the event of **infringement of the contractual protective rights by a third party**, the following shall apply:

a) Each Party shall **inform the other Party** of any infringement of the contractual protective rights that becomes known to it.

b) In the event of infringement of one or more contractual protective rights, the **Licensor shall have the primary right** to take action against the infringer.<br> The Licensee shall be obligated to provide the Licensor with **all information and assistance necessary** for the enforcement of claims.

c) The **allocation of costs** for legal enforcement shall be determined **in consultation** between the Parties.

d) If the Licensor receives **proceeds from damages** or settlements paid by the infringer, it shall remit such proceeds to the Licensee **in proportion to the cost contribution**.

e) Should the Licensor **waive its right to pursue enforcement**, it shall inform the Licensee thereof.<br> In that case, the Licensee shall be entitled to **take action against the infringer at its own expense**.<br> The same shall apply if the Licensor, after a **reasonable period**, beginning from the point when all relevant circumstances are known, **has not initiated legal action**.<br> In such cases, **damages received from the infringer shall accrue solely to the Licensee**.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Licensor shall **defend the contractual protective rights** against **third-party challenges**, such as **actions for nullity and/or cancellation requests**, on its own behalf and in **consultation with the Licensee**.<br>
 The allocation of costs shall be agreed between the Parties.<br>
 The Licensee's **obligation to pay license fees** remains **unaffected**.

&nbsp;&nbsp;&nbsp;&nbsp;3. If the Licensee is **attacked by third parties** for infringement
 of intellectual property rights as a result of using the contractual protective rights, it
 shall **immediately notify the Licensor** and provide the Licensor with the opportunity
 to participate in any potential litigation.<br>
 The Licensor shall not, however, be obligated to do so.<br>
 Nonetheless, the Licensor shall **assist the Licensee** in conducting such litigation.<br>
 The **costs** shall be borne by the **Licensee**.

 **§ 12 Confidentiality**

&nbsp;&nbsp;&nbsp;&nbsp;1. The Parties mutually undertake to maintain **confidentiality** regarding all information and knowledge exchanged or to be exchanged **before or during the term** of this Agreement, as well as knowledge acquired concerning the **principles, methods, manufacture, new developments, improvements, and other details** relating to the
 contractual products and operational processes concerning the performance of the contract
 — even if such information is **not explicitly designated as secret or confidential**.<br>
 This shall not apply where **disclosure is necessary** to obtain official authorizations
 or approvals, or if the Licensor is **legally required** to disclose such information
 by law or by judicial and/or regulatory order.

&nbsp;&nbsp;&nbsp;&nbsp;2. The obligation of confidentiality shall not extend to information
 for which the Licensee can **prove** that such information was **already publicly known** without its involvement at the time of conclusion of this Agreement, or that it was **made public by third parties**.<br>
 It also shall not extend to information already **in possession of the Licensee** prior
 to disclosure by the Licensor.<br>
 In such a case, the Licensee shall **immediately notify** the Licensor that such information
 was already known in whole or in part, and shall **provide appropriate evidence** thereof.

&nbsp;&nbsp;&nbsp;&nbsp;3. The Licensee may make the information accessible **only to such employees** for whom knowledge thereof is **indispensable for the manufacture** of the
 contractual products.

&nbsp;&nbsp;&nbsp;&nbsp;4. The Licensee shall impose this **confidentiality obligation** on **all of its employees** and **external third parties** who, by virtue of their
 activities, may gain knowledge of the contractual product capable of being utilized.<br>
 This confidentiality obligation shall, to the extent legally permissible, also be **imposed on employees for the period following termination** of their employment contract, and shall
 be **secured by a contractual penalty clause**.

&nbsp;&nbsp;&nbsp;&nbsp;5. The obligation of confidentiality shall remain in effect for a **period of five years beyond the term of this Agreement**.

 **§ 13 Term of the Contract**

&nbsp;&nbsp;&nbsp;&nbsp;1. This Agreement shall **enter into force** upon the **final signature** by both Parties.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Agreement shall initially have a term until **31 March 2029**.<br>
 The Agreement shall be **automatically extended** unless it is **terminated by the Licensee** by **30 September 2028**.<br>
 If no termination occurs, the Agreement shall expire upon the **expiration of the last contractual protective right**.

&nbsp;&nbsp;&nbsp;&nbsp;3. Notwithstanding the foregoing, **each Party** shall have the
 right to **terminate the Agreement without notice for good cause**.<br>
 The Parties agree that **good cause** shall exist in particular if:

a) The Licensee **fails to submit** the required **applications for approval** of the contractual products under § 7;<br> b) The Licensee is **in default for more than three months** with **accounting and/or payment of license fees**, despite a reminder and a **written grace period of six weeks**;<br> c) The Licensee, despite warning and a **written grace period of six months**, **fails to fulfill its obligation** to exercise the license and commence production under § 6, or later **suspends exercise** of the license for a period of six months;<br> d) Either Party, despite warning and a reasonable grace period, **violates other essential contractual obligations**;<br> e) The **majority shareholding structure** of either Party changes in such a way that **more than 50% of the voting rights** are held by another participant, and as a result of the changed ownership, it is **unreasonable for the other Party to continue** the Agreement.<br> A merely **indirect change in ownership** in the Licensee shall **not generally justify termination**.

&nbsp;&nbsp;&nbsp;&nbsp;4. In the event of termination of the Agreement pursuant to paragraph
 3, the Licensee shall **no longer be entitled**, upon the effectiveness of termination,
 to **sell or deliver** already produced contractual products.

&nbsp;&nbsp;&nbsp;&nbsp;5. Upon termination pursuant to paragraph 3, the Licensee shall **return to the Licensor** all documents concerning the contractual products received from the Licensor
 at the beginning and during the term of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;6. In the event of termination **by DWI**, DWI shall **assume the Licensee's position** in any existing **sublicense agreements** and continue
 them with the sublicensees.<br>
 The Licensee hereby **declares its consent** to the transfer of all **contractual rights and obligations** arising from sublicenses to DWI, and DWI **accepts this transfer**.<br>
 The Parties agree that DWI's obligation to assume shall apply **only to sublicenses** that **solely concern the subject matter of this Agreement**.

 **Mixed contracts**, such as sublicenses combined with **service and/or production agreements** or similar contracts, shall not be affected.<br> Such contracts with sublicensees or third parties shall **end upon termination** of this Agreement.<br> The Licensee shall ensure that this is **stipulated** in its sublicense or third-party agreements by including **appropriate provisions**.

In the event of termination **by the Licensee**, DWI shall **not assume** any sublicense agreements.<br> These agreements shall **end upon termination** of this Agreement.<br> The Licensee must also provide **corresponding clauses** in its sublicense or third-party contracts.

&nbsp;&nbsp;&nbsp;&nbsp;7. Payments already made under this Agreement shall **remain unaffected** by termination.

&nbsp;&nbsp;&nbsp;&nbsp;8. Any termination of this Agreement shall be **effective only in written form** and must be **delivered by registered mail**.

 **§ 14 Prohibition of Assignment**

This Agreement and the rights and obligations regulated herein **may not be transferred** by either Party to third parties **without the consent** of the other Party.<br> § 9 paragraph 3 shall remain unaffected.

 **§ 15 Collateral Agreements, Written Form, Export Control, and Applicable Law**

&nbsp;&nbsp;&nbsp;&nbsp;1. **No collateral agreements** have been made.

&nbsp;&nbsp;&nbsp;&nbsp;2. **General terms and conditions** of the Licensee shall **not form part of this Agreement**, even if known, unless their validity has been **expressly agreed to in writing**.

&nbsp;&nbsp;&nbsp;&nbsp;3. **Amendments and supplements** to this Agreement must be made **in writing** in order to be legally effective.<br>
 This also applies to any **waiver of the written form requirement** itself.<br>
 The **primacy of individual agreements** (§ 305b German Civil Code, *BGB*) shall
 remain unaffected.

&nbsp;&nbsp;&nbsp;&nbsp;4. The Licensee is aware that the contractual protective rights **may be subject to export control regulations** of the Federal Office for Economic Affairs and
 Export Control (*Bundesamt für Wirtschaft und Ausfuhrkontrolle*).<br>
 Any **transfer of contractual protective rights abroad**, in any form — such as **granting licenses, sale of the contractual protective rights, or publication**, as well
 as the **transfer of products** manufactured on the basis of the contractual protective
 rights — may be **subject to export control**.

&nbsp;&nbsp;&nbsp;&nbsp;5. This Agreement shall be governed by the **laws of the Federal Republic of Germany**, to the **exclusion of conflict of laws rules** and the **United Nations Convention on Contracts for the International Sale of Goods (CISG)**.

&nbsp;&nbsp;&nbsp;&nbsp;6. The **Annexes** form an **integral part** of this Agreement.<br>
 In the event of an **unintentional discrepancy** between the provisions of this Agreement
 and those of the Annexes, the **provisions of this Agreement shall prevail**.

 **§ 16 Place of Performance and Jurisdiction**

&nbsp;&nbsp;&nbsp;&nbsp;1. The **place of performance** shall be **Aachen**.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Parties shall at all times engage in **discussion and exchange** regarding all questions and disagreements in connection with this Agreement.<br>
 Should an **amicable settlement** fail, the Parties agree that the **exclusive place of jurisdiction** for all legal disputes arising from or in connection with this Agreement
 shall be **Aachen**.

 **§ 17 Final Provisions**

&nbsp;&nbsp;&nbsp;&nbsp;1. Should any provision of this Agreement be or become **invalid or unenforceable**, the **validity of the remaining provisions** shall not be affected.

&nbsp;&nbsp;&nbsp;&nbsp;2. The invalid or unenforceable provision shall be **replaced** by a provision that is **legally permissible** and that **most closely reflects** the
 intent of the original provision.

&nbsp;&nbsp;&nbsp;&nbsp;3. The same shall apply in the event of a **gap** in the Agreement.

 **Signatures**

---

| | |
|:---|:---|
| **For DWI** | **For CS** |
| **RWTH Innovation GmbH** | **CS Diagnostics Pharma GmbH** |
| Aachen, __________ | Bruckmühl, __________ |
| *Dr. rer. nat. Jörg von Appen* | *Thomas Fahrhöfer* |
| Aachen, __________ |  |
| *ppa. Ramona Steininger* | |
| For the Department *Advanced Materials for Biomedicine* |  |
| *Prof. Laura de Laporte* |  |

---

 **Annex 1 – List of Contractual Protective Rights**

---

| | | | |
|:---|:---|:---|:---|
| **Country** | **Title / Keyword** | **Filing Date** | **File Reference** |
|  | **Invention: SpaceGel – Spacer Hydrogel for Organ Shielding During Radiation of Prostate Carcinomas** | Reported on **11.01.2023**; Claimed on **13.01.2023** | (DWI-LD015) |
| **DE** | **A System for the Production of a Degradable Hydrogel** | **29.03.2023** | **DE10 2023 108 039.3** |

---

## Exhibit 10.3

**Exhibit 10.3**

 **EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT**

This Exclusive License and Distribution Agreement (this "Agreement") is entered into as of this 2nd of January, 2025 (the "Effective Date"), by and between CS Interpharm General Trading Co. LLC, a Dubai entity (the "Licensor," or "CSI") and CS Diagnostics, Corp., a Wyoming corporation, with its principal address at Stresemannallee 4c, Neuss, Germany 41460 (the "Licensee," or "CSDX"). Licensor and Licensee are collectively referred hereto as "Parties" and each individually as "Party."

 **RECITALS** 

WHEREAS, Licensor owns certain intellectual property, know-how, proprietary information, and related

rights concerning the product described in Exhibit A (the "Product");

WHEREAS, Licensor desires to grant Licensee the exclusive right to use, market, distribute, and commercialize the Product solely within the United States of America, subject to the terms and conditions of this Agreement; and

WHEREAS, Licensee desires to obtain such exclusive rights from Licensor for its internal business purposes, subject to the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Definitions

"***Affiliate***" means any entity directly or indirectly controlling, controlled by, or under common control with

a Party.

"***Intellectual Property***" means patents, trademarks, copyrights, trade secrets, know-how, technical data, formulae, designs, and other proprietary rights owned by CSI and related to the Product.

"***Net Sales***" means gross amounts invoiced by CSDX or its sublicensees from the sale of Products in the

Territory, less customary deductions (returns, chargebacks, taxes, shipping).

"***Person***" means an individual, corporation, partnership, joint venture, limited liability entity, governmental authority, unincorporated organization, trust, association, or other entity.

"***Territory***" means the United States of America and its territories and possessions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Grant of License

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **2.1** <u>Exclusive License</u>. Licensor grants Licensee the exclusive right and license to use, import, market, promote, distribute, and sell the Product in the Territory during the Term**.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2 <u>License Restrictions</u>. Except as this Agreement expressly permits**,** Licensee shall not, and shall not permit any other Person to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2.1 transfer any ownership rights in the Intellectual Property, such remains with Licensor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2.2 rent, lease, lend, sell, sublicense, assign, distribute, transfer, or otherwise make available the Product to any third party; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2.3 grant sublicenses without the prior written consent of Licensor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.3 <u>Intellectual Property Rights</u>. Licensee acknowledges and agrees that the Product are licensed, not sold, to Licensee by Licensor and Licensee does not have under or in connection with this Agreement any ownership interest in the Product, or in any related Intellectual Property rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.4 <u>Licensee Cooperation and Notice of Infringement</u>. Licensee shall, during the Term, take all commercially reasonable measures to safeguard the Product from infringement, misappropriation, theft, misuse, or unauthorized access.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 <u>No Other Grant of Rights</u>. Except as expressly provided herein, nothing in this Agreement shall be construed to confer upon Licensee any ownership interest, license, or other rights by implication, estoppel, or otherwise in or to any intellectual property rights, products, technology, or biological materials of Licensor or any third party, regardless of whether such rights, products, technology, or materials are known to Licensee at the Effective Date or become known thereafter. All rights not expressly granted to Licensee under this Agreement are expressly reserved by Licensor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Confidentiality

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.1 <u>Confidential Information</u>. In connection with this Agreement, each Party (the "Disclosing Party") may disclose or make available Confidential Information to the other Party (the "Receiving Party"). Subject to Section 3.2, "Confidential Information" means confidential information belonging to the Disclosing Party and its Affiliates that are not generally known to the public, including, but not limited to, information concerning the Property, business plans, financial statements, and other information provided pursuant to this Agreement, operating practices and methods, expansion plans, strategic plans, marketing plans, contracts, customer lists, or other business documents that the Disclosing Party treats as confidential, in any format whatsoever (including oral, written, electronic, or any other form or medium).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.2 <u>Exclusions</u>. Confidential Information does not include information that: (a) was rightfully known to the Receiving Party without restriction on use or disclosure prior to such information being disclosed or made available to the Receiving Party in connection with this Agreement; (b) was or becomes generally known by the public other than by the Receiving Party's or any of its Representatives' noncompliance with this Agreement; (c) was or is received by the Receiving Party on a non-confidential basis from a third party that was not or is not, at the time of such receipt, under any obligation to maintain its confidentiality; or (d) was or is independently developed by the Receiving Party without reference to or use of any Confidential Information.

Notwithstanding any other provisions of this Agreement, the Receiving Party's obligations under this Section 3 with respect to any Confidential Information that constitutes a trade secret under any applicable Law will continue until such time, if ever, as such Confidential Information ceases to qualify for trade secret protection under one or more such applicable Laws other than as a result of any act or omission of the Receiving Party or any of its Representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.3 <u>Compelled Disclosures</u>. If the Receiving Party or any of its Representatives is compelled by applicable Law to disclose any Confidential Information then, to the extent permitted by applicable Law, the Receiving Party will: (a) promptly, and prior to such disclosure, notify the Disclosing Party in writing of such requirement so that the Disclosing Party can seek a protective order or other remedy or waive its rights under Section 3.3; and (b) provide reasonable assistance to the Disclosing Party in opposing such disclosure or seeking a protective order or other limitations on disclosure. If the Disclosing Party waives compliance or, after providing the notice and assistance required under this Section 3, the Receiving Party remains required by applicable law to disclose any Confidential Information, the Receiving Party will disclose only that portion of the Confidential Information that, on the advice of the Receiving Party's legal counsel, the Receiving Party is legally required to disclose.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Obligations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1 <u>Licensor</u>. Licensor shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1.1 provide Licensee with access to technical information, regulatory data, and other know-how reasonably necessary for Licensee to commercialize the Product in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1.2 maintain and protect Intellectual Property at its expense, including patent filings and renewals, whether within the Territory or globally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1.3 not, during the Term, license, sell, assign, or transfer the Product in the Territory to any other Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1.4 cooperate and provide all necessary documentation and technical support.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2 <u>Licensee</u>. Licensee shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2.1 use commercially reasonable efforts to market and sell the Product in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2.2 obtain and maintain all regulatory approvals (*e.g.*, FDA, EPA, or other U.S. agencies) necessary for the lawful commercialization of the Product in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2.3 provide quarterly sales, revenue, and regulatory progress reports to Licensor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2.4 comply with all applicable laws and regulations in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2.5 sponsor any U.S. regulatory applications and approvals. Notwithstanding any other provisions set forth herein, all U.S. regulatory approvals shall be held in Licensee's name but licensed use of Licensor's data shall remain the Licensor's property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Mutual Representation and Warranties

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.1 Each Party represents, warrants, and covenants to the other Party that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.1.1 it is duly organized, validly existing and in good standing as a corporation or other entity under the Laws of the jurisdiction of its incorporation or other organization;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.1.2 it has the full right, power, and authority to enter into and perform its obligations and grant the rights, licenses, and authorizations it grants and is required to grant under this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.1.3 the execution of this Agreement by its representative whose signature is set forth at the end of this Agreement has been duly authorized by all necessary corporate or organizational action of such Party; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.1.4 when executed and delivered by both Parties, this Agreement will constitute the legal, valid, and binding obligation of such Party, enforceable against such Party in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Fees

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.1 <u>Royalties</u>. Licensee shall pay Licensor a royalty of _2.5_% of Net Sales of the Product in the Territory, payable quarterly within 30 days after the end of each calendar quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.2 <u>Upfront or Annual Fee</u>. Licensee shall pay Licensor an upfront license fee of $20,000 upon execution of this Agreement, and thereafter an annual license maintenance fee of $_5000 .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.3 <u>Audit Rights</u>. Licensor may, no more than once per year, audit Licensee's books and records relating to Product sales in the Territory, at Licensor's expense (unless an underpayment of more than 5% is discovered, in which case Licensee shall bear the audit cost).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Term and Termination

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.1 <u>Term</u>. This Agreement shall commence on the Effective Date and continue for ten (10) years (the

"Term"), unless terminated earlier in accordance with this Section 7.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.2 <u>Termination for Cause</u>. Either Party may terminate this Agreement upon 60 days' written notice

if the other Party materially breaches this Agreement and fails to cure within such period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.3 <u>Termination for Insolvency</u>. Either Party may terminate if the other Party becomes insolvent, files for bankruptcy, or ceases operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.4 <u>Effect of Termination</u>. Upon termination, Licensee shall cease all use of the Product and Intellectual Property in the Territory, return or destroy Licensor's confidential information, and discontinue all sales. Unsold inventory shall be handled as agreed by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Enforcement of Intellectual Property Rights

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.1 <u>Right to Enforce</u>. During the Term, Licensee shall have the exclusive right, at its own expense, to enforce its rights under this Agreement against any third party that (i) directly or indirectly imports, markets, distributes, or sells the Product in the Territory without authorization, or (ii) otherwise interferes with Licensee's exclusive rights in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.2 <u>Notice</u>. Licensee shall promptly notify Licensor of any such actual or threatened infringement or interference of which it becomes aware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.3 <u>Licensor Cooperation</u>. Licensor shall reasonably cooperate with Licensee, at Licensee's expense,

in connection with any such enforcement action, including joining as a necessary party if required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.4 <u>Recovery</u>. Any recovery obtained in connection with such action shall be first applied to reimburse the enforcing Party's reasonable costs and expenses, and the balance, if any, shall be shared as determined by Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.5 <u>Licensor's Reserved Rights</u>. Licensor retains the right, at its discretion and expense, to bring or assume control of any enforcement action relating to its Intellectual Property outside the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Miscellaneous

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.1 <u>Further Assurances</u>. On a Party's reasonable request, the other Party shall, at the requesting Party's sole cost and expense, execute and deliver all such documents and instruments, and take all such further actions, as may be necessary to give full effect to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.2 <u>Relationship of the Parties</u>. The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement will be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the Parties, and neither Party shall have authority to contract for or bind the other Party in any manner whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.3 <u>Governing Law</u>. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Wyoming applicable to the terms set forth in this Agreement. The Parties hereto hereby consent to the jurisdiction of the state courts located in the State of Wyoming over the Parties and any disputes, claims, actions, suits and proceedings related to this agreement or the transactions contemplated herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.4 <u>Other Agreements</u>. The Parties each represents to the other that it is not a party to any other agreements or commitments that would hinder its performance or cause any conflicting interests from his/her obligations under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.5 <u>Construction</u>. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties and no presumption or burden of proof will arise favoring or disfavoring any Parties by virtue of the authorship of any of the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.6 <u>Arbitration</u>. Any dispute, controversy or claim arising out of or in connection with this Agreement or any breach or alleged breach hereof shall, upon the request of any party involved, be submitted to, and settled by, arbitration in the city in which the principal place of business of the Licensor is then located. Any award rendered shall be final and conclusive upon the parties and a judgment thereon may be entered in a court of competent jurisdiction. The expenses of the arbitration shall be borne equally by the parties to the arbitration, provided that each party shall pay for and bear the cost of its own experts, evidence and attorneys' fees, except that in the discretion of the arbitrator any award may include the attorney's fees of a party if the arbitrator expressly determines that the party against whom such award is entered has caused the dispute, controversy or claim to be submitted to arbitration as a dilatory tactic or in bad faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.7 <u>Notices</u>. All notifications and communications hereunder shall be in writing. All notifications made to the Licensor under this Agreement shall be made to the following address:

To: CS Interpharm General Trading Co. LLC<br> Attention: Mohammad EsSayed

Address: Bay Square, 809, Business Bay, Dubai, UAE

All notifications made to the Licensee under this Agreement shall be made to the following address:

To: CS Diagnostics, Corp.

Attention: Thomas Fahrhoefer

Address: Stresemannallee 4c, Neuss, Germany 41460

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.8 <u>Severability</u>. In the event any one or more of the provisions of this agreement is held to be invalid or otherwise unenforceable, the enforceability of the remaining provisions shall be unimpaired.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.9 <u>Amendment</u>. This Agreement, in part or in whole, may not be altered, amended, changed, supplemented, waived or modified in any respect or particular unless the same shall be in writing and agreed to by the affirmative vote or written consent of all Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.10 <u>Entire Agreement</u>. This Agreement represents the entire understanding of the Parties superseding all prior agreements, understandings, and discussions whether conveyed orally or in writing, and there are no other warranties, commitments, understandings or representations with respect to this agreement.

IN WITNESS WHEREOF, the Parties hereto have executed this Exclusive License and Distribution Agreement as of the date set forth above.

---

| | | | |
|:---|:---|:---|:---|
| **LICENSOR:** <br>CS INTERPHARM GENERAL TRADING<br> CO. LLC  | **LICENSOR:** <br>CS INTERPHARM GENERAL TRADING<br> CO. LLC  | **LICENSEE:<br>** <br>CS DIAGNOSTICS, CORP.  | **LICENSEE:<br>** <br>CS DIAGNOSTICS, CORP.  |
| By: | ![](essayed_sig.jpg) | By: | ![](fahrhoefer_sig.jpg) |
| Name: | Mohammad EsSayed | Name: | Thomas Fahrhoefer |
| Title: | Managing Director | Title: | President of the Board |

---

## Exhibit 10.4

**Exhibit 10.4**

Cs Interpharm General Trading LLC 17/02/2025

809, B002 Bay Square Business<br> Bay, Dubai United Arab<br> Emirates

 <u>Waiver of all Rights for Medusa SDP and fulﬁlment of sales agreement</u>

In reference to the signed Sales Agreement on March 2024 and all its following amendments and issued letters, and pursuant to the signed Settlement Agreement dated 17/02/2025.

I, Luke Wilson, a British citizen, passport number xxxxxx875, and United Arab Emirates ID number xxx-xxxx-xxxx470-2 hereby, conﬁrm the fulﬁlment and conclusion of the sales of Medusa SDP and all its rights and assets to CS Interpharm General Trading LLC.

I hereby, waive, release, and relinquish any and all claims, demands of ownership - current or future - of MEDUSA SDP and all its related companies, partners, aﬃliates, brand, trademark, social media, assets and any equity worldwide.

I hereby indemnify and hold CS Interpharm general trading LLC and its directors, oﬃcers, shareholders, partners, employees and agents, harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses.

![](wilson_sig.jpg)

Luke Wilson

Dubai, 17 February 2025

## Exhibit 23.1

**Exhibit 23.1**

![](csbetterhealth_logo.jpg)

 **CS DIAGNOSTICS CORP** 

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **FINANCIAL STATEMENTS WITH PCAOB AUDITORS CONSENT** <br>**FOR PERIOD ENDING DECEMBER 31, 2023**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **AUDITOR LETTER<br> BALANCE SHEET<br> STATEMENT CASH FLOWS<br> INCOME STATEMENT** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY<br> FINANCIAL NOTES** |

---

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 1 of 12

 **C S DIAGNOSTICS CORP**

 **INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| Balance Sheets as of December 31, 2023, and December 31, 2022 | 5 |
| Statements of Operations for the year ended December 31, 2023, and December 31, 2022 | 6 |
| Statements of Stockholders' Equity for the year ended December 31, 2023, and 2022 | 7 |
| Statements of Cash Flows for the year ended December 31, 2023, and 2022 | 8 |
| Notes to the Financial Statements | 9 |

---

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 2 of 12

![](olayinka_header.jpg)

 **Report of the Independent Registered Public Accounting Firm**

 **To the shareholders and the board of directors of CS DIAGNOSTICS CORP.**

 ***Opinion on the Financial Statements***

We have audited the accompanying balance sheets of **CS Diagnostics Corp.** (the "Company") as of December 31, 2023, and 2022 and the related statements of operations, changes in shareholders' equity and cash flows, for each of the two years in the period ended December 31, 2023, and the related notes collectively referred to as the "financial statements. In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and 2022, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

 **Going Concern**

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,768,689) at December 31, 2023. The continuation of the Company as a going concern through December 31, 2023, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

These factors raise substantial doubt about the company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of the uncertainty.

 ***Basis for Opinion***

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the

U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 **Critical Audit Matters**

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. We have decided to communicate the matter below.

 **Valuation of Intangible Assets**

As discussed in Note 1 to the financial statements, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS Protect Hydrogel is a hydrogel-based tissue spacer.

We identified the Audit of valuation of intangible assets as a critical audit matter because of the significant estimates and management assumptions used. Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor's judgement and an increase extent of effort.

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 3 of 12

 **The primary procedures we performed include:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. We reviewed and challenged the reasonableness of key management
 assumptions used for the estimate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. We reviewed the report of the independent valuation firm that
 performed the valuation of the intangible assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. We assessed the suitability of the method used by the expert
 in valuation of the assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. We evaluated the reasonableness of
 management significant assumptions used in developing discounted cashflow such as future
 projection of revenue growth and profitability and estimating the working capital needs by
 testing the data used by management in its analysis to compare to historical data.

![](olayinka_sig.jpg)

 **OLAYINKA OYEBOLA & CO.**

 **(Chartered Accountants)**

We have served as the Company's auditor since February 2022.

 **March 11th, 2024.**

 **Lagos Nigeria**

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 4 of 12

**C S DIAGNOSTICS CORP<br> BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | December 31,<br> 2023 | December 31, 2022<br> (Audited)<br> Restated |
| **<u>ASSETS</u>** |  |  |
| Current Assets:  |  |  |
| Cash | 20363 | 12804 |
| Other receivables | - | - |
| Total current asset | $20363 | $12804 |
| Intangible assets | 499400000 |  |
| Total Assets | $499420363 | $12804 |
| **<u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u>** |  |  |
| Current Liabilities: | $— | $— |
| Account Payables | 12822 | 4107 |
| Non-Current Liabilities | $- | $40000 |
| Total Liabilities | 12822 | 44107 |
| <u>Stockholders' Deficit:</u> |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.00001 par value; 250,000,000 shares authorized, 110,790,200 shares issued and outstanding as of December 31, 2023, and 135,287,214 shares December 31, 2022 | 1108 | 1352 |
| &nbsp;&nbsp;&nbsp;Preferred stock Series A, $0.001 par value;5,000 shares authorized, 10 shares issued and outstanding as of December 31, 2023, and 2022 |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock Series B, $0.001 par value; 20,000,000 shares authorized, 20,000,000 shares issued and outstanding as of December 31, 2023, and 2022 | 2000 | 2000 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 504173122 | 4712037 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (4768689) | (4746692) |
| Total Stockholders' Deficit | 499407541 | (31303) |
| Total Liabilities and Stockholders' Deficit | $499420363 | $12804 |

---

*The accompanying notes are an integral part of these financial statements.*

 

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 5 of 12

 

**CS DIAGNOSTICS CORP.**

**STATEMENTS OF OPERATONS**

---

| | | |
|:---|:---|:---|
| | For the Years Ended<br> December 31, | For the Years Ended<br> December 31, |
|  | 2023 | 2022 |
| Revenue | $126038 | $25500 |
| Operating Expenses: |  |  |
| Professional fee | $54026 | $6040 |
| General & administrative expenses | $94009 | $14255 |
| Total operating expenses | 148035 | 20292 |
| Income /(loss) from operations | (21997) | 5205 |
| Other Income / (Expense) |  |  |
| Net Income / (loss) | $(21997) | $5205 |
| Basic and diluted loss per share | $(0.00) | $(0.00) |
| Basic and diluted weighted average shares | 110790200 | 135287214 |

---

 

*The accompanying notes are an integral part of these financial statements*.

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 6 of 12

**CS DIAGNOSTICS CORP.<br> STATEMENT OF STOCKHOLDERS' (DEFICIT)**

**FOR THE YEAR ENDED DECEMBER 31, 2023, AND 2022.**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Preferred Stock B | Preferred Stock B | Common Stock | Common Stock | | | |
|  | Shares | Amount | Shares | Amount | Additional<br>Paid-in Capital | Accumulated<br>Deficit |<br>Total |
| Balance, January 1, 2022 | 20000000 | $2000 | 135287214 | $1352 | $4712037 | $(4751897) | $(36508) |
| Preferred stock issued |  |  |  |  |  |  |  |
| Net loss for the year | - | - | - | - | - | 5205 | 5205 |
| Balance, December 31, 2022 | 20000000 | 2000 | 135287214 | 1352 | 4712037 | (4746692) | (31303) |
| Balance, January 1, 2023 | 20000000 | $2000 | 135287214 | $1352 | $4712037 | (4746692) | $(31303) |
| Reverse stock split | **-** | **-** | (134497015) | (1344) |  |  | (1344) |
| Shares issued in acquisition of assets |  |  | 110000000 | 1100 | 499461085 |  | 499462185 |
| Net income for the year | - | - | - | - | - | (21997) | (21997) |
| Balance, December 31, 2023 | 20000000 | 2000 | 110790200 | 1108 | 504171322 | (4768689) | 499407541 |

---

*The accompanying notes are an integral part of these financial statements*.

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 7 of 12

**C S DIAGNOSTICS CORP**

**STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | Year Ended | Year Ended |
|  | December 31, | December 31, |
|  | 2023 | 2022 |
| Cash flows from operating activities: |  |  |
| Net profit / (loss) | $(21997) | $17901 |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Changes in assets and liabilities: |  |  |
| Other receivables |  |  |
| Account payables | 31285 | 7599 |
| Net cash used in operating activities | 9288 | 25500 |
| Cash flows from investing activities: |  |  |
| Intangible Asset | (499444401) | <u> </u> |
|  | (499444401) |  |
| Cash flows from financing activities: |  |  |
| Additional paid in capital | 499422309 |  |
| Loan forgiven |  | - |
| Net cash provided by financing activities | 499422309 | - |
| Net increase (decrease) in cash | (12804) | 25500 |
| Cash, beginning of period | 12804 | - |
| Cash, end of period | $- | $25500 |

---

*The accompanying notes are an integral part of these financial statements.*

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 8 of 12

**C S DIAGNOSTICS CORP**

**Notes to the Financial Statements<br> December 31, 2023, and December 31, 2022**

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology.

On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200.

On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*<u>Basis of Presentation</u>*

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

*<u>Use of Estimates</u>*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

*<u>Concentrations of Credit Risk</u>*

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.

*<u>Cash and Cash Equivalents</u>*

The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended December 31, 2023, and December 31, 2022.

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 9 of 12

*<u>Fair Value of Financial Instruments</u>*

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below:

Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates.

Level 3: Level 3 inputs are unobservable inputs.

The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values.

The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates.

*<u>Income Taxes</u>*

We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740- 10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

*<u>Net income (loss) per common share</u>*

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the year ended December 31, 2023 and December 31, 2022, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 10 of 12

*<u>Recent Accounting Pronouncements</u>*

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 - GOING CONCERN**

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,792,727) at December 31, 2023. The continuation of the Company as a going concern through December 31, 2023, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

**NOTE 4 – INCOME TAXES**

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

Net deferred tax assets consist of the following components as of:

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br> **2023** | **December 31,**<br> **2022** |
| Federal income tax benefit attributable to: | Federal income tax benefit attributable to: | Federal income tax benefit attributable to: |
| Current Operations | $— | $— |
| Less: valuation allowance |  |  |
| Net provision for Federal income taxes | $— | $— |

---

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br> **2023** | **December 31,**<br> **2022** |
| Deferred tax asset attributable to: |  |  |
| Net operating loss carryover | $— | $(3333) |
| Less: valuation allowance |  | 3333 |
| Net deferred tax asset | $— | $— |

---

At December 31, 2023, the Company had net operating loss carry forwards of approximately $(4,792,727) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the December 31, 2023, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 11 of 12

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015.

**NOTE 5 – SUBSEQUENT EVENTS**

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

OTC Markets Group Inc.Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 12 of 12

## Exhibit 23.2

**Exhibit 23.2**

![](cscorp_logo.jpg)

 **CS DIAGNOSTICS CORP**

 **FINANCIAL STATEMENTS** 

 **FOR PERIOD ENDING** 

 **December 31, 2024**

 **BALANCE SHEET STATEMENT<br> STATEMENT CASH FLOWS<br> INCOME STATEMENT**

 **STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY<br> FINANCIAL NOTES**

![](cscorp_logo.jpg)

CS DIAGNOSTICS CORP. CSDX

INDEX TO FINANCIAL STATEMENTS

---

| |
|:---|
| Balance Sheets as of December 31, 2024, and December 31, 2023 |
| Statements of Operations for the twelve months period ended December 31, 2024, and December 31, 2023 |
| Statements of Stockholders' Equity for twelve months period ended December 31, 2024, and December 31, 2023 |
| Statements of Cash Flows for the twelve months period ended December 31, 2024, and December 31, 2023 |
| Notes to the Financial Statements |

---

![](cscorp_logo.jpg)

Report of the Independent Registered Public Accounting Firm

To the shareholders and the board of directors of CS DIAGNOSTICS CORP.

 *Opinion on the Financial Statements*

We have audited the accompanying balance sheets of CS Diagnostics, Corp. (the "Company") as of December 31, 2024, and 2023 and the related statements of operations, changes in shareholders' equity and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes collectively referred to as the "financial statements. In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and 2023, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

Going Concern

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,767,928) at December 31, 2024. The continuation of the Company as a going concern through December 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

These factors raise substantial doubt about the company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of the uncertainty.

 *Basis for Opinion*

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

![](olayinka_sig.jpg)

OLAYINKA OYEBOLA & CO.

(Chartered Accountants)

We have served as the Company's auditor since 2022. <br> March 31st, 2025.

Lagos Nigeria

![](cscorp_logo.jpg)

---

| |
|:---|
| **CS DIAGNOSTICS CORP. CSDX** |
| **BALANCE SHEET** |
| **FOR THE PERIOD ENDED December 31 2024** |

---

---

| | | |
|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2023** |
|  | *Audited* | *Audited* |
| *<u>Assets</u>* |  |  |
| **Current Assets** |  |  |
| Cash | 501 | 20363 |
| Other Receivables |  |  |
| **Total Current Assets** | $**501** | $**20363** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499400501** | $**499420363** |
| <u><u>**Liabilities and Stockholders' Deficit**</u></u>  |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 1428 | 12822 |
| Non-current liabilities |  |  |
| **Total Liabilities** | $**1428** | $**12822** |
| **Shareholder's Deficit** |  |  |
| Common stock, $0.00001 par value; 250,000,000 shares authorized,137,290,200 shares issued and outstanding as of December 31, 2024 | 1373 | 1108 |
| Preferred stock Series A, $0.001 par value;5,000 shares authorized, 10 shares issued and outstanding as of December 31, 2024 |  |  |
| Preferred stock Series B, $0.001 par value; 19,998,675 shares authorized, 19,999,375 shares issued and outstanding as of December 31, 2024, | 2000 | 2000 |
| Additional paid-in capital | 504163629 | 504173122 |
| Accumulated deficit | (4767928) | (4768689) |
| **Total Stockholders' Deficit** | $**499399073** | $**499407541** |
| **Total Liabilities and Stockholders' Deficit** | $**499400501** | $**499420363** |

---

The accompanying notes are an integral part of these financial statements.

![](cscorp_logo.jpg)

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF OPERATIONS** |
| **FOR THE PERIOD ENDED December 31, 2024** |

---

---

| | | |
|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2023** |
| Revenue | 110911 | 126038 |
| **Revenue** | $**110910.60** | $**126038.00** |
| *Operating Expenses* |  |  |
| Professional Fee | 109755 | 54026 |
| General & Administrative Expenses | 395 | 94009 |
| Total Operating expenses | 110150 | 148035 |
| **Income/(loss) from Operations** | $**761** | $**(21997)** |
| Other Income / (Expense) |  |  |
| Debt Written off |  |  |
| Net Income / (loss) | $761 | $(21997) |
| Basic and diluted loss per share | 0.00 | 0.00 |
| **basic and diluted loss weighted average shares** | **137290200** | **110790200** |

---

*The accompanying notes are an integral part of these financial statements.*

 

 

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF STOCKHOLDERS (DEFICIT)** |
| **FOR THE PERIOD ENDED December 31, 2024** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Preferred Stock B** | <br>**Preferred Stock B** | <br>**Common Stock** | <br>**Common Stock** | <br>**Additional** | <br>**Accumulated** | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Paid-in Capital** | **Deficit** | **Total** |
| Balance, January 1, 2023 | 20000000 | $2000 | 135287214 | $1352 | $4712037 | $(4746692) | $(31303) |
| Reversed Stock Split |  |  | (134497014) | $(1344) |  |  | $(1344) |
| Shares Issued in acquisition of Assets |  |  | 110000000 | $1100 | $499461085 |  | $499462185 |
| Net income (loss) for the year |  |  |  |  |  | $(21997) | $(21997) |
| **Balance, December 31, 2023** | **20000000** | $**2000** | **110790200** | $**1108** | $**504173122** | $**(**4768689**)** | $**499407541** |
| Balance, January 1, 2024 | 20000000 | $2000 | 110790200 | $1018 | $504173122 | $(4798689) | $499407451 |
| Shares Issued/Converted | (1325) | $0 | 26500000 | $355 | $(9493) |  | $(9138) |
| Net income (loss) for the period ended September 30, 2024 |  |  |  |  |  | $761 | $761 |
| Shares Issued in acquisition of Assets |  |  |  |  |  |  |  |
| **Balance, December 31, 2024** | **19998675** | $**2000** | **137290200** | $**1373** | $**504163629** | **(4767928)** | $**499339073** |

---

*The accompanying notes are an integral part of these financial statemen ts.*

 

 

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF CASH FLOWS** |
| **FOR THE PERIOD ENDED December 31, 2024** |

---

---

| | | |
|:---|:---|:---|
|  | <br>**December 31, 2024** | <br>**December 31, 2023** |
| **Cash flows from operating activities** |  |  |
| Net profit/ (loss) | 761 | (21997) |
| Adjustment to reconcile net loss to net cash used in operating activities | Adjustment to reconcile net loss to net cash used in operating activities | Adjustment to reconcile net loss to net cash used in operating activities |
| Changes in assets and liabilities |  |  |
| Other Receivables | 8842 |  |
| Account payables | 1428 | 31285 |
| **Net cash used in operating activities** | $**11030** | $**9288** |
| **Cash flows from investing activities** |  |  |
| Intangible Asset | (499444401) | (499444401) |
| **Net cash provided by Investing activities** | $**(499444401)** | $**(499444401)** |
| **Cash flows from financing activities** |  |  |
| Additional Capital Paid Up | 499444401 | 499422309 |
| Loan forgiven |  |  |
| **Net cash provided by financing activities** | $**499444401.00** | $**499422309.00** |
| Net increase /(decrease) in cash | 11030 | (12804) |
| Cash beginning of period | 0 | 12804 |
| **Cash end of period** | $**11030** | $**0** |

---

*The accompanying notes are an integral part of these financial statements.*

 

 

**C S DIAGNOSTICS CORP**

**Notes to the Financial Statements<br> December 31, 2024, and December 31, 2023**

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

**CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology.**

On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200.

On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel- based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*<u>Basis of Presentation</u>*

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

*<u>Use of Estimates</u>*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

![](cscorp_logo.jpg)

*<u>Concentrations of Credit Risk</u>*

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.

*<u>Cash and Cash Equivalents</u>*

The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023

*<u>Fair Value of Financial Instruments</u>*

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below:

Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates.

Level 3: Level 3 inputs are unobservable inputs.

The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values.

The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates.

*<u>Income Taxes</u>*

We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

![](cscorp_logo.jpg)

We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

*<u>Net income (loss) per common share</u>*

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended March 31, 2024 and 2023, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company

*<u>Recent Accounting Pronouncements</u>*

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 - GOING CONCERN**

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,760,125) at March 31, 2024. The continuation of the Company as a going concern through March 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

**NOTE 4 – INCOME TAXES**

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

![](cscorp_logo.jpg)

Net deferred tax assets consist of the following components as of:

---

| | | |
|:---|:---|:---|
|  | **December**<br> **31, 2024** | **December**<br> **31, 2023** |
| **Federal income tax benefit attributable to:** |  |  |
| **Current Operations** | $— | $— |
| **Less: valuation allowance** |  |  |
| **Net provision for Federal income taxes** | $— | $— |

---

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following:

---

| | | |
|:---|:---|:---|
|  | **December**<br> **31, 2024** | **December**<br> **31, 2023** |
| **Deferred tax asset attributable to:** |  |  |
| **Net operating loss carryover** | $— | $— |
| **Less: valuation allowance** |  |  |
| **Net deferred tax asset** | $— | $— |

---

At September 30, 2024, the Company had net operating loss carry forwards of approximately $(4,759,589) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the June 30, 2024, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015.

**NOTE 5 – SUBSEQUENT EVENTS**

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

## Exhibit 99.1

**Exhibit 99.1**

![](cscorp_logo.jpg)

CS DIAGNOSTICS CORP.

**State of Incorporation:** Wyoming<br> **I.R.S. Employer Identification No.:** 20-1290331<br> **Principal Executive Offices:** <br> 1603 Capitol Avenue, Suite 413, Cheyenne, WY 82001, USA

+1 (307) 395 7333

www.csdcorp.us

info@csdcorp.us

**Securities to be registered pursuant to Section 12(b):** None<br> **Securities to be registered pursuant to Section 12(g):** Common Stock, $0.00001 par value

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **FORWARD-LOOKING STATEMENTS** | **4** |
| **Business** | **4** |
| &nbsp;&nbsp;&nbsp;Overview | 4 |
| &nbsp;&nbsp;&nbsp;Corporate History | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *Reverse Merger* | *5* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Affiliated Companies* | *6* |
| &nbsp;&nbsp;&nbsp; Products | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*CS Protect-Hydrogel* | *7* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*MEDUSA (Long-Acting Disinfectant)* | *9* |
| &nbsp;&nbsp;&nbsp;Plan of Operations | 11 |
| &nbsp;&nbsp;&nbsp;Leased Offices | 11 |
| **RISK FACTORS** | **11** |
| &nbsp;&nbsp;&nbsp;Risks Related to the Company | 11 |
| &nbsp;&nbsp;&nbsp; Risks Related to Company's Business and Operations | 15 |
| &nbsp;&nbsp;&nbsp;Risks Related to being a Publicly Traded Company | 21 |
| &nbsp;&nbsp;&nbsp; Risks Related to the Industry | 24 |
| &nbsp;&nbsp;&nbsp; Additional Risks | 24 |
| **SECURITY OWNERSHIP** | **25** |
| &nbsp;&nbsp;&nbsp;Beneficial Owners and Management | 25 |
| **DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE** | **27** |
| &nbsp;&nbsp;&nbsp;Directors and Officers | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Thomas Fahrhoefer, 55* | *27* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Mohammad EsSayed, 47* | *27* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Sabrina Kummer Godehardt, 45* | *27* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Janel Luzana, 41* | *28* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Mahmoud A. Al-Sayyed, 54* | *28* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Dr. Ralf Herwig, 60* | *28* |
| &nbsp;&nbsp;&nbsp;Executive Compensation | 28 |
| &nbsp;&nbsp;&nbsp;Limitation of Liability and Indemnification | 29 |
| &nbsp;&nbsp;&nbsp;Stock and Stock Option Issuances in 2023 and 2024 | 30 |
| &nbsp;&nbsp;&nbsp;Related Party Transactions | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *License Agreements* | *31* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *Common Ownership and Control* | *32* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *Administrative Resources* | *32* |
| **DESCRIPTION OF CAPITAL STOCK** | **32** |
| &nbsp;&nbsp;&nbsp;Common Stock | 32 |
| &nbsp;&nbsp;&nbsp;Preferred Stock | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Series A Preferred Stock* | *32* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Series B Preferred Stock* | *33* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Series C Preferred Stock* | *33* |

---

2 www.csdcorp.us

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;Recent Issuances of Securities | 34 |
| **CAPITALIZATION** | **35** |
| **Management's Discussion and Analysis of Financial Condition and Results of Operation (MD&A)** | **36** |
| &nbsp;&nbsp;&nbsp;Overview and Business Summary | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Market Risk and Sensitivity Analysis* | *36* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Qualitative Discussion of Market Risk* | *37* |
| &nbsp;&nbsp;&nbsp;Results of Operations | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Fiscal Year 2024 Compared to 2023* | *37* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Revenues* | *38* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Operating Expenses* | *38* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Net Income* | *38* |
| &nbsp;&nbsp;&nbsp;Liquidity and Capital Resources | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Capital Structure and Cash Position* | *38* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Cash Burn and Going Concern* | *39* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Financing Plans* | *39* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Capital Expenditures and Requirements* | *39* |
| &nbsp;&nbsp;&nbsp;Critical Accounting Estimates and Judgments | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Intangible Asset: CS Protect-Hydrogel Valuation* | *41* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Intangible Asset: MEDUSA Valuation* | *41* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Other areas of significant accounting judgment include:* | *42* |
| &nbsp;&nbsp;&nbsp;Known Trends, Events, and Uncertainties | 43 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Regulatory Approval and Commercialization Timeline* | *43* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Product Launch and Manufacturing* | *43* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Market Adoption and Competition4* | *44* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Commercial Potential vs. Risks* | *44* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Diversification and Other Products* | *44* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Management and Organizational Changes* | *45* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Macroeconomic and Market Conditions* | *45* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Manufacturing, Suppliers, and Supply Chain Risks* | *46* |
| &nbsp;&nbsp;&nbsp;Conclusion | 46 |
| &nbsp;&nbsp;&nbsp;Going forward |  |
| **LEGAL PROCEEDINGS** | **46** |
| **SIGNATURES** | **47** |
| **INDEX TO FINANCIAL STATEMENTS** | **48** |

---

3 www.csdcorp.us

**FORWARD-LOOKING STATEMENTS**

This Form 10 contains certain statements that discuss future expectations, contain projections of results of operations or financial condition or state other "forward-looking" information. The words "believe," "expect," "anticipate," "intend," "estimate," "may," "should," "could," "will," "plan," "future," "continue," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, the actual results could differ materially from these forward-looking statements. This registration statement, including the information contained in the Business, Risk Factors, and MD&A sections, has been prepared under the supervision of the Company's officers and directors, each of whom has reviewed and approved its contents.

**Business**

**Overview**

CS Diagnostics Corp. ("CS Diagnostics," "CSDX," or the "Company") is a medical technology and distribution company focused on developing and commercializing therapeutic and preventive solutions aimed at improving patient care and outcomes.

The Company is part of the CS Group, an international healthcare group with affiliated operations in Europe, the Middle East, and the United States. The CS Group consists of CS Diagnostics Pharma GmbH ("CS Pharma"), an entity organized in Germany; CS Interpharm General Trading Co. LLC ("CS Interpharm"), an entity organized in Dubai, United Arab Emirates; CS Diagnostics Corp. ("CSDX"), an entity organized in Wyoming, United States; and CS Istanbul Saglik Ticaret A.S. ("CSI Turkey"), an entity organized in Turkey (collectively, "CS Group").

CS Pharma has operated since 2006 as a wholesaler of MRI and radiology consumables—such as syringes, tubes, and injectors—and maintains established customer and supplier relationships within the German market. CS Interpharm, founded in 2013, engages in the general trade of MRI and radiology consumables and owns the MEDUSA disinfectant product line marketed throughout the Middle East. CS Pharma and CS Interpharm collectively hold equity interests in CSDX, reflecting CS Group's integrated cross-border structure.

The Company benefits from this affiliation with CS Group through shared technical expertise and knowledge of comparative regulatory experience to support the Company's commercialization of its two licensed products—CS Protect-Hydrogel and MEDUSA—in the United States.

CSDX possess the exclusive rights to develop, seek approval for, and commercialize CS Protect-Hydrogel ("Hydrogel") within the United States, a degradable hydrogel designed to act as a protective spacer during radiation therapy. The Hydrogel is intended to reduce radiation exposure to surrounding healthy tissue and may have potential applications across multiple cancer types. The underlying patent for the Hydrogel is held by DWI – Leibniz-Institut für Interaktive Materialien e.V. ("DWI"). DWI and CS Diagnostics Pharma GmbH ("CS Diagnostics Pharma") entered into a license agreement granting CS Diagnostics Pharma the exclusive right to use and commercialize the Hydrogel technology. Pursuant to a subsequent agreement, CS Diagnostics Pharma granted CSDX exclusive rights and a license to use, exploit, seek regulatory clearances and commercialize the Hydrogel within the United States. CS Diagnostics Pharma later on was dissolved. Following the dissolution of CS Diagnostics Pharma, all of its rights under the exclusive license agreement with DWI were transferred to CSDX. As a result, CSDX succeeded to CS Diagnostics Pharma's position as the exclusive licensee of the Hydrogel technology and now holds the full economic and commercial rights associated with the development, regulatory advancement, and commercialization of the Hydrogel product within the United States. Although the underlying Hydrogel patents remain owned by DWI, CSDX now possesses the exclusive U.S. commercialization rights and the corresponding commercial value derived from that license.

4 www.csdcorp.us

MEDUSA is a proprietary long-acting surface disinfectant product that provides extended antimicrobial protection on treated surfaces. CS Interpharm General Trading Co. LLC ("CS Interpharm"), an affiliate of CSDX, fully owns MEDUSA and currently manufactures (through third party vendors) and distributes MEDUSA in Europe and the Middle East. CS Interpharm grants CSDX an exclusive right and license to use, exploit, seek regulatory clearances and commercialize MEDUSA within the United States.

Looking ahead, the Company's near-term objective is to secure the necessary regulatory clearances in the United States for both Hydrogel and MEDUSA and to commence full commercial distribution of these products within its licensed territories. The Company expects that successful regulatory authorization and commercialization would enable it to generate operating revenues from product sales and expand its presence in the U.S. healthcare market. The Company is not presently a direct party to any revenue-generating or other commercially material agreements with universities, hospitals, or other medical partners referenced in prior group-level communications. Should such agreements become material to the Company's business or financial condition in the future, they will be publicly disclosed in accordance with applicable regulatory requirements.

CS Diagnostic Corp. is currently listed on the US OTCQB Markets under the trading symbol "CSDX", (OTCQB- CSDX).

**Corporate History**

The Company was originally incorporated in the State of Nevada on September 25, 1996 under the name DWC Installations, Inc. ("DWC Installations"). Following the Plan of Reorganization entered with The Children's Internet, Inc., which closed on July 3, 2002, the Company subsequently changed its name to The Children's Internet, Inc. On October 20, 2010, to the Company reincorporated in the State of Wyoming, and on February 15, 2015, the Company changed its name to FlashZero Corp. ("Flashzero").

 **Reverse Merger** 

On April 4, 2022, following the execution of a Securities Purchase Agreement between FlashZero and La pharm GmbH, a German entity ("La pharm"),, FlashZero ceased its prior operations. Thereafter, La pharm continued the business under a new structure and name, CS Diagnostics Corp., reflecting a transformation of the Company's business model toward medical technology and distribution. On August 3, 2023, the Company changed its name to CS Diagnostics Corp..

Following the execution of the Securities Purchase Agreement between FlashZero and La pharm in April 4, 2022, th following shares were distributed to the Company's affiliates:

&nbsp;&nbsp;&nbsp;&nbsp;· CS Interpharm received
 15,000,000 common shares;

&nbsp;&nbsp;&nbsp;&nbsp;· CS Pharma received
 60,352,000 common shares, 10 Series A Preferred shares, and 9,989,000 Series B Preferred
 shares;

&nbsp;&nbsp;&nbsp;&nbsp;· Euro Gus Group
 received 20,000,000 common shares; and

&nbsp;&nbsp;&nbsp;&nbsp;· La pharm received
 15,000,000 common shares.

5 www.csdcorp.us

Subsequently, La pharm merged into CS Pharma, as the surviving entity. As a result of the merger, La pharm ceased to exist as a separate legal entity. For updated and detailed information regarding current share ownership and capital structure, see "Security Ownership of Certain Beneficial Owners and Management" and "Description of Capital Stock."

 **Affiliated Companies** 

CS Diagnostics is a member of the "CS Group," an international healthcare group with operations in Europe and Middle East. The members of CS Group are as follows (collectively, "CS Group"):

&nbsp;&nbsp;&nbsp;&nbsp;· CS Diagnostics
 Pharma GmbH ("CS Pharma"), an entity organized in Germany;

&nbsp;&nbsp;&nbsp;&nbsp;· CS Interpharm General
 Trading Co. LLC ("CS Interpharm"), an entity organized in Dubai, United Arab
 Emirates;

&nbsp;&nbsp;&nbsp;&nbsp;· CS Diagnostics
 Corp. ("Company" or "CSDX"), an entity organized in Wyoming, United
 States; and

&nbsp;&nbsp;&nbsp;&nbsp;· CS Istanbul Saglik
 Ticaret A.S. ("CSI Turkey"), an entity organized in Turkey.

![](g11142541012ga2_ex991pg6a.jpg)

CS Pharma, based in Germany, has owned, manufactured, and distributed magnetic resonance imaging (MRI) radiology products and related medical devices since 2006 throughout Europe and the Middle East.. CS Pharma previously served as the exclusive distributor of the first-generation SpaceOAR® hydrogel spacer in Germany and Austria pursuant to an Exclusive International Distribution Agreement with Augmenix, Inc. dated June 15, 2011. Augmenix was later acquired by Boston Scientific, which subsequently terminated the distribution agreement. During the term of that agreement, CS Pharma was contractually restricted from marketing or selling competing products in the designated territory. These restrictions did not survive the termination of the agreement, and no ongoing obligations remain in effect for CS Pharma, the Company, or any of its affiliates.

CS Pharma currently holds a majority of the Company's outstanding Common Stock, as well as all of the issued and outstanding Series A Preferred Stock and a majority of the Series B Preferred Stock. Each of these securities carries voting rights and, collectively, provides CS Pharma with majority voting power in the Company. See Description of Capital Stock and Capitalization. The ultimate beneficial owner of CS Pharma is our President and Chief Executive Officer, Mr. Thomas Fahrhoefer. For illustration purposes, our beneficial ownership chart is as follows:

![](g11142541012ga2_ex991pg6b.jpg)

6 www.csdcorp.us

CS Interpharm, based in Dubai, United Arab Emirates, has operated since 2013 as a general trading company focused on MRI and radiology consumables and is also the owner of the MEDUSA disinfectant product line. While the Company draws on the experience of its affiliates and industry experts, it is not currently party to any material agreements with universities or medical partners.

The Company currently has a licensing agreement in place with CS Interpharm General Trading Co. LLC, granting the exclusive rights to distribute one of our products, MEDUSA. See Related Party Transactions for additional information regarding this agreement.

 **Products** 

The Company does not currently manufacture or market any proprietary products. The Company intends to conduct its business primarily through the licensing and commercialization of products developed, licensed, and, or owned by its affiliated entities within the CS Group. These include, among others, (i) Hydrogel, a specialty gel formulation used in radiology and imaging applications, and (ii) MEDUSA, a disinfectant product line marketed in the Middle East by CS Interpharm. The Company has existing license agreement with its affiliates granting CSDX the rights to market, distribute, and further develop the Hydrogel and MEDUSA products in the United States. The implementation of these licenses and related commercialization activities remains subject to applicable regulatory approvals and licensing requirements in the United States.

**CS Protect-Hydrogel**

This product is a tissue spacer gel for use in radiation therapy, designed to separate healthy tissue from malignant tissue during treatment. Hydrogel is an injectable "organ spacer" initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. CS Pharma was previously the European distributor for the first-generation spacer (SpaceOAR®) and has leveraged that experience to develop Hydrogel as a second-generation spacer with significant improvements, unlike the incumbent product (now marketed by Boston Scientific Corporation after its $500 million acquisition of Augmenix, Inc. in 2018). CS Pharma is no longer the distributor for SpaceOAR since Boston Scientific's acquisition of Augmenix. Therefore, SpaceOAR is now a competing product of Hydrogel since it no longer distributes SpaceOAR.

Hydrogel is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. This improves hygiene and ease of use, eliminating a potential contamination step and simplifying application. Moreover, Hydrogel's molecular structure and properties enable it to be used in multiple cancer types beyond prostate cancer – e.g. cervical, esophageal, bladder, and breast cancer – whereas the competitor's spacer gel is approved exclusively for prostate use. Management believes these unique advantages (broader applicability, improved safety and convenience) give Hydrogel a strong unique selling proposition (USP) in the tissue space market. Management believes that Hydrogel, if successfully approved by the applicable regulatory authorities, may have potential advantages in usability and applicability across multiple cancer types. However, there can be no assurance that regulatory approval will be obtained in a timely manner, or at all, or that the product will achieve market acceptance. The commercial launch will entail significant costs for clinical trials, regulatory approvals, and marketing efforts in each target jurisdiction. On March 2025 the company announced the appointment of a dedicated employee to pursue an FDA approval for the Hydrogel. Completion of these trials and studies does not necessarily mean that Hydrogel will receive FDA approval.

**<u>Unique Selling Proposition (USP) of CS Protect Hydrogel</u>**

It is the belief of management that Hydrogel is a more advanced hydrogel both from the molecular structure, chemical physical properties and medical applications. The molecular structure of SpaceOAR predominately consists of water and polyethylene glycol (PEG).

7 www.csdcorp.us

Hydrogel has the following practical, hygienic, medical and economic advantages:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Hydrogel is supplied in a "ready-to-use" format, allowing
 immediate application upon removal from its sterile packaging. This eliminates additional
 preparation or assembly steps, reduces the risk of contamination risk of contamination, and
 avoids introducing another hygenic risk area within the treatment environment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Based on management's internal cost modeling, Hydrogel is expected
 to be manufactured at a lower unit cost than current market alternatives (such as SpaceOAR®),
 providing flexibility in pricing strategy once regulatory clearance is obtained. The Company
 has not yet commercialized Hydrogel, and these estimates are based on internal production
 data and comparisons to publicly available market pricing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. No risk of wrong mixture (especially wrong sequence) and therefore no potential patient's missed appointment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Extended application range; besides prostate cancer also for cervical, esophageal, bladder and breast cancer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Lower personnel costs during treatment due to the elimination of assistance for mixing the hydrogel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. Lower room utilization costs per patient as there is no longer a risk of patients having to be treated again due to incorrect mixtures
(higher number of patients per treatment room) lower cleaning costs due to the ready-to-use principle.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. Fewer lawsuits and/or insurance claims due to incorrectly mixed hydrogels requiring the patient to be treated again.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. Lower purchase price as for the competitor product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. The molecular structure of CS Protect-Hydrogel enables adjustment
 of its solid-state duration before dissolution by body fluids. This variability allows the
 hydrogel to be adapted for different radiation therapy regimens, which vary in session number
 and duration across cancer types.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. The Company expects that the U.S. Food and Drug Administration (FDA)
 will classify CS Protect-Hydrogel as a Class II medical device, subject to clearance through
 the 510(k) premarket notification process.

 **<u>Laboratory Studies</u>** 

Between 2020 and 2023, Hydrogel underwent molecular development and stability testing (in vitro) and animal testing (in vivo) at the Technical University of Aachen and the DWI Leibniz Institute in Germany. These studies were sponsored by CS Diagnostics Pharma. Human clinical testing has not yet been conducted and will only proceed if required by regulatory authorities. The studies demonstrated that, unlike first-generation hydrogels requiring complex assembly in the operating room, Hydrogel is designed as a ready-to-use formulation. This characteristic may reduce the risks of assembly errors, minimize procedure time, and limit contamination risk. The molecular flexibility of the formulation may also allow use across multiple cancer types. However, these results are limited to laboratory and animal studies, and no assurance can be given that regulatory approval will be obtained or that these characteristics will translate into clinical outcomes.

**<u>Regulatory Matters and Compliance</u>**

Hydrogel is a medical device and requires registration or approval by the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA or the German Federal Institute for Drugs and Medical Devices (BfArM) after CE testing and certification in Germany. Registration or approval is preceded by a testing procedure. The Company has engaged Lachman Consultants to advise on the preparation of this submission. The process generally includes: (i) identification of a legally marketed predicate device; (ii) preparation of draft labeling and instructions for use; (iii) submission of technical comparisons to the predicate device; and (iv) completion of required bench, biocompatibility, and performance testing. In addition, approval by BfArM under the European Medical Device Regulation will be required for marketing in Germany and other European jurisdictions. The Company notes that separate regulatory approvals may be required for each specific cancer indication for which marketing authorization is sought. No human clinical studies have been initiated to date; such studies will be conducted only if requested by the relevant regulatory authorities. Management has been advised by its regulatory consultants that the general timeline for FDA clearance of Hydrogel in the United States may range from approximately 6 to 12 months and, in Germany, approximately 6 to 8 months for testing procedures and registration with BfArM. These estimates are based on standard review periods and are subject to significant uncertainty. Actual timing may differ materially, and there can be no assurance that approval will be obtained within these timeframes, or at all. See Risks—Related to Regulatory Approval and Management's Discussion and Analysis—Regulatory Approval and Commercialization Timeline.

8 www.csdcorp.us

 **<u>Intellectual Property (Patent) Registration</u>** 

An international patent application has been filed under the Patent Cooperation Treaty ("PCT") for DWI - Leibniz-Institut Für Interaktive Materialien E.V., with the World Intellectual Property Organization ("WIPO"), Application No. PCT/EP2024/058243, filed in the European Patent Office ("EPO") as receiving office, on March 27, 2024. The application was published by WIPO as WO2024/200506. The underlying Hydrogel concept and formulation were originally developed and invented by Mr. Thomas Fahrhoefer, who subsequently collaborated with DWI to advance the technology. The patent application was prepared and filed by the Company's outside patent counsel, Paul & Albrecht, on behalf of the patent owner. The application relates to degradable hydrogel technology intended for use as a spacer in radiotherapy. If granted, national and regional phase entries would provide potential patent protection in multiple jurisdictions, with a maximum term of 20 years from the filing date.

CS Pharma has entered into an exclusive licensing agreement with DWI granting CS Pharma full rights and authority to use, manufacture, and commercialize the Hydrogel product. Pursuant to a separate agreement between CS Pharma and CSDX, CS Pharma has granted CSDX the exclusive rights to market, distribute, and further develop Hydrogel within the United States and other designated territories. The effectiveness of CSDX's licensing rights remains subject to applicable regulatory clearances and product registration requirements in the United States, where commercialization is planned.

**MEDUSA (Long-Acting Disinfectant)**

MEDUSA is a proprietary surface disinfectant product developed by CS Interpharm that is designed to provide extended antimicrobial protection. Laboratory studies conducted at independent facilities in Europe and the Middle East indicate that MEDUSA forms a polymer film on treated surfaces that retains measurable antimicrobial activity for up to ten days after application, whereas alcohol-based disinfectants typically remain active for only minutes.

The presence of MEDUSA on a treated surface can be verified by color-changing test strips that react with the residual polymer film. A visible color change confirms that the disinfectant coating remains in place, although these strips do not measure microbial counts directly. Because MEDUSA adheres to surfaces, its antimicrobial effect has been observed to persist even when surfaces come into contact with organic material such as dust or skin oils, unlike many alcohol-based disinfectants that lose effectiveness under such conditions.

While laboratory testing has demonstrated a reduction in microbial activity compared to controls, these findings are limited to in vitro studies. MEDUSA has not yet received regulatory approval in the United States, and there can be no assurance that laboratory results will be confirmed in commercial use or that regulatory approvals will be obtained in a timely manner, or at all. The Company intends to pursue registration with the EPA, which requires extensive chemistry, toxicology, and environmental data.

 **<u>Laboratory Studies</u>** 

Laboratory studies of MEDUSA have been conducted at METS UAE Laboratory, the Fraunhofer Institute Testing Laboratory, and an independent Bacteria and Fungi Testing Laboratory in Germany. These studies were sponsored by CS Pharma and CS Interpharm. The studies compared MEDUSA to alcohol-based disinfectants, which typically demonstrate 8–15 minutes of effectiveness. No human testing has been conducted.

9 www.csdcorp.us

To evaluate MEDUSA's disinfectant activity after ten days of surface application, sterilized metal test surfaces were sprayed with MEDUSA perpendicularly from a distance of approximately 20 cm (one pump per application). Control surfaces were sprayed with phosphate-buffered saline (PBS<sup>1</sup>) only. All test surfaces were stored under sterile conditions at room temperature for ten days. After this period, 50 μL<sup>2</sup> of test organisms were applied to the surfaces and incubated at room temperature for 15 minutes. A 1 mL neutralizing solution was then added to stop the activity of MEDUSA. The disinfectant effect was assessed by measuring the reduction in colony-forming units (CFU) for bacteria and fungi or plaque-forming units (PFU) for viruses, compared to untreated controls. A ≥ 5 log reduction<sup>3</sup> for bacteria or a ≥ 4 log reduction<sup>3</sup> for viruses and yeasts/fungi was considered a positive effect.

After 10 days the test solutions of MEDUSA conferred a strong, limited virucidal (ability to kill or inactivate viruses) effect to the surface, demonstrating a greater than 6-log reduction<sup>3</sup> in PFU of Phi-6<sup>4</sup>. A slight reduction in CFU for gram-positive bacteria, gram-negative bacteria and yeasts/fungi was noted. While the necessary log reductions<sup>3</sup> to denote bactericidal (able to kill bacteria) or yeasticidal (able to kill yeast, which is a type of fungus, like the one that causes yeast infections or makes bread rise) properties were not obtained, a mild reduction was observable, nonetheless. While these results suggest MEDUSA may offer longer-lasting disinfection than standard alcohol-based products, there can be no assurance that future regulatory reviews or commercialization will confirm these outcomes.

After 10 days on the surface, MEDUSA retained strongly virucidal properties against an enveloped virus<sup>5</sup>, Phi-6<sup>4</sup>.

MEDUSA is fully authorized for sale in the European markets and in the United Arab Emirates, with manufacturing facilities located in UAE, Turkey, and United Kingdom. In June 2025, the Company initiated discussions with an EPA-registered agent to be gain knowledge on pursuing marketing for MEDUSA within the US market.

 **<u>Regulatory Matters</u>** 

The Company is preparing a submission of its disinfectant product, MEDUSA, to the EPA. This process will involve registration of Polyquat DMA/E 50 as a new active ingredient for non-food contact uses with residual antimicrobial activity, together with applications for end-use products incorporating this active ingredient. The EPA review process requires extensive chemistry, toxicology, ecotoxicology, and environmental fate data.

The Company has a tentative engagement agreement with Technology Sciences Group Inc. (dba Sagentia Regulatory) ("Sagentia") to support EPA regulatory strategy. Following FDA clearance of Hydrogel, the Company intends to evaluate the commercial and regulatory pathways for MEDUSA and, if appropriate, proceed with a formal engagement under this agreement for Sagentia to advise on EPA submissions and compliance requirements.

MEDUSA is expected to be regulated under the Federal Insecticide, Fungicide, and Rodenticide Act ("FIFRA"), administered by the EPA. Before the product may be marketed in the United States, the Company must obtain EPA registration and ensure that all manufacturing facilities are registered as EPA establishments. Ongoing compliance with environmental regulations may require periodic reporting, product testing, and labeling review. Failure to comply with applicable EPA or state requirements could result in civil penalties, product recalls, or suspension of registration.

&nbsp;&nbsp;&nbsp;&nbsp;**__________________________________**

<sup>1</sup> Phosphate-Buffered Saline (PBS) – a salty water solution that matches the salt levels in the human body. Scientists use it to keep cells and viruses in a natural, stable condition during experiments.

<sup>2</sup> Symbol for microliter. 1 microliter = 1 millionth of a liter.

<sup>3</sup> "Log reduction" is a way scientists measure how much a treatment (like a disinfectant) reduces the number of germs. Each "log" means a tenfold (10 times) reduction in the number of germs. 1 log reduction = 90% fewer germs (10 times less). 2 log reduction = 99% fewer germs (100 times less). 5 log reduction = 99.999% fewer germs (102,510 times less). 6 log reduction = 99.9999% fewer germs (1,002,510 times less).

<sup>4</sup> A type of virus often used in lab experiments. Scientists like using it because it has a similar "envelope" (outer coating) to human viruses like flu or coronavirus, so it's a safe substitute to test disinfectants.

<sup>5</sup> Some viruses have an extra outer coating (envelope) made of fat and proteins. This coating makes them more sensitive to disinfectants, because the envelope can be destroyed. Examples: flu virus, HIV, coronavirus are enveloped viruses.

10 www.csdcorp.us

 **Plan of Operations** 

Over the next 12 months, the Company plans to focus on obtaining the necessary regulatory clearances and establishing the operational framework required to commercialize the Hydrogel and MEDUSA product lines in the United States. This includes (i) coordinating with CS Pharma and CS Interpharm to complete product testing and documentation in support of FDA and related registrations, (ii) engaging qualified regulatory consultants and distributors to facilitate U.S. market entry, and (iii) initiating discussions with potential strategic partners, hospitals, and imaging centers for pilot distribution. During this period, the Company expects to incur expenses related primarily to regulatory compliance, professional services, and business development activities. The Company does not expect to generate material revenue until the required approvals are obtained and initial distribution agreements are in place.

For additional information regarding the Company's financial position and anticipated funding needs, see also "Capitalization" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."

**Leased Offices**

The Company does not directly lease an office space. The Company maintains a registered office for administrative and correspondence purposes located at 1603 Capitol Avenue, Suite 413, Cheyenne, Wyoming 82001, which serves as its principal executive office.

The Company does not own or operate any physical facilities. Certain administrative and operational functions may be supported by its affiliates, particularly CS Interpharm, which maintains leased offices in the ordinary course of business for the CS Group's international operations. CS Interpharm is the lessee under three offices that are used for general administrative purposes:

&nbsp;&nbsp;&nbsp;&nbsp;· City of Neuss in Germany (headquarter)

&nbsp;&nbsp;&nbsp;&nbsp;· City of Bruckmühl in Germany

&nbsp;&nbsp;&nbsp;&nbsp;· Dubai, United Arab Emirates

You can find more information about our business on our website at: http://csdcorp.us/

**RISK FACTORS**

 *Investing in our company's securities involves a high degree of risk. You should carefully consider and review the risks described below, together with all other information included or referred to in this report before purchasing our shares. There are also numerous risks and uncertainties that are not known to us as of the time of this report and we might not consider its significance, which could adversely affect our business, financial condition, or results of operations. In such event, the trading price of our common stock could decline and you may lose all or part of your investment.*

**Risks Related to the Company**

*We expect to incur operating losses and experience negative cash flow and it is uncertain whether we will achieve future profitability.*

11 www.csdcorp.us

We anticipate incurring operating losses until we generate sufficient revenue from our operations. Achieving profitability depends on our ability to ensure our products function as intended, gain market acceptance, and successfully develop and launch additional products and, or services. We cannot guarantee that we will generate sales or reach profitability. As a result, we cannot predict the extent of future losses or how long it may take to achieve profitability, if at all.

*We may need to raise additional funds to finance our capital requirements, which is dilutive to your investment.*

Our cash requirements may vary materially from those now planned depending on numerous factors, including the status of our marketing efforts, our business development activities, the results of future research and development, and competition. We may need to raise additional funds to finance our capital requirements through private or public financing before such point for a variety of reasons, including our inability to achieve more substantial revenue operations as we anticipated, and to achieve a profitable level of operations. Such financing could include equity issuances, which could dilute existing shareholders's share value, or debt financing, which may impose restrictions on our operations, including limitations on our ability to pursue acquisitions or incur additional indebtedness. In addition, such securities may contain rights, preferences or privileges senior to those of the rights of our current shareholders. There can be no assurance that additional funds will be available on terms attractive to us or at all. If adequate funds are not available, we may be required to delay or scale back our regulatory, marketing, and distribution activities, or otherwise materially reduce our operations. Any inability to raise adequate funds could have a material adverse effect on our business, results of operations, and financial condition.

*We may not be able to attain profitability without additional funding, which may be unavailable.*

We have limited capital resources. Unless we begin to generate sufficient revenues to finance operations as a going concern, the Company may experience liquidity and solvency problems. Such liquidity and solvency problems may force the Company to cease operations if additional financing is not available. No known alternative resources of funds are available in the event we do not generate sufficient funds from operations.

*Our lack of history makes evaluating our business difficult.*

We have a limited operating history and we may not sustain profitability in the future. In order to obtain and sustain profitability, we must:

- compete with larger, more established competitors;

- build, maintain, and enhance our portfolio of healthcare-related products as well as our overall brand recognition; and

- adapt to meet changes in our markets and competitive developments.

We may not be successful in accomplishing these objectives. Further, our lack of operating history makes it difficult to evaluate our business and prospects. Our prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development, particularly companies in highly competitive industries. The historical information in this report may not be indicative of our future financial condition and future performance.

12 www.csdcorp.us

 *Our Bylaws limit the liability of, and provide indemnification for, our officers and directors.*

Our Bylaws generally limit our officers' and directors' personal liability to the Company for breach of fiduciary duty except for breach of the duty of loyalty or acts or omissions not made in good faith or which involve intentional misconduct or a knowing violation of law. Our Bylaws provide indemnification for our officers and directors to the fullest extent authorized by the Wyoming Business Corporation Act against all expense, liability, and loss, including attorney's fees, judgments, fines excise taxes or penalties and amounts to be paid in settlement reasonably incurred or suffered by an officer or director in connection with any action, suit or proceeding, whether civil or criminal, administrative or investigative (hereinafter a "Proceeding") to which the officer or director is made a party or is threatened to be made a party, or in which the officer or director is involved by reason of the fact that he is or was an officer or director of the Company, or is or was serving at the request of the Company whether the basis of the Proceeding is an alleged action in an official capacity as an officer or director, or in any other capacity while serving as an officer or director. Thus, the Company may be prevented from recovering damages for certain alleged errors or omissions by the officers and directors for liabilities incurred in connection with their good faith acts for the Company. Such an indemnification payment might deplete the Company's assets. Shareholders who have questions regarding the fiduciary obligations of the officers and directors of the Company should consult with independent legal counsel. It is the position of the Securities and Exchange Commission that exculpation from and indemnification for liabilities arising under the Securities Act of 1933, as amended, and the rules and regulations thereunder is against public policy and therefore unenforceable.

 *Our management and key decision-makers are located outside the United Staes, which may create operational and regulatory challenges.*<br>The Company's executive management and key decision-makers are located outside the United States. As a result, the Company's ability to effectively manage operations, maintain direct oversight of U.S. compliance matters, and respond promptly to regulatory or administrative issues may be affected by differences in time zones, business practices, and legal systems. In addition, because certain officers and directors reside outside the United States, it may be difficult or impossible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them. These factors could limit investors' legal recourse and create additional administrative or operational risks for the Company.

 *We rely on financial support from our affiliates, and the withdrawal or reduction of such support could adversely affect our operations.*

The Company currently relies on financial support from its affiliates within the CS Group to fund its operating expenses and regulatory activities. The Company does not yet generate revenue independently and may continue to depend on such affiliate funding until its commercial operations are established. There is no assurance that this financial support will continue at current levels or at all. If any affiliate were to reduce, delay, or discontinue its financial assistance, the Company may be unable to meet its obligations, pursue regulatory approvals, or execute its business plan. The loss or limitation of affiliate support could have a material adverse effect on the Company's business, results of operations, and financial condition.

 *Our internal controls and financial reporting procedures may not be adequate as we transition to becoming a public reporting company.*

CS Group has historically operated as a private entity with limited accounting and financial reporting personnel and procedures. As we transition to becoming a public reporting company, we are subject to additional regulatory, accounting, and reporting requirements under the Securities Exchange Act of 1934. Our existing internal controls, systems, and procedures may not be sufficient to ensure timely and accurate financial reporting or compliance with the requirements of the Sarbanes-Oxley Act of 2002. Establishing and maintaining effective internal controls will require significant time, resources, and management attention. If we are unable to design and implement effective controls and procedures, we may be unable to meet our reporting obligations, and our financial statements could contain material misstatements, which could adversely affect investor confidence and the market value of our securities.

13 www.csdcorp.us

*We depend heavily on key personnel, and turnover of key senior management could harm our business.*

Our future business and results of operations depend in significant part upon the continued contributions of our Chief Executive Officer. If we lose his services or if he fails to perform in his current position, or if we are not able to attract and retain skilled employees who are located within the United States, our business could suffer. A significant turnover in our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend on the skills and abilities of these key employees in managing the product development, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future.

 *The manufacturers, vendors, and suppliers of our licensed products contract directly with our affiliates, not with us, which could limit our control and expose us to operational and legal risks*.

The Company's licensed products, Hydrogel and MEDUSA, are manufactured, packaged, and supplied by third parties under contracts held by its affiliates within the CS Group. Because the Company is not a direct party to these agreements, it has limited ability to enforce the terms of such contracts or to ensure continued performance by the manufacturers, vendors, or suppliers. Any breach, nonrenewal, or modification of these contracts by our affiliates or their counterparties could disrupt the supply of our products, delay commercialization efforts, or increase costs.

In addition, the Company's reliance on affiliates to manage key supplier relationships may result in conflicts of interest or differing business priorities between the Company and its affiliates. If our affiliates fail to maintain good standing with these counterparties or experience operational or financial difficulties, our access to critical manufacturing and supply arrangements could be adversely affected. Any such disruption could materially harm our business, operating results, and financial condition.

 *Any product defect, contamination, or labeling non-compliance could result in recalls, regulatory sanctions, or litigation.*

The Company's licensed products, Hydrogel and MEDUSA, are subject to stringent quality control and labeling requirements under U.S. and foreign regulations, including oversight by the FDA, EPA, and corresponding international authorities. Any actual or perceived defect, contamination, or labeling error in these products could result in mandatory or voluntary recalls, import detentions, or enforcement actions by regulatory agencies. In addition, the Company or its affiliates could face product liability claims, customer disputes, or reputational harm arising from product performance or safety issues.

Because the Company relies on affiliates and third-party manufacturers for production and quality assurance, it has limited direct oversight of the manufacturing process. Failure by any of these parties to maintain compliance with applicable manufacturing or labeling standards could disrupt operations, result in costly corrective actions, and materially and adversely affect the Company's business, results of operations, and financial condition.

 *Our ability to deliver products depends on third-party shipping, logistics, and warehousing providers.*

The Company relies on third-party vendors for the storage, handling, and transportation of its products. Because the Company does not maintain its own distribution or warehousing facilities, any delay, disruption, or service failure by these providers could impair our ability to fulfill orders or meet customer expectations. Factors such as shipping delays, port congestion, customs clearance issues, labor shortages, or transportation cost increases could materially affect our delivery schedules and operating expenses.

In addition, these third-party providers are subject to their own operational, financial, and regulatory risks, which are beyond the Company's direct control. Any disruption in their operations—whether due to equipment failure, compliance issues, or financial distress—could result in lost sales, increased costs, or reputational harm. Such events could materially and adversely affect our business, results of operations, and financial condition.

14 www.csdcorp.us

 *Negative publicity involving our affiliates or products could harm market acceptance and sales.*

The Company's reputation and the commercial success of its products depend in part on the perception of its affiliates and their brands. Because Hydrogel and MEDUSA are licensed from affiliated companies, any negative publicity, regulatory action, or adverse event involving those affiliates—or the products themselves—could materially impact the Company's reputation and ability to attract customers. Allegations of product defects, regulatory noncompliance, or unethical business practices by affiliates, even if unfounded, may damage the credibility of the Company's products in the marketplace.

Public perception plays a significant role in the healthcare industry, where trust, safety, and brand reputation are critical to product adoption. Any adverse media coverage or reputational harm affecting our affiliates or products could reduce demand, result in the loss of customers or distribution partners, and have a material adverse effect on our business, results of operations, and financial condition.

 **Risks Related to Company's Business and Operations** 

 *Adverse economic or other conditions in the markets in which we operate could negatively affect demand for our products and overall operating results.*

Our operating results are dependent upon our ability to successfully commercialize and distribute our licensed products. If we are unable to generate sufficient revenues to meet our cash requirements—including operating expenses, regulatory costs, and working capital needs—our financial condition and results of operations could be materially and adversely affected.

The following factors, among others, may negatively impact our operating performance:

- overall national and global economic conditions, including inflation, supply chain disruptions, or changes in healthcare spending;

- delays or increased costs associated with regulatory approvals;

- changes in demand for diagnostic and medical consumable products or the introduction of competing technologies;

- reliance on third-party manufacturers and logistics providers located outside the United States;

- changes in government policies, import duties, or healthcare regulations;

- natural disasters, public health crises, or geopolitical events that disrupt supply chains or distribution; and

- changes in tax laws or trade policies that increase the cost of doing business.

 *Our future revenue and reputation may be affected by litigation or other liability claims.*

We have not procured a general liability insurance policy for our business. To the extent that we suffer a loss of a type which would normally be covered by general liability, we would incur significant expenses in defending any action against us and in paying any claims that result from a settlement or judgment against us. Adverse publicity could result in a loss of consumer confidence in our products.

 *We have limited marketing capability.*

We have limited marketing capabilities and resources. In order to achieve market penetration, we will have to undertake significant efforts and expenditures to create awareness of, and demand for, our licensed products. Our ability to penetrate the market and build our client base will be substantially dependent on our marketing efforts. Our failure to successfully develop our marketing capabilities, both internally and through third-party alliances, would have a material adverse effect on our business, operating results and financial condition. Further, there can be no assurance that, if developed, such marketing capabilities will lead to sales of our products and services.

15 www.csdcorp.us

 *Our investments in product research and development may not yield anticipated returns, which would harm our operating results and reduce the amount of funds available for distributions.*

A key component of our growth strategy is to remain open to exploring new and innovative healthcare supplies or medical consumable products through potential acquisitions, licensing arrangements, or joint ventures. As of the date of this filing, the Company has not entered into any definitive transactions or material agreements related to these initiatives. These opportunities, if pursued, are intended to complement the Company's current focus on oncology supportive care, infection control, and regulatory distribution services, which are presently conducted by the Company's affiliates in Europe and the MENA region, and not by the Company in the United States. However, our ability to identify, evaluate, and successfully integrate such opportunities is uncertain, and any such activities will be subject to significant risks, including:

&nbsp;&nbsp;&nbsp;&nbsp;· our inability to
 obtain financing for acquisitions or partnerships on acceptable terms, or at all; and, or

&nbsp;&nbsp;&nbsp;&nbsp;· competition from
 more established and better-capitalized healthcare-related companies.

 *Delays or denials in obtaining regulatory approvals from the FDA or EPA could materially affect our ability to commercialize our licensed products.*

Our business strategy depends on obtaining and maintaining regulatory approvals from the U.S. Food and Drug Administration ("FDA") and the Environmental Protection Agency ("EPA") for the Hydrogel and MEDUSA product lines before they can be imported, marketed, or sold in the United States. The approval process is often lengthy, costly, and unpredictable. Regulatory agencies may require additional data, impose new testing requirements, or delay approval due to factors outside of our control. If such approvals are delayed or not obtained, the Company's anticipated growth and financial performance could be materially affected. Even if approvals are obtained, they may be subject to limitations, ongoing compliance obligations, or post-market requirements that could increase costs or restrict marketing activities. Failure to obtain, maintain, or comply with regulatory approvals could have a material adverse effect on our business, results of operations, and financial condition.

 *If we fail to effectively manage operational growth as we expand our commercialization activities, our business and results of operations may be adversely affected.*

As the Company transitions from a development-stage enterprise to active commercialization of its licensed products, it will be required to expand its operational, financial, and compliance capabilities. Managing relationships with multiple affiliates, third-party manufacturers, logistics providers, and regulatory consultants will place increasing demands on our management and systems. If we fail to develop and maintain appropriate operational controls, quality assurance processes, and financial reporting systems, our ability to manage growth effectively may be impaired.

In addition, as the Company increases its reliance on external personnel and service providers, it must ensure effective coordination and oversight. Failure to do so could result in product delays, compliance issues, or reputational harm. Any inability to effectively manage these growing operational requirements could materially and adversely affect our business, financial condition, and results of operations.

 *We operate in both established and emerging markets, and demand for our products in these markets is uncertain.*

The Company intends to distribute and commercialize its licensed Hydrogel and MEDUSA products in both established and emerging markets. Although these products are currently approved and marketed in certain jurisdictions, the Company has limited experience in introducing and promoting them under its own brand or through new distribution channels. Market acceptance in each territory will depend on factors such as regulatory approval, pricing, distribution efficiency, and the willingness of healthcare providers to adopt new suppliers or formulations.

16 www.csdcorp.us

The Company's market research to date has been conducted primarily by internal personnel and through its affiliates, and the Company has limited data regarding potential sales volumes, pricing dynamics, or customer demand in the United States and other target markets. As a result, the Company cannot predict the rate or extent of market acceptance for its products.

In addition, both the diagnostic and disinfectant product markets are highly competitive and evolving, with frequent entry of new suppliers and technologies. If demand for our products fails to develop as anticipated, develops more slowly than expected, or if competing products gain greater market share, our business, operating results, and financial condition could be materially and adversely affected.

 *We depend on the reputation, relationships, and market presence of our affiliates to introduce our products into new markets.*

The Company's initial commercialization strategy relies heavily on the established reputation, customer relationships, and distribution networks of its affiliates within the CS Group, including CS Pharma and CS Interpharm. These affiliates have operated in the radiology and medical supply sectors for several years and maintain established supplier and customer relationships in Europe and the Middle East. The Company's ability to successfully introduce its products into new markets, including the United States, depends in part on leveraging these existing relationships.

If our affiliates experience operational difficulties, reputational issues, or changes in ownership or management, the Company's access to their distribution channels and expertise could be disrupted. In addition, there can be no assurance that our affiliates will continue to allocate resources or provide the same level of support to the Company in the future. Any such reduction in cooperation or reputational harm affecting our affiliates could materially and adversely impact our market entry, brand perception, and overall business performance.

 *Our reliance on affiliates and third parties located outside the United States subjects us to foreign operational, regulatory, and compliance risks.*

The Company depends on its affiliates and third-party partners located in Europe and the Middle East for the manufacturing, packaging, and shipment of its licensed products. As a result, the Company's operations are subject to the risks typically associated with conducting business internationally, including logistical challenges, currency fluctuations, supply chain disruptions, changes in import and export regulations, and the potential imposition of tariffs or trade restrictions.

In addition, the Company's affiliates and suppliers operate under foreign legal and regulatory frameworks that may differ significantly from those in the United States. The Company must ensure that its products are manufactured, labeled, and handled in compliance with both U.S. and foreign standards, including those imposed by the FDA, EPA, and corresponding international authorities. Any failure by an affiliate or supplier to comply with applicable laws or maintain required certifications could result in regulatory delays, product seizure, or reputational harm to the Company. These factors could materially and adversely affect the Company's business, results of operations, and financial condition.

 *We face significant competition from established companies with greater resources and market presence.*

The markets for diagnostic consumables and disinfectant products are highly competitive and characterized by the presence of large, well-capitalized companies with established brands, distribution networks, and customer relationships. Many of our potential competitors have substantially greater financial, technical, regulatory, and marketing resources than we do. These competitors may have existing relationships with hospitals, imaging centers, and distributors that could make market entry more difficult for us.

17 www.csdcorp.us

We also expect competition from new market entrants offering similar or substitute products, including lower-cost or private-label alternatives. Competitive pressures may result in pricing reductions, loss of market share, or reduced margins. While the Company believes its affiliation with the CS Group and its access to established product lines such as Hydrogel and MEDUSA provide competitive advantages, there can be no assurance that we will be able to achieve or maintain a meaningful market position. Increased competition or the introduction of new products by others could have a material adverse effect on our business, operating results, and financial condition.

 *Our affiliate's prior distribution of competing products, SpaceOAR, could indirectly expose us to litigation or reputational risks.*

One of the Company's affiliates previously distributed the SpaceOAR product, a first-generation hydrogel spacer used in radiology and related medical applications. The Company's licensed Hydrogel product represents a second-generation iteration of a similar technology, and both products may compete in certain markets. Although the Company was not directly involved in the sale or distribution of SpaceOAR, its affiliation with the prior distributor may expose it to indirect risks, including potential reputational harm or claims of commercial conflict arising from the distribution of competing products.

In addition, to the extent that litigation, product liability claims, or regulatory investigations were to arise from the distribution or promotion of SpaceOAR or similar products, the Company could be drawn into such proceedings through indemnification, contractual, or corporate affiliation theories. Any such matter could result in legal costs, management distraction, or reputational damage that could materially and adversely affect the Company's business and financial condition.

 *Our financial projections are based on assumptions that may not materialize and actual results may differ materially*

We have disclosed financial projections for MEDUSA, including potential revenues of approximately USD 80 million in 2025 and USD 460 million within three years. These projections are based on numerous assumptions, including estimated market size and growth, geographic penetration, pricing, gross margins, and customer usage patterns. The projections also assume that we will receive regulatory approvals, expand into multiple regions, and secure reliable manufacturing and distribution partners.

There can be no assurance that these assumptions will prove accurate. If regulatory approvals are delayed or denied, if our pricing or cost assumptions do not hold, if competitors achieve greater market penetration, or if customers adopt the product at lower levels than expected, our actual results could differ materially from the projections disclosed. Investors should not place undue reliance on our financial forecasts, which are inherently uncertain and should not be considered guarantees of future performance.

*We may be subject to regulatory inquiries, claims, suits and prosecutions which may impact on our profitability.*

Any failure or perceived failure by us to comply with applicable laws and regulations, in general, may subject us to regulatory inquiries, claims, suits and prosecutions. We can give no assurance that we will prevail in such regulatory inquiries, claims, suits and prosecutions on commercially reasonable terms or at all. Responding to, defending and/or settling regulatory inquiries, claims, suits and prosecutions may be time-consuming and divert management and financial resources or have other adverse effects on our business. A negative outcome in any of these proceedings may result in changes to or discontinuance of some of our services, potential liabilities or additional costs that could have a material adverse effect on our business, results of operations, financial condition and future prospects.

18 www.csdcorp.us

 *Failure to maintain adequate data privacy and information security measures could expose us to business disruptions or reputational harm.*

Although the Company does not currently collect or store large volumes of personal or patient data, it relies on electronic systems and third-party service providers to manage business, regulatory, and financial information. As the Company expands its operations, it may become subject to federal, state, and foreign laws governing data protection and cybersecurity. Any actual or perceived failure to safeguard proprietary or confidential information—including data shared with affiliates, healthcare customers, or vendors—could disrupt operations, damage the Company's reputation, or lead to regulatory inquiries and financial exposure.

The Company will continue to monitor evolving data privacy and security requirements, but it cannot guarantee that its systems or those of its service providers will be free from breach or unauthorized access. Any such event could have a material adverse effect on the Company's business and results of operations.

 *We rely on third parties for certain information technology and data management functions, and any breach or misuse of information could harm our business and reputation.*

The Company depends on third-party service providers and cloud-based systems to store, transmit, and manage business, financial, and regulatory information, as necessary. Although the Company does not collect or process consumer or patient data, it maintains confidential business information and may, in the future, process limited customer or supplier data as part of its distribution activities. If these systems or service providers were compromised, misused, or accessed without authorization—whether through a cybersecurity incident, employee error, or third-party failure—the Company could experience business interruptions, reputational damage, or potential legal exposure.

The Company relies on commercially available security, encryption, and authentication technologies; however, no system is completely secure. Advances in technology or new methods of intrusion could result in security breaches despite reasonable safeguards. The Company may be required to expend significant resources to prevent, detect, or remediate such incidents, and any failure to do so could materially and adversely affect its business, operations, or financial condition.

 *Disruptions in the global supply chain or geopolitical developments could adversely affect our ability to import and distribute Hydrogel and MEDUSA.*

The Company depends on affiliates and third-party manufacturers located in Europe and the Middle East for the production, packaging, and shipment of the Hydrogel and MEDUSA product lines. Any interruption in these supply chains—whether due to geopolitical instability, trade restrictions, transportation delays, raw material shortages, or regulatory changes—could adversely affect the availability, cost, and timely delivery of our products.

Political or economic developments in the regions where our affiliates operate, including sanctions, conflicts, or shifts in trade policy, could also disrupt manufacturing or logistics activities. In addition, changes in customs procedures, tariffs, or import/export regulations may increase costs or delay clearance of shipments into the United States. Any prolonged disruption in supply, manufacturing, or transportation could materially and adversely impact the Company's ability to commercialize its products, generate revenue, and achieve its business objectives.

 *We rely on a limited number of third-party manufacturers and suppliers, and any disruption could delay or prevent commercialization of our products*

We do not currently manufacture our products in-house and instead rely on third-party manufacturers and suppliers. For MEDUSA, production is conducted through our affiliates that have contracted with Turkuaz Factory (Europe) and Gulf Center Group (Middle East). Because our supply chain depends on a limited number of third-party manufacturers and suppliers, we are exposed to risks if any of these parties experiences regulatory, operational, or financial difficulties, or if our relationships with them are otherwise disrupted. Broader industry trends, such as supply chain shortages and cost inflation, may also affect the availability and cost of raw materials and sterile packaging. If we are unable to secure sufficient manufacturing capacity or obtain necessary supplies on acceptable terms, our commercialization timelines could be delayed, our costs could increase, and our business and financial condition could be materially and adversely affected.

19 www.csdcorp.us

 *Our ability to achieve a national exchange listing has been materially impacted by recent shareholder actions and related litigation*.

In early 2025, a minority shareholder disposed of a large volume of CSDX shares, contributing to a significant decline in our stock price from approximately $3-5 per share in late 2024 to sub-penny levels. This activity, and the resulting loss of market confidence, has impaired our relationships with potential investors and service providers, including broker-dealers, and has forced us to initiate litigation against the shareholder. While the outcome of this litigation is uncertain, the immediate impact has been to delay and potentially jeopardize our plans to meet the quantitative and qualitative requirements for listing on a national securities exchange. There can be no assurance that we will be able to restore investor confidence, achieve the necessary share price levels, or otherwise satisfy the listing criteria in the future.

 *Changes in tariffs, customs procedures, or import regulations could increase our costs and delay product availability.*

The Company's products are manufactured by third-parties located outside the United States and must be imported for U.S. distribution. As a result, the Company is subject to tariffs, import duties, and customs clearance requirements imposed by U.S. and foreign authorities. Changes in trade policy, import classification, or tariff schedules—whether due to new legislation, international trade disputes, or changes in enforcement priorities—could materially increase the cost of importing Hydrogel and MEDUSA into the United States.

In addition, delays or complications in customs clearance, changes in documentation requirements, or increased inspection activity could disrupt the Company's supply chain and postpone product delivery. Any such increase in import costs or delay in product availability could materially and adversely affect the Company's profit margins, operating results, and ability to meet market demand.

 *Our business depends entirely on two licensed products that we do not own, and both are subject to extensive regulatory oversight.*

The Company's current business operations are focused solely on the distribution and commercialization of two licensed products—Hydrogel and MEDUSA—which are owned and manufactured by affiliated entities. As a result, the Company's future revenue and growth prospects depend on the continued validity of these license agreements and the ability of its affiliates to maintain product quality, regulatory compliance, and production capacity. Because the Company does not own the underlying intellectual property or manufacturing facilities for these products, it has limited control over their development, pricing, or supply.

Both Hydrogel and MEDUSA are subject to extensive regulation by multiple authorities, including the U.S. FDA, the EPA, and foreign regulatory bodies. Any delay, suspension, or withdrawal of regulatory approvals—or any noncompliance by the Company or its affiliates—could restrict or prevent the sale of these products in one or more markets. The Company's reliance on a limited number of licensed products and its exposure to complex regulatory requirements heighten the risk that adverse events, compliance issues, or market changes could have a material adverse effect on its business, results of operations, and financial condition.

 *We do not own the intellectual property for our licensed products and could lose our rights if the underlying license agreements are breached or terminated.*

The Company's operations depend entirely on its rights under license agreements with affiliated entities that own the intellectual property for Hydrogel and MEDUSA. Because the Company does not own these intellectual property rights, its ability to market, distribute, or further develop the products is subject to the continuing validity and enforceability of those license agreements. If the Company or its affiliates were to breach any material term of the licenses, or if the agreements were terminated or not renewed, the Company could lose the rights necessary to commercialize its products.

20 www.csdcorp.us

In addition, the Company has limited ability to control or influence the actions of the licensors with respect to maintaining patent protection, regulatory approvals, or trade secrets. Any dispute with an affiliate or third-party licensor regarding ownership, scope, or performance under a license agreement could result in costly litigation or arbitration, delay commercialization efforts, or result in the loss of critical rights. The termination or impairment of the Company's license rights would have a material adverse effect on its business, results of operations, and financial condition.

*We may not maintain sufficient insurance coverage to protect against potential product liability claims or business interruption losses.*

The Company's operations expose it to potential risks, including product liability, regulatory enforcement, and business interruptions arising from supply chain delays, shipping incidents, or other unforeseen events. Although the Company intends to maintain insurance coverage customary for its industry, such coverage may not be adequate to cover all potential losses or liabilities. In addition, certain risks—such as regulatory actions, product recalls, or reputational harm—may not be insurable or may only be covered in part.

If the Company were subject to a significant product liability claim, litigation, or other event resulting in losses exceeding available coverage, it could incur substantial costs, divert management's attention, and experience a material adverse effect on its business, financial condition, and results of operations.

*A U.S. government shutdown or reduced federal agency operations could delay regulatory approvals and adversely affect our commercialization timeline.*

The Company's business depends on obtaining and maintaining regulatory approvals from U.S. government agencies, including the FDA and the EPA. In the event of a U.S. government shutdown, lapse in appropriations, or other disruption in federal agency operations, the review and approval of applications, import documentation, and other regulatory submissions could be delayed or suspended. Any such delay could postpone the commercialization of our licensed products, increase compliance costs, and negatively affect our ability to generate revenue according to planned timelines. Prolonged or repeated shutdowns could materially and adversely impact the Company's business, financial condition, and results of operations.

**Risks Related to being a Publicly Traded Company**

*Market Volatility*

The Company's common stock is publicly traded, and the market price of the stock may experience significant volatility due to various factors, including financial results, changes in the Company's business or industry, general market conditions, and economic trends. Such volatility may impact on the valuation of the Company and, indirectly, the value of the Shares.

*Potential Dilution* 

As a publicly traded company, the Company may issue additional shares of common or preferred stock in the future, which could dilute the interests of existing shareholders, including investors in the offered securities. Such dilution may result from financing activities, employee compensation plans, or strategic transactions.

21 www.csdcorp.us

*Dependence on Market Perception* 

The performance and valuation of the Company's publicly traded common stock may depend significantly on market perception and investor sentiment. Negative news, adverse developments, or unfavorable market conditions could harm the Company's reputation and adversely impact its financial condition and operations.

*Compliance with Public Company Reporting Obligations* 

As a publicly traded company, the Company is subject to periodic reporting and other disclosure requirements under applicable securities laws. Compliance with these obligations involves significant costs, and any failure to timely or accurately meet these requirements could result in regulatory penalties, reputational harm, and adverse impacts on the Company's financial performance.

*Insider Ownership and Control*

Our President and Chief Executive Officer, Mr. Thomas Fahrhoefer, is the ultimate beneficial owner of both CS Diagnostics Pharma GmbH and CS Interpharm General Trading Co. LLC, and holds a majority of our outstanding voting securities, including 66.90% of the outstanding common stock, 100% of the outstanding Series A Preferred Stock, and 68.31% of the outstanding Series B Preferred Stock. As a result, these insiders exercise significant control over all matters requiring shareholder approval, including the election of directors, approval of mergers or other business combinations, and other significant corporate actions. This concentration of ownership may:

&nbsp;&nbsp;&nbsp;&nbsp;· reduce the ability of minority shareholders to influence or approve corporate decisions;

&nbsp;&nbsp;&nbsp;&nbsp;· delay, defer, or prevent a change in control of the Company, even when such a transaction may be favorable to other shareholders;

&nbsp;&nbsp;&nbsp;&nbsp;· discourage potential acquirers from making a tender offer or pursuing other transactions; and

&nbsp;&nbsp;&nbsp;&nbsp;· permit our controlling shareholder to determine his own compensation and perquisites, which could reduce funds available for net income
or reinvestment in the business.

This concentration of ownership and voting power could conflict with the interests of our minority shareholders and may adversely affect the value of their investment.

*Risks of Delisting or Trading Suspension* 

The Company's common stock is listed on OTC Markets. If the Company fails to meet applicable listing or trading requirements, its stock could be delisted or suspended from trading, which could significantly impair its liquidity and value, as well as the Company's ability to raise capital.

*Litigation and Regulatory Risks* 

Publicly traded companies often face heightened risks of shareholder litigation, regulatory scrutiny, and enforcement actions. Such risks could result in significant legal costs, settlements, or damages and may adversely impact the Company's financial condition.

*Impact of Securities Laws on Resale of Shares* 

The Company's status as a publicly traded company may subject investors to certain legal and regulatory restrictions on the resale of the offered securities, particularly if the resale involves significant ownership stakes or affiliates of the Company.

*Disclosure of Material Non-Public Information* 

As a publicly traded company, the Company must carefully manage its disclosure obligations. Purchasers of the offered securities should be aware that they may, at times, have access to material non-public information that could restrict their ability to trade in the Company's publicly traded securities under applicable insider trading laws.

22 www.csdcorp.us

*We may, in the future, issue additional Shares which would reduce investors' percentage of ownership and may dilute our common membership unit value.*

Our Articles of Incorporation authorize the issuance of 4,000,000 shares of the Series C Preferred Stock. The issuance of Preferred Stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the units held by our investors and might have an adverse effect on any trading market for our common units.

*We are subject to compliance with securities law, which exposes us to potential liabilities, including potential rescission rights.*

We may offer to sell our securities to investors pursuant to certain exemptions from the registration requirements of the Securities Act of 1933, as well as those of various state securities laws. The basis for relying on such exemptions is factual; that is, the applicability of such exemptions depends upon our conduct and that of those persons contacting prospective investors and making the offering. We may not seek any legal opinion to the effect that any such offering would be exempt from registration under any federal or state law. Instead, we may elect to relay upon the operative facts as the basis for such exemption, including information provided by investors themselves. If any such offering did not qualify for such exemption, an investor would have the right to rescind its purchase of the securities if it so desired. It is possible that if an investor sought rescission, such investor would succeed. A similar situation prevails under state law in those states where the securities may be offered without registration in reliance on the partial preemption from the registration or qualification provisions of such state statutes under the National Securities Markets Improvement Act of 1996. If investors were successful in seeking rescission, we would face severe financial demands that could adversely affect our business and operations. Additionally, if we did not in fact qualify for the exemptions upon which we relied, we may become subject to significant fines and penalties imposed by the SEC and state securities agencies.

*There is no current established trading market for our Shares and if a trading market does not develop, purchasers of our securities may have difficulty selling their Shares.*

There is currently no established public trading market for our Shares and an active trading market in our Shares may not develop or, if developed, may not be sustained. No market makers have committed to becoming market makers for our Shares and none may do so in the future.

*Because we do not intend to pay any cash dividends on our Shares our members will not be able to receive a return on their Shares unless they sell them.*

We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our Shares in the foreseeable future. Unless we pay dividends, our members will not be able to receive a return on their Shares unless they sell them. There is no assurance that members will be able to sell Shares when desired.

*Our ability to meet the standards to be listed on a national exchange has been materially impacted by a recent shareholder action and related litigation.*

In early 2025, a minority shareholder disposed of a large volume of CSDX shares, contributing to a significant decline in our stock price from approximately $3.00 per share in late 2024 to sub-penny levels. This activity, and the resulting loss of market confidence, has impaired our relationships with potential investors and service providers, and has forced us to initiate litigation against the shareholder. While the outcome of this litigation is uncertain, the immediate impact has been to delay and jeopardize our plans to meet the quantitative and qualitative requirements for listing on a national securities exchange. There can be no assurance that we will be able to restore investor confidence, achieve the necessary share price levels, or otherwise satisfy the listing criteria in the near future.

23 www.csdcorp.us

 **Risks Related to the Industry** 

 *Competitive pricing pressures could reduce our margins and profitability.*

The markets for diagnostic and disinfectant products are price-sensitive and highly competitive. Larger, established companies often have greater purchasing power, distribution networks, and production efficiencies, enabling them to offer lower prices. To remain competitive, the Company may be required to reduce its pricing or increase marketing and promotional spending, which could reduce gross margins. Sustained pricing pressure, changes in customer purchasing behavior, or aggressive discounting by competitors could materially and adversely affect the Company's revenue, profitability, and financial condition.

 *Rapid technological change in the medical consumables industry could render our products less competitive or obsolete.*

The healthcare products industry is characterized by continuous innovation and the frequent introduction of new materials, devices, and technologies. The Company's licensed products, Hydrogel and MEDUSA, may face competition from newer or more effective alternatives developed by others. If the Company and its affiliates fail to keep pace with technological advancements or shifts in industry standards, customer demand for our products could decline. Any technological obsolescence or inability to adapt to market trends could materially and adversely affect our business and operating results.

 *Changes in healthcare regulations or reimbursement policies could reduce demand for our products.*

Healthcare providers' purchasing decisions are often influenced by reimbursement policies under government and private insurance programs. Changes in Medicare, Medicaid, or other reimbursement frameworks may alter the economics of using or purchasing diagnostic and disinfectant products. In addition, new regulations or procurement rules affecting hospitals and imaging centers could limit the adoption or approved uses of our products. Any such regulatory or reimbursement changes could reduce demand, constrain pricing flexibility, and adversely affect the Company's business and financial performance.

 *Public health crises or pandemics could disrupt our supply chains or affect product demand.*

Global health emergencies—such as pandemics, epidemics, or other public health crises—could disrupt manufacturing, logistics, and international trade, leading to supply shortages or shipping delays for our products. Such events may also shift healthcare system priorities, causing customers to delay or reduce purchases of diagnostic consumables. Additionally, public health crises can lead to travel restrictions, regulatory delays, and economic uncertainty that may affect both supply and demand. Any prolonged disruption resulting from such events could materially and adversely affect the Company's operations, revenue, and financial condition.

 **Additional Risks** 

The risks described above are not the only risks that may affect the Company. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also have a material adverse effect on our business, financial condition, results of operations, or the value of our securities. Investors should carefully consider all of the information in this Form 10, including the risk factors described herein, before making an investment decision.

24 www.csdcorp.us

**SECURITY OWNERSHIP**

**Beneficial Owners and Management**

The following table sets forth information with respect to the beneficial information of our Common Stock and Preferred Stock as of September 30, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;· Each person who we know to beneficially owns more than 5% of our outstanding voting securities (*i.e.* Common Stock, Series A
Preferred Stock, and Series B Preferred Stock),

&nbsp;&nbsp;&nbsp;&nbsp;· Each of our director and named executive officer, and

&nbsp;&nbsp;&nbsp;&nbsp;· All directors and executive officers as a group.

Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act and includes voting and/or investment power with respect to securities. Percentages are based on the following issued and outstanding stock of the Company as of September 30, 2025, see below. See also Risk Factors—Insider Ownership and Control, Description of Capital Stock, and Capitalization.

&nbsp;&nbsp;&nbsp;&nbsp;· Common Stock: 137,340,200 shares

&nbsp;&nbsp;&nbsp;&nbsp;· Series A Preferred: 10 shares

&nbsp;&nbsp;&nbsp;&nbsp;· Series B Preferred: 19,992,575 shares

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of <br> Officer/Director or <br> Control Person** | **Affiliation with <br> Company** | **Number <br> of shares <br> owned** | **Share <br> type/class** | **Ownership Percentage of** |
| **Name of <br> Officer/Director or <br> Control Person** | **(Officer/Director/Owner <br> of more than 5%)** | **Number <br> of shares <br> owned** | **Share <br> type/class** | **Class Outstanding** |
| Thomas Fahrhoefer | President | 91881896 | Common | 66.90% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CS Diagnostics Pharma GmbH | >5% | 74855800 | Common | 54.50% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CS Interpharm General Trading Co. LLC | > 5% | 17026096 | Common | 12.40% |
| Fast Balance CEDE & CO | >5% | 9075301 | Common | 6.61% |
| Thomas J Migotsch | Chief Operational Officer | 480000 | Common | 0.35% |
| Thomas Fahrhoefer | President | 10 | Preferred A | 100.00% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CS Diagnostics Pharma GmbH | >5% | 10 | Preferred A | 100.00% |
| Thomas Fahrhoefer | President | 13655206 | Preferred B | 68.31% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CS Diagnostics Pharma GmbH | >5% | 7924180 | Preferred B | 39.64% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CS Interpharm General Trading Co. LLC | > 5% | 5731026 | Preferred B | 28.67% |
| Association Continental de Reassurance NV | >5% | 1499625 | Preferred B | 7.50% |
| Thomas Graus | >5% | 1273737 | Preferred B | 6.40% |
| Antonio Santoli | >5% | 1273737 | Preferred B | 6.40% |
| All directors and executive officers as a group | All directors and executive officers as a group | 92361896 | Common | 67.25% |
| All directors and executive officers as a group | All directors and executive officers as a group | 13655206 | Preferred B | 68.31% |

---

 

25 www.csdcorp.us

Note: As of September 30, 2025, our President and Chief Executive Officer, Mr. Thomas Fahrhoefer, beneficially owns 66.90% of our outstanding common stock, 100% of our outstanding Series A Preferred Stock, and approximately 68.31% of our outstanding Series B Preferred Stock. Because the Series A Preferred Stock carries super-voting rights and the Series B Preferred Stock votes on a one-for-one basis with our common stock, Mr. Fahrhoefer effectively controls all matters submitted to a vote of our shareholders. This concentration of ownership allows him to exercise significant influence over the election of directors, approval of mergers and acquisitions, amendments to our charter documents, and other significant corporate matters.

![](g11142541012ga2_ex991pg26.jpg)

As a result, Mr. Fahrhoefer's control may limit the ability of minority shareholders to influence corporate decisions, and may delay, defer, or prevent a change in control of the Company. See Risk Factors, Description of Capital Stock, and Capitalization.

26 www.csdcorp.us

**DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE**

**Directors and Officers**

The following table identifies the individuals appointed by our Board of Directors to serve as the Company's directors and executive officers. The Company does not currently have any employees; instead, these individuals serve in their respective officer roles pursuant to appointments by the Board and also hold officer and/or director positions within an affiliated company. Our directors were elected by majority written consent of the stockholders in lieu of a shareholders' meeting. Directors serve one-year terms and until their successors are duly elected and qualified. Officers are appointed by the Board of Directors, and their terms of office are subject to the discretion of the Board.

---

| | |
|:---|:---|
| Name | Position |
| Thomas Fahrhoefer | President, Chief Executive Officer, & Chairman of the Board of Directors |
| Mohammad EsSayed | Vice President, Chief Financial Officer, & Director |
| Sabrina Kummer Godehardt | Business Development, & Director |
| Janel Luzana | Corporate Secretary |
| Mahmoud A. Al-Sayyed | Independent Director |
| Dr. Ralf Herwig | Independent Director |

---

 **Thomas Fahrhoefer, 55** 

Mr. Fahrhoefer is the founder of the CS Diagnostics Group and an expert in pharmaceutical distribution and healthcare business development. After studies in medicine and pharmacy, he built a career in pharmaceutical sales and management, including roles at Pfizer Germany (2001–2003) and Sanochemia AG (in the diagnostics business unit). In 2009, Mr. Fahrhoefer founded CS Diagnostics Pharma GmbH in Germany, growing it into the current CS Group comprising CS Diagnostics Pharma GmbH, CS Interpharm LLC, and CS Diagnostics Corp. Under his leadership, the Company is pursuing innovative solutions for example, without limitation, the Hydrogel. Mr. Fahrhoefer has been the President and a Director of the Company since the change-in-control in April 2022, and he also serves as the Chairman of the Board.

 **Mohammad EsSayed, 47** 

Mr. EsSayed has over 22 years of professional experience in finance, banking, and executive management. He holds multiple finance degrees and certifications, including an MBA in International Corporate Banking and the CFA (Chartered Financial Analyst) designation. Prior to joining CS Diagnostics, Mr. EsSayed served as CFO and Managing Director for other companies, and he has a strong background in financial planning, corporate finance, and governance. CS Diagnostics benefits from his extensive financial management experience. He was appointed as CFO and Vice President of the Company in 2022. In this capacity, Mr. EsSayed manages the Company's financial strategy, accounting and reporting, and investor relations functions.

 **Sabrina Kummer Godehardt, 45** 

Ms. Godehardt is a certified office communication clerk with over 15 years of experience in medical administration and practice management. She worked as practice manager in a radiology and nuclear medicine clinic from 2015 to 2024, with additional responsibility for IT systems. Since June 2024, she serves as Head of Sales Coordination at CS Pharma. She holds IHK certifications in practice and marketing management and is proficient in MS Office, Lexware, Picture Archiving and Communication Systems ("PACS") and Radiology Information Systems ("RIS") systems, and various administrative tools.

27 www.csdcorp.us

An IHK certification refers to credentials or documentation issued by the German Chamber of Industry and Commerce (Industrie- und Handelskammer) confirming compliance with applicable trade, training, or quality standards in Germany.

PACS and RIS platforms are widely adopted imaging management systems used by hospitals and diagnostic centers to capture, store, and manage medical images and patient data.

 **Janel Luzana, 41** 

Ms. Luzana serves as the Company's Corporate Secretary, responsible for corporate records, compliance with corporate governance requirements, and assisting the executive team on legal/administrative matters. She joined the Board as part of the 2022 reorganization. Ms. Luzana's professional biography is not elaborated in the available disclosure, but she is identified as the Corporate Secretary in official filings.

 **Mahmoud A. Al-Sayyed, 54** 

Mahmoud A. Al-Sayyed is a senior executive nearly three decades of experience in investment advisory, corporate strategy, and governance. His background includes expertise in initial public offerings, mergers and acquisitions, business valuation, and financial modeling. He has held various leadership and board positions, bringing a wealth of management and oversight experience. He is a recipient of the Best 100 Arab CEOs Award and the Professional Excellence Award, recognizing his leadership impact and contributions to business excellence in the region. Mr. Al-Sayyed's career highlights include developing corporate strategies, executing performance management programs, and serving on supervisory boards and board committees in an advisory capacity. He joined CS Diagnostics as an independent Board member to provide guidance on corporate finance, strategy, and compliance.

 **Dr. Ralf Herwig, 60** 

Dr. Herwig is a board-certified physician since 1995 with a doctorate in medicine (magna cum laude) from and habilitation in urology. He received his medical degree Münster/Westfalia, Germany and Dublin, Ireland (Royal College of Surgeons in Ireland, Coomb Hospital, James Conolly Memorial Hospital). He holds professorial titles and serves as President of both the Austrian Andrological Society and the International Autism Association (2025). Dr. Herwig is a certified urologist by the German Medical Association and is a member of several professional organizations, including the German Society of Urology and the European Association of Urology. His expertise spans urology, andrology, minimally invasive surgery, molecular biology, and sexual medicine, supported by extensive scientific training and over a dozen memberships in international medical societies. He is Editor-in-Chief of multiple scientific journals and has received several prestigious awards for his research.

**Executive Compensation**

On July 18<sup>th</sup> 2024, a shareholder resolution was issued for changes in CSDX board of directors as follows:

Mr. Thomas Migotsch as well as the previous independent director Dr. Lauren Kate Ugur were replaced by Ms. Sabrina K. Godehardt as Director of Business Development, and Dr. Ralf Herwig as independent director.

On August 9<sup>th</sup> 2024, a shareholder resolution was issued for changes in CSDX board of directors as follows: Mr. Thomas Migotsch and Mr. Thomas Graus ("Mr. Graus") as well as the previous independent directors Mrs. Csilla Kanderka and Mrs. Delia-Alexandra Kreutner were replaced by Mr. Mohammad EsSayed as VP, Director and CFO, Dr. Ralf Herwig and Mr. Mahmoud Ahmad Hashim AL-Sayed take on their role as independent directors, and Ms. Janel Luzana as an Officer and Company Secretary.

28 www.csdcorp.us

Mr. Thomas Graus ("Mr. Graus") entered into a compensation agreement with the Company for services rendered from March 28, 2022 through August 9, 2024. Under the terms of the agreement, Mr. Graus was entitled to receive compensation of €72,000 by December 31, 2024, which was expressly conditioned upon the Company receiving capital from investors on or before that date. Because the Company did not receive such capital, the €72,000 payment was not earned and was not paid to Mr. Graus. The Company and Mr. Graus have agreed to meet by end of this fiscal year, 2025, to discuss, in good faith, whether an alternative payment arrangement is appropriate.

Officer:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and <br> principal <br> position** | **Fiscal <br> Year** | **Salary <br> ($)** | **Bonus <br> ($)** | **Stock <br> Awards <br> ($)** | **Option <br> Awards <br> ($)** | **Non-<br> equity <br> incentive <br> plan <br> compensation** | **Non-<br> qualified <br> deferred <br> compensation <br> earnings** | **All other <br> compensation** | **Total <br> ($)** |
| Thomas Fahrhoefer | 2025 | - | - | - | - | - | - | - | - |
| Mohammad EsSayed | 2025 | - | - | - | - | - | - | - | - |
| Sabrina Kummer Godehardt | 2025 | - | - | - | - | - | - | - | - |
| Janel Luzana | 2025 | - | - | - | - | - | - | - | - |

---

Directors:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and <br> principal <br> position** | **Fees earned or <br> paid in cash($)** | **Stock <br> Awards <br> ($)** | **Option <br> awards <br> ($)** | **Non-equity incentive <br> plan compensation** | **Non-qualified deferred <br> compensation earnings** | **All other <br> compensation** | **Total <br> ($)** |
| Thomas Fahrhoefer | - | - | - | - | - | - | - |
| Mohammad EsSayed | - | - | - | - | - | - | - |
| Sabrina Kummer Godehardt | - | - | - | - | - | - | - |
| Janel Luzana | - | - | - | - | - | - | - |
| Mahmoud A. Al-Sayyed | - | - | - | - | - | - | - |
| Dr. Ralf Herwig | - | - | - | - | - | - | - |

---

**Limitation of Liability and Indemnification**

The Wyoming Business Corporation Act (the "WBCA"), under which the Company is organized, permits the inclusion in a corporation's Bylaws of a provision limiting or eliminating the personal monetary liability of directors to a corporation or its stockholders for breaches of their fiduciary duty as directors. Such a provision may not limit or eliminate the liability of a director for: (i) acts or omissions that involve intentional misconduct, fraud, or a knowing violation of law; (ii) transactions from which the director derives an improper personal benefit; (iii) unlawful distributions under the WBCA; or (iv) breaches of the duty of loyalty to the corporation or its stockholders. Accordingly, any limitations permitted by the WBCA applies only to the "duty of care" of directors protecting them from personal liability for unintentional errors in judgment made in good faith.

29 www.csdcorp.us

The Company's Bylaws include a provision eliminating the personal monetary liability of directors to the fullest extent permitted by Wyoming law. As a result, stockholders may bring monetary claims against a director only for conduct involving disloyalty, bad faith, intentional misconduct, knowing violations of law, improper personal benefit, or unlawful distributions, and not for negligence or gross negligence in the performance of their duties of care. The WBCA limitation applies only to actions brought against a person in their capacity as a director and does not extend to any actions brought against such person in another capacity, including as an officer, or under other applicable laws such as the federal securities laws.

In addition, the Company's Bylaws provides that the Company will indemnify its directors, officers, employees and other agents to the fullest extent permitted by Wyoming law. This indemnification includes reimbursement for expenses incurred in defending any proceeding to which such persons are made a party by reason of their service to the Company, provided they acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the Company.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, or controlling persons of the Company pursuant to the foregoing provisions, the Company has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event a claim for indemnification against such liabilities (other than payment of expenses incurred in the successful defense of any action) is asserted by a director, officer, or controlling person, the Company will, unless the matter has been settled by controlling precedent, submit the question to a court of appropriate jurisdiction for a determination of whether such indemnification is against public policy, and will abide by the final adjudication of such issue.

As of the date of this filing, there is no pending litigation or proceeding involving any director, officer, employee or agent of the Company for which indemnification is being sought, and the Company is not aware of any pending or threatened litigation that may result in such a claim. The Company may also maintain directors' and officers' liability insurance ("D&O insurance") to provide additional protection for its directors and officers against certain liabilities, subject to the terms and limitations of such policies.

**Stock and Stock Option Issuances in 2023 and 2024**

The following table details all stock and stock option issuances made to Company officers and directors during fiscal years 2023 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **<u>Date</u>** | **<u>Securities</u>** | **<u>Class of <br> Securities</u>** | **<u>Amount <br> Per Share</u>** | **<u>Issued To</u>** | **<u>Purpose</u>** | **<u>Exemption</u>** |
| 08/01/23 | (134974014) | Common | $0.0001 | All Shareholders | Reverse Split: 1 for 100,000 and forward split 1 to 200 | 4(a)(2) |
| 09/27/23 | 65000000 | Common | $4.54 | CS Diagnostics Pharma GmbH (1) | Asset Purchase Agreement | 4(a)(2) |
| 09/27/23 | 20000000 | Common | $4.54 | CS Interpharm LLC (2) | Asset Purchase Agreement | 4(a)(2) |

---

<u>Notes:</u>

1. The beneficial owner is the Company's Chief Executive Officer, President and Director Thomas Fahrhoefer

2. The beneficial owner is the Company's Chief Executive Officer, President and Director Thomas Fahrhoefer

30 www.csdcorp.us

**Related Party Transactions**

 **License Agreements** 

 **<u>Hydrogel License Agreement</u>** 

The Hydrogel product, titled "Space-Gel; Spacer Hydrogel for Organ Shielding During Radiation Treatment of Prostate Carcinoma" (DWI file reference: DW-LD015), was developed by the DWI Leibniz Institute for Interactive Materials, Department of Advanced Materials for Biomedicine ("DWI"), through its inventors Mr. Andreas Krüger, Prof. Dr.-Ing. Laura de Laporte, and Dr. Jens Köhler. DWI is the sole holder of the intellectual property rights and related patent applications covering the Hydrogel product.

On March 21, 2024, DWI, represented by RWTH Innovation GmbH, entered into an exclusive license agreement with CS Diagnostics Pharma GmbH ("CS Pharma"), granting CS Pharma the exclusive right to manufacture, market, sublicense, and commercialize products based on the Hydrogel product for use in prostate cancer applications. Under the agreement, CS Pharma is authorized to grant sublicenses with DWI's consent and is responsible for maintaining the licensed intellectual property and obtaining the necessary regulatory approvals for commercialization.

CSDX acquired all of the assets of CS Pharma, including all rights, title, and interests CS Pharma held in the Hydrogel product line. As a result of this acquisition, CSDX now holds all exclusive rights to market, distribute, and further develop Hydrogel in the United States and all other territories previously covered by CS Pharma's licenses. DWI remains the ultimate patent holder, and CSDX's exclusive rights to Hydrogel are derived from the rights transferred through the asset acquisition.

 **<u>MEDUSA License Agreement</u>** 

The MEDUSA product line was originally developed, formulated, and invented solely by Mr. Thomas Fahrhoefer, the Company's President and Chief Executive Officer. Mr. Fahrhoefer personally funded the development of MEDUSA and subsequently entered into a partnership with an individual who represented that he had the experience and capabilities to support the product's commercialization. The partnership did not succeed as anticipated and was later terminated. Following the termination of that relationship, CS Interpharm General Trading Co. LLC ("CS Interpharm"), an entity wholly owned and controlled by Mr. Fahrhoefer, entered into a binding purchase agreement on August 7, 2024 to acquire full ownership of the MEDUSA product line from the former partner.

Following this acquisition, on January 2, 2025, CS Interpharm entered into an exclusive license agreement with CS Diagnostics Corp. ("CSDX"), granting CSDX the exclusive rights to market, distribute, and commercialize MEDUSA within the United States and other designated territories. As a result, CS Interpharm remains the sole owner of the MEDUSA intellectual property, while CSDX holds the exclusive commercialization rights in the United States pursuant to the license agreement.

31 www.csdcorp.us

 **Common Ownership and Control** 

Mr. Thomas Fahrhoefer, the Company's President, Chief Executive Officer, and controlling stockholder, is also the ultimate beneficial owner of CS Pharma and CS Interpharm, which are parties to the Company's product license agreements. As a result, these entities are considered related parties.

 **Administrative Resources** 

The Company's principal executive office is located in Cheyenne, Wyoming. Certain administrative functions, including operations, IT, and record-keeping support, are performed using resources shared with affiliates under informal arrangements without formal lease or cost allocation agreements.

**DESCRIPTION OF CAPITAL STOCK**

**Common Stock**

The Company is authorized to issue up to 250,000,000 Shares of Common Stock, $0.00001 par value per share, of which 137,340,200 are issued and outstanding. Holders of our common stock are entitled to one vote for each share in the election of directors and on all matters submitted to a vote of stockholders. There is no cumulative voting in the election of directors.

The holders of the common stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore.

Upon the liquidation, dissolution or winding up of the Company, the remaining assets of the Company available for distribution to stockholders will be distributed among the holders of Common Stock, pro rata based on the number of Shares of common stock held by each.

Holders of common stock generally have no preemptive, subscription, redemption or conversion rights. The outstanding Notes of common stock are, when issued, fully paid and nonassessable.

As of September 30, 2025, we have 317 shareholders of record, and our outstanding common shares is 137,340,200.

**Preferred Stock**

The Company is authorized to issue up to 25,000,000 shares of Preferred Stock, par value $0.00001 per share, of which 19,992,585 shares are issued and outstanding. The Company has created three (3) classes of preferred stock with distinct rights and privileges.

**Series A Preferred Stock**

The Company is authorized to issue up to 1,000,000 shares of Series A Preferred Stock, par value $0.00001 per share, of which 10 shares are issued and outstanding. The holder of the Series A Preferred Stock are entitled to vote pari passu with holders of the Company's common stock on the following basis: four times the sum of (a) the total number of shares of common stock which are issued and outstanding together with; (b) the total number of shares of any other series of preferred stock which are issued and outstanding.

The holders of the Series A Preferred Stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore. The Series A Preferred Stock is designated as "Super Voting Stock" and carries no conversion rights. Holders of Series A Preferred Stock do not have the right to convert their shares into shares of common stock or any other class of the Company's securities.

32 www.csdcorp.us

The holder of the Series A Preferred Stock holds a dividend preference over the Series B Preferred Stock and common stock of the Company.

Upon liquidation, the holders of the Series A Preferred Stock are entitled to receive an amount equal to the sum of (a) the original issue price of the Series A Preferred Stock multiplied by; (b) the number of shares of Series A Preferred Stock owned by such holder upon liquidation, as adjusted for any for any recapitalizations. This right is senior to any other class of securities of the Company.

**Series B Preferred Stock**

The Company is authorized to issue up to 20,000,000 shares of Series B Preferred Stock, par value $0.00001 per share, of which 19,992,575 shares are issued and outstanding. Holders of the Series B Preferred Stock are entitled to convert each share of stock into 20,000 shares of the Company's common stock, with the limitation of no greater than 9.90% of the total issued and outstanding common stock of the Company.

The holder of the Series B Preferred Stock are entitled to vote pari passu with holders of the Company's common stock on a one-to-one basis.

The holders of the Series B Preferred Stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore. The holder of the Series B Preferred Stock holds a hold a dividend preference junior in right to that of the Series A Preferred Stock and Series C Preferred Stock but senior in right to the common stock of the Company.

Upon an event of liquidation, the holders of the Series B Preferred Stock are entitled to receive, to the extent available, an amount equal to $1.00 per share (or $0.997 per share for aggregate subscriptions exceeding $100,000), as adjusted for any stock dividends, splits, combinations and capitalization, plus all declared but unpaid dividends. After payment of this preference amount in full, any remaining distributable assets shall be distributed ratably among the holders of the Company's common stock.

**Series C Preferred Stock**

The Company is authorized to issue up to 4,000,000 shares of Series C Preferred Stock, par value $0.00001 per share, with a stated value of $1,000 per share ("Stated Value"), of which zero (0) shares are issued and outstanding. The Series C Preferred Stock does not carry any voting rights.

Holders of the Series C Preferred stock are entitled to receive an annual dividend in the amount of 6.5% per annum, payable semi-annually, in arrears, on each February 1st and August 1st, respectively, of each year. All unpaid dividends shall accrue. Dividends shall be paid in cash to the extent funds are legally available for such payment. The Series C Preferred Stock carries a dividend preference over all other classes of securities of the Company.

The holders of the Series C Preferred Stock shall have the right to convert their shares into Common Stock at a price equal to 90% of the thirty (30)-day average ask price of the Common Stock as quoted on any national securities exchange where the Company's securities are listed or traded, calculated as of the date the conversion notice is delivered to the Company. After three (3) years of issuance of Series C Preferred Stock, the Company may compel redemption in whole or in part, at its option, at an amount equal to the Stated Value.

Upon an event of liquidation, the holders of the Series C Preferred Stock are entitled to receive, to the extent available, an amount equal to the Stated Value together with any accrued but unpaid dividends. The Series C Preferred Stock carries a liquidation preference over the common stockholder of the Company, although subordinate to stockholders of Series A and B Preferred Stock.

33 www.csdcorp.us

**Recent Issuances of Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Date of <br> Transaction | Transaction <br> Type <br> (*e.g.* new <br> issuance, <br> cancellation, shares <br> returned <br> to <br> treasury) | Number <br> of Shares <br> Issued (or <br> cancelled) | Class <br> of <br> Securities | Value <br> of <br> Shares <br> Issued <br> ($/per <br> share) <br> at <br> Issuance | Were <br> the <br> shares <br> issued <br> at a <br> discount to <br> market <br> price at <br> the <br> time of <br> issuance <br> (Yes/No) | Individual/Entity <br> Shares <br> were issued to <br> (entities must <br> have <br> individual <br> with <br> voting/investment <br> control <br> disclosed) | Reason for <br> share <br> issuance <br> (*e.g.* for <br> cash or <br> debt <br> conversion) <br> - OR- <br> Nature of <br> Services <br> Provided | Restricted <br> or <br> Unrestricted <br> as of <br> this <br> filing. | Exemption or <br> Registration <br> Type |
| 05-09-2022 | Issuance | 10011000 | Preferred Series B | 1000 | No | Patientrac Limited<sup>1</sup> | Pursuant to the Securities<br> Purchase<br> Agreement for services<br> rendered, *e.g.*<br> acquisition costs,<br> payments and organization reinstatements | Restricted | 4(a)(2) |
| 08-01-2023 | Corporate Action Reverse split 1 to 100,000 and Forward Split 1 to 200 | -134497014 | Common | 0.00001 | No | Corporate Action all Shareholders | Same | Restricted and Unrestricted | 4(a)(2) |
| 09-27-2023 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Issuance<br>| 65000000 | Common | $4.54 | No | CS Diagnostics Pharma GmbH<sup>2</sup> | Asset Purchase Agreement | Restricted | 4(a)(2) |
| 09-27-2023 | Issuance<br>| 20000000 | Common | $4.54 | No | CS Interpharm LLC<sup>2</sup> | Asset Purchase Agreement | Restricted | 4(a)(2) |

---

<u>Note</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares
in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and
on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The beneficial owner of both CS Diagnostics Pharma GmbH and CS Interpharm LLC is Thomas Fahrhoefer, Dubai, UAE.

34 www.csdcorp.us

**CAPITALIZATION**

---

| |
|:---|
| **CS DIAGNOSTICS CORP. CSDX** |
| **BALANCE SHEET** |
| **FOR THE PERIOD ENDED SEPTEMBER 30 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** <br>**(Unaudited)**  | **December 31, 2024** <br>**(Audited)**  |
| *Assets* |  |  |
| **Current Assets** |  |  |
| Cash | 13 | 501 |
| Other Receivables | 31000 |  |
| **Total Current Assets** | $**31013** | $**501** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499431013** | $**499400501** |
| **Liabilities and Stockholders' Deficit** |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 1609 | 1428 |
| Non-current liabilities |  |  |
| **Total Liabilities** | $**1609** | $**1428** |
| **Shareholder's Equity / (Deficit)** |  |  |
| Common stock, $0.00001 par value; 250,000,000 shares authorized,137,340,200 shares issued and outstanding as of September 30, 2025 | 1373 | 1373 |
| Preferred stock Series A, $0.00001 par value;1,000,000 shares authorized, 10 shares issued and outstanding as of September 30, 2025 |  |  |
| Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of September 30, 2025 | 2000 | 2000 |
| Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2025 | 40 |  |
| Additional paid-in capital | 504161838 | 504163629 |
| Accumulated deficit | (4735847) | (4767928) |
| **Total Stockholders' Equity /(Deficit)** | $**499429404** | $**499399073** |
| **Total Liabilities and Stockholders' Equity /(Deficit)** | $**499431013** | $**499400501** |

---

35 www.csdcorp.us

**Management's Discussion and Analysis of Financial Condition and Results of Operation (MD&A)**

**Overview and Business Summary**

CSDX is a medical technology and distribution company focused on improving therapy outcomes in cancer treatment and reducing side effects for patients. The Company provides medical industry partners with access to international markets and regulatory approval services in Europe and the MENA region, while also developing its own innovative products.

In August 2023, CSDX underwent a corporate reorganization – changing its name from FlashZero Corp. to CS Diagnostics Corp. – and repositioned its business within the healthcare sector. A pivotal event was the licensing of the Hydrogel product in September 2024, when CSDX obtained the exclusive rights to market and commercialize the product its parent group. Hydrogel is a hydrogel-based tissue spacer used in radiation therapy to increase the distance between malignant tumors and healthy tissue, thereby protecting healthy tissue from high-dose radiation damage. This spacer is injected in liquid form into the space between cancerous and healthy tissues (e.g. between the prostate and rectum in prostate cancer), and it biodegrades after about six months. Importantly, Hydrogel is a sterile, "ready-to-use" product that can be applied directly without on-site preparation, and it is intended for use not only in prostate cancer radiotherapy but also in other cancer types such as cervical, esophageal, bladder, and breast cancers.

As of the end of 2024 and through the first quarter of 2025, the Company's primary focus has been advancing the Hydrogel toward commercialization and regulatory approval, while managing its financial position following its reorganization. The Company's common stock is quoted on the OTCQB market under the ticker "CSDX."

In January 2025, the Company obtained exclusive license of MEDUSA, a next-generation disinfectant product, to market and commercialize within the U.S. markets. MEDUSA is an advanced long-acting surface disinfectant that has received regulatory clearance in the EU and UAE and is currently pending regulatory approval in the United States. MEDUSA's commercialization is at an early stage, and its future market acceptance, sales levels, and regulatory outcomes remain uncertain.

Management has noted third-party industry reports estimating that the global disinfectant market exceeds USD 8 billion annually, including a 2024 estimate of approximately USD 8.4 billion from Persistence Market Research and a 2023 estimate of USD 8.6 billion from Allied Market Research. These figures are based on current market conditions and are highly dependent on data provider methodologies and definitions of market scope. There can be no assurance that the Company will capture any meaningful share of this market or achieve significant commercial success. We cannot give assurance on our ability to penetrate this market, the extent of any market share it may achieve, or the timing of such results. The inclusion of MEDUSA in the Company's product lineup reflects management's strategy to expand its operations by leveraging its experience with regulatory approvals and product distribution. Hydrogel remains the Company's lead product candidate and the central focus of its development activities. Management, under the supervision of the Company's executive officers and directors, has prepared this discussion and analysis to reflect the Company's current operations, strategy, and expectations.

 **Market Risk and Sensitivity Analysis** 

As a development-stage medical technology company, CSDX is exposed to limited but identifiable market risks arising primarily from its financing, international operations, and supply chain arrangements. The Company does not engage in speculative trading or hold derivative financial instruments. Its exposure to market risk currently arises from instruments and transactions entered into for purposes other than trading.

The Company does not currently have interest-bearing debt obligations. Cash balances are maintained in U.S. dollar-denominated accounts with major financial institutions and are subject to nominal interest rate risk. A hypothetical 100-basis-point change in prevailing interest rates would not materially affect the Company's results of operations or financial condition given its current cash position and lack of outstanding borrowings.

36 www.csdcorp.us

Because the Company's affiliates, suppliers, and licensors are located in Europe and the Middle East, the Company may be exposed to fluctuations between the U.S. dollar (USD), euro (EUR), and UAE dirham (AED). Currently, license fees and product costs are denominated primarily in euros. Based on the Company's 2024 intercompany and regulatory expenditures denominated in euros, a hypothetical 10% strengthening of the euro against the U.S. dollar would have increased total expenses by approximately $12,000, assuming comparable transaction levels. The Company does not currently use foreign currency hedging instruments but may evaluate hedging strategies as cross-border activity expands.

The Company's cost structure could be indirectly affected by fluctuations in the prices of medical-grade polymers, sterilization materials, and logistics inputs such as energy and packaging. These commodities are purchased through affiliates and contract manufacturers; however, sustained increases in raw material costs could increase manufacturing or import expenses. Management estimates that a 10% increase in material and shipping costs could increase total product acquisition costs by approximately 5–7%, depending on volume and mix.

The Company's common stock trades on the OTCQB market and may be subject to high volatility due to limited trading volume, investor sentiment, and the Company's early-stage status. A material decline in share price could reduce the Company's ability to raise additional capital or use equity for future acquisitions.

 **Qualitative Discussion of Market Risk** 

The Company monitors market risk exposure through periodic management reviews and conservative financial policies. Management does not engage in speculative or leveraged investment strategies and seeks to minimize foreign exchange and interest rate exposure by:

&nbsp;&nbsp;&nbsp;&nbsp;· Maintaining the
 majority of cash in U.S. dollar accounts;

&nbsp;&nbsp;&nbsp;&nbsp;· Denominating intercompany
 payments in euros or U.S. dollars where practicable; and

&nbsp;&nbsp;&nbsp;&nbsp;· Establishing fixed-price
 arrangements with suppliers and logistics providers to reduce commodity cost volatility.

Management believes that its current market risk exposures are not material to its consolidated financial position. However, as the Company expands its international operations and begins generating revenue, exposure to foreign currency, commodity price, and equity market volatility could increase. The Company intends to continually evaluate and, if appropriate, implement risk management strategies to mitigate such exposures.

**Results of Operations**

**Fiscal Year 2024 Compared to 2023**

For the fiscal year ended December 31, 2024, the Company generated modest revenues of $110,911, compared to $126,038 in the prior year 2023. This slight decline in revenue year-over-year reflects the Company's early-stage operations and a continued focus on product development and regulatory preparation. These revenues stem from CSDX's legacy service business (assisting with medical product distribution/approvals) or initial product sales, as full commercial sales of Hydrogel had not commenced by 2024. Despite the small decrease in top-line, the Company's bottom-line improved year-over-year. CSDX reported a net profit of $761 for 2024, a turnaround from a net loss of $21,997 in 2023. This swing to roughly break-even results was achieved primarily through expense management.

37 www.csdcorp.us

Operating expenses in 2024 totaled $110,150, down 25% from $148,035 in 2023. Notably, general and administrative (G&A) expenses were sharply lower in 2024 (only $395, versus $94,009 in 2023), indicating significant cost-cutting or the absence of prior-year one-time costs. By contrast, professional fees (which can include legal, consulting, and accounting costs) increased to $109,755 in 2024 from $54,026 in 2023. The higher professional fees in 2024 are attributable to corporate activities such as auditing, regulatory compliance, and the transactions surrounding the Hydrogel asset acquisition and public listing process. These professional costs were largely offset by the drastic reduction in G&A overhead, resulting in near break-even operating income of $761 for 2024 (versus a $21,997 operating loss in 2023). The improvement reflects management's efforts to streamline operations and focus expenditures on essential corporate and development activities. Basic and diluted earnings per share were $0.00 for both years, given the negligible net income and the Company's expanded share count after the 2023 equity issuance for the Hydrogel acquisition. Weighted average shares outstanding increased from about 110.8 million in 2023 to 137.3 million in 2024, reflecting new shares issued as part of the asset purchase and any other equity issuances during 2024.

 **Revenues** 

Total revenues for the nine months ended September 30, 2025, were $94,200, compared to $106,381 for the same period in 2024, representing a decrease of approximately 11%. This decline was primarily attributable to reduced diagnostic service activity and lower one-time licensing income relative to the prior year. The Company anticipates that the implementation of new service agreements and the expansion of its diagnostic offerings will stabilize and potentially increase revenues during the remainder of 2025.

 **Operating Expenses** 

Total operating expenses decreased significantly to $62,119 for the nine-month period ended September 30, 2025, from $92,933 for the same period in 2024. The reduction was mainly due to lower professional fees as several one-time legal, audit, and consulting engagements were completed in 2024. Research and development expenses were minimal as the Company shifted resources from product development to commercialization. General and administrative expenses rose modestly to $22,424, reflecting increases in compliance-related and reporting costs associated with the Company's OTCQB listing status.

 **Net Income** 

For the nine months ended September 30, 2025, the Company recorded net income of $32,081, compared with $13,448 in the prior-year period. The improvement resulted primarily from the reduction in operating expenses and the absence of any significant financing or debt-related costs.

**Liquidity and Capital Resources**

**Capital Structure and Cash Position**

CSDX's financial condition at year-end 2024 reflects a company that has acquired a major intangible asset but has very limited liquidity. As of December 31, 2024, the Company's balance sheet shows total assets of approximately $499.4 million, almost entirely consisting of the Hydrogel intangible asset valued at $499.4 million, with only $501 in cash on hand. By March 31, 2025, cash had increased to $51,386 (unaudited) as the Company received some funds from operations or small financing activities during Q1. Current assets at March 31, 2025 were $106,112, including cash and new accounts receivable of about $54,726, while current liabilities were $74,931 (primarily accounts payable and accruals). The working capital position remains strained – current liabilities slightly exceeded current assets at Q1's end, and the cash on hand is minimal relative to the Company's needs for product development and launch. CSDX has essentially no long-term debt as of Q1 2025, and total liabilities are very low (only ~$75K). However, stockholders' equity is dominated by the large intangible asset value offset by a corresponding amount recorded in additional paid-in capital. The Company's shareholders' deficit was about $499.4 million at year-end 2024, reflecting the recognition of the hydrogel asset and the equity issued for its purchase. The accumulated deficit stood at $(4.77) million at December 31, 2024, only slightly improved to $(4.74) million by March 31, 2025 due to the small profits earned in late 2024 and Q1 2025. This deficit is the result of prior years' losses, as the Company is only now moving toward profitability on a very small scale.

38 www.csdcorp.us

**Cash Burn and Going Concern**

The Company's historical operations have been funded by equity infusions from its shareholders/parent group rather than by sustainable cash flows. Net cash used in operating activities continued in early 2025 given ongoing expenses and the need to build inventory and infrastructure for product launches. The going concern note in the 2024 financial statements emphasizes that the Company's ability to continue as a going concern is dependent on improving profitability and obtaining financial support from shareholders or other external financing. Management acknowledges that additional capital will be required for the planned operational activities and that there is uncertainty regarding the ability to raise such capital. These conditions raise substantial doubt about CSDX's ability to continue as a going concern absent new funding. The Company's strategy to address this includes seeking external financing and leveraging the value of its assets to secure investment.

**Financing Plans**

CSDX recognizes that its current liquidity is limited thus, the Company took steps to bolster its capital resources. To address this need, the Company has authorized a private placement financing under Rule 506(c) of Regulation D of the Securities Act of 1933, as amended, intended to be offered solely to accredited investors. The Company seeks to raise up to $10 million, with a minimum target of $5 million.

If the Company is successful in raising the $5 million minimum, it intends to allocate the net proceeds approximately as follows:

&nbsp;&nbsp;&nbsp;&nbsp;· U.S. based manufacturing
 – establish production capacity for the Hydrogel product subject to regulatory approval
 and commercialization in the United States;

&nbsp;&nbsp;&nbsp;&nbsp;· Research and development
 – support additional clinical and product development activities for Hydrogel and other
 pipeline products;

&nbsp;&nbsp;&nbsp;&nbsp;· Operational expansion – fund staffing, business development, and general corporate infrastructure to support growth; and

&nbsp;&nbsp;&nbsp;&nbsp;· Regulatory activities – cover costs of license applications, approvals, and related regulatory filings in the United States
and other jurisdictions.

This offering will not be filed and neither of the securities being offered will be registered with the Securities and Exchange Commission. Instead, the Company will file a Form D notice within 15 days after the first sale of securities in the offering.

The ability to complete the financing on acceptable terms, or at all, remains uncertain. Failure to raise the minimum target keeps the Company reliant on interim support from its major shareholders for meeting obligations and would require the Company to scale back or delay its planned activities, including U.S. manufacturing and regulatory initiatives.

**Capital Expenditures and Requirements**

CSDX currently has no significant capital expenditures disclosed for 2024, as it does not yet have large-scale manufacturing facilities of its own (the Hydrogel production for initial markets may be handled through partners or existing capacity of the CS Diagnostics Group). However, in preparation for commercial launch, the Company will need to invest in production tooling, inventory build-up, and distribution capabilities, particularly as it approaches the U.S. market entry by 2026. The Company's ability to raise additional capital through equity is evidenced by its prior issuances: in late 2023, it issued 110 million shares (valued at $500 million) to acquire the Hydrogel IP, and it has the option to issue more shares if needed (authorized common stock is 250 million shares). Potential future equity issuances could, however, result in dilution to existing shareholders. Besides equity financing, management may also explore strategic partnerships or licensing arrangements to share the costs of commercialization. At this time, the Company has no off-balance sheet arrangements or significant contractual obligations aside from standard accounts payable and the pending financing agreement.

39 www.csdcorp.us

In summary, CSDX's liquidity position is presently very tight, but management has taken steps to secure needed capital. Successful consummation of the planned $5 million financing (or similar funding) is essential for the Company to fund its operations over the next 12-18 months, including completing regulatory approval processes and initiating product sales at scale. If such financing were to be delayed or fail to close, the Company would need to rely on further shareholder loans or curtail its activities. Management believes that the value of its core technology and the size of the market opportunities will ultimately enable the Company to obtain sufficient capital to execute its plans, but it recognizes the need to demonstrate progress (such as obtaining FDA approval and initial revenues) to maintain investor support. The Company will continue to monitor its cash flow closely and will update its capital plan as needed to ensure it can meet its short-term liabilities and invest in growth initiatives.

**Critical Accounting Estimates and Judgments**

The preparation of CSDX's financial statements in accordance with U.S. GAAP requires management to make certain estimates and judgments that have a significant impact on reported results and financial position. The Company's most critical accounting estimate at this stage revolves around the valuation and potential amortization or impairment of the Hydrogel intangible asset. This intangible asset is carried at approximately $499.4 million on the balance sheet, reflecting the value assigned to the acquired product technology and intellectual property. Management recorded this asset based on the fair value of consideration given – 110,000,000 shares of common stock issued in September 2023 – which was determined by reference to a third-party valuation of the Hydrogel's discounted future commercial potential (over €960 million) and a benchmark transaction (Boston Scientific's 2018 purchase of a similar spacer product for $500 million). This valuation approach embodies significant judgments about the Hydrogel's future revenue, market adoption, and cash flow generation. No amortization expense has been recorded on the Hydrogel intangible through 2024, suggesting that management may consider this asset to have an indefinite life at present (or that amortization will commence once the product is fully commercialized). This treatment is a critical judgment; if the Hydrogel is deemed to have a finite life (for example, tied to patent expirations or a product lifecycle), the Company would need to amortize the $499 million asset over its useful life, which would greatly increase annual expenses and could quickly eliminate any accounting profits. Management will need to continually evaluate the appropriate useful life and amortization method for this asset as commercialization progresses.

Impairment considerations: Given the Company's lack of substantial revenue to date and the early stage of product approval, there is inherent uncertainty as to whether the Hydrogel asset will ultimately generate cash flows to support its carrying value. Management performs impairment analyses as part of its critical accounting judgments. If facts and circumstances (such as a significant delay in FDA approval, lower-than-expected market demand, or inability to secure commercialization funding) indicate that the Hydrogel asset's carrying amount may not be recoverable, the Company would conduct an interim impairment test. Any impairment charge could be material, as the $499.4 million intangible constitutes virtually the entire asset base of CSDX. Investors should understand that a write-down of this asset, if required, would severely impact the Company's reported equity and could reclassify the Company as a development stage entity with negative net worth. Management believes the recorded value is supported by external data (e.g., the precedent acquisition by Boston Scientific) and the broad potential applications of the Hydrogel technology, but it acknowledges that this is a key area of estimation uncertainty.

40 www.csdcorp.us

 **Intangible Asset: CS Protect-Hydrogel Valuation** 

The Company acquired the rights to Hydrogel, a degradable hydrogel designed for use as a spacer in radiotherapy.

The valuation of Hydrogel was supported by an independent analysis prepared by a certified public auditor, which applied a discounted cash flow methodology. The independent analysis estimated a net present value of approximately €961 million based on projected global commercialization of Hydrogel. Key assumptions in the valuation included:

&nbsp;&nbsp;&nbsp;&nbsp;· Market size: Approximately
 385,400 annual addressable patients in the U.S. and EU across prostate, cervical, esophageal,
 bladder, and breast cancers.

&nbsp;&nbsp;&nbsp;&nbsp;· Pricing: Assumed
 average selling prices of €1,100–€1,300 per unit in the EU and approximately
 USD 2,000 per unit in the U.S.

&nbsp;&nbsp;&nbsp;&nbsp;· Market penetration:
 Gradual adoption reaching ~50% of the addressable market by 2029–2030.

&nbsp;&nbsp;&nbsp;&nbsp;· Cost structure:
 Production costs of approximately €150–€180 per unit and variable distribution
 costs estimated at 25% of revenue.

&nbsp;&nbsp;&nbsp;&nbsp;· Discount rate:
 A 10% risk- and maturity-adjusted discount rate applied to projected cash flows over a 10-year
 product life cycle.

Although the independent valuation produced an estimated value of €961 million, management recorded the asset at $499.4 million to reflect the product's early development stage, absence of current revenues, and uncertainty associated with obtaining regulatory approvals and achieving commercialization. Management believes this approach reflects a prudent and supportable estimate of fair value under applicable accounting standards.

Management notes that the valuation is subject to significant risks and uncertainties, including regulatory outcomes, competition, adoption rates, and pricing dynamics. As of the date of this filing, Hydrogel has not received regulatory approval within the United States and has not generated revenue. There can be no assurance that actual results will be consistent with the assumptions used in the valuation.

 **Intangible Asset: MEDUSA Valuation** 

In prior disclosures, the Company presented internal projections of USD 80 million in revenue for 2025 and USD 460 million within three years. These projections are based on a third-party valuation study of MEDUSA and reflect a number of assumptions regarding market conditions and product adoption. Specifically:

&nbsp;&nbsp;&nbsp;&nbsp;• Geographic Markets: The projections assume commercialization
 in Europe, North America, the Middle East & Africa, and Asia/Pacific, which together
 represent the majority of the global surface disinfectant market.

&nbsp;&nbsp;&nbsp;&nbsp;• Market Size and Growth: The total addressable disinfectant
 market in these regions is estimated at approximately USD 5.46 billion in 2023, growing to
 USD 8.84 billion in 2030, representing a CAGR of approximately 7.1%.

&nbsp;&nbsp;&nbsp;&nbsp;• Market Penetration: The forecasts assume MEDUSA achieves a
 0.1% market share in 2025, increasing to approximately 3.0% by 2030, reflecting gradual adoption
 among healthcare, hospitality, and institutional customers.

&nbsp;&nbsp;&nbsp;&nbsp;• Pricing: MEDUSA is expected to be offered in multiple formats
 (sprays and wipes) at price points ranging from approximately USD 2.49 to USD 10.99 per unit,
 positioning the product in the mid-market segment.

&nbsp;&nbsp;&nbsp;&nbsp;• Cost Structure: Average gross margins are projected at 72–74%,
 based on production costs relative to expected price points. Distribution expenses are assumed
 at approximately 35% of sales, including partner/wholesaler margins, freight/logistics, and
 sales/marketing expenses.

&nbsp;&nbsp;&nbsp;&nbsp;• Usage Effect: Because MEDUSA provides longer-lasting surface
 protection compared to alcohol-based disinfectants, the projections assume a weighted 15%
 reduction in application frequency by institutional customers such as hotels and hospitals.

41 www.csdcorp.us

These projections are subject to significant risks and uncertainties. MEDUSA has not yet received regulatory approval in the United States, and there can be no assurance that the assumptions underlying these forecasts will prove accurate, that regulatory approval will be obtained, or that actual results will not differ materially. Investors should not place undue reliance on these projections, which are presented solely to provide insight into management's current expectations based on available data.

**Other areas of significant accounting judgment include:**

&nbsp;&nbsp;&nbsp;&nbsp;· Going Concern Assessment: As discussed in the Liquidity section, management must evaluate whether the Company can continue as a going
concern for the next 12 months. This involves judgment about future financing and revenue. While the 2024 financials were prepared on
a going concern basis, substantial doubt was disclosed, and management's plans to alleviate that doubt (through financing and improving
profitability) were outlined. This assessment is revisited in each reporting period.

&nbsp;&nbsp;&nbsp;&nbsp;· Deferred Tax Assets:
 The Company has accumulated losses (approximately $4.7 million deficit) that could give rise
 to deferred tax assets. However, given the Company's short operating history in its
 new line of business and uncertainty about future taxable income, management has determined
 that a full valuation allowance is necessary. This means no deferred tax asset is recognized
 on the balance sheet for net operating loss carryforwards, since it is not "more likely
 than not" that such **assets would be realized.** This judgment affects the tax
 expense and will be revisited if the Company begins generating substantial taxable profits.

&nbsp;&nbsp;&nbsp;&nbsp;· Revenue Recognition:
 While current revenues are small, management ensures proper cut-off and recognition of all
 service and product revenues. The Company currently generates minimal consulting revenue
 from affiliated entities for providing support on certain U.S.-related matters, and such
 revenue is recognized when the related servicecs are performed and earned. Any product sales
 will be recognized upon delivery of product to customers (assuming no further performance
 obligations). Given that some Q1 2025 sales were on credit, the Company also evaluates collectability.
 To date, revenue recognition has not involved complex arrangements, but as product sales
 grow (especially with MEDUSA and Hydrogel in multiple markets), management will need to consider
 any licensing deals, consignment arrangements, or usage-based pricing which could introduce
 more complexity.

&nbsp;&nbsp;&nbsp;&nbsp;· Stock-Based Transactions: The Company's issuance of shares for asset acquisition and any future equity financing (such as the
Series C Preferred proposed issuance) are accounted for at fair value. Management relies on valuation techniques to determine fair value
of shares, especially since the stock is thinly traded. Any discrepancy in these estimates would affect additional paid-in capital and
could have tax implications for the parties involved.

Management believes that the above critical accounting estimates are based on reasonable assumptions and consistently applied. However, actual results could differ from these estimates, and changes in assumptions or market conditions could require adjustments to carrying values or recognition of additional expenses in future periods. The Company's audit for 2024 resulted in an unqualified opinion with no critical audit matters identified beyond the going concern emphasis, indicating that the external auditors concurred with management's accounting treatments and estimates as of that time.

42 www.csdcorp.us

**Known Trends, Events, and Uncertainties**

As CSDX moves beyond its restructuring phase and into active commercialization, several key trends, events, and uncertainties will influence its financial condition and operations:

**Regulatory Approval and Commercialization Timeline**

 **<u>CS Protect-Hydrogel</u>**

The Company has submitted its 510(k) premarket-notification application for Hydrogel to the US FDA. Based on guidance from the Company's regulatory consultants, management understands that the typical FDA review period for medical devices of this type may range from approximately six to twelve months; however, the Company currently anticipates that the review process may extend beyond normal timeframes due to recent federal government closures and resulting administrative delays.

The timing and outcome of any regulatory determination remain uncertain and are entirely subject to the FDA's review process, which may take longer than management currently anticipates. The Company has not received any clearance or approval from the FDA, and there can be no assurance that such authorization will be obtained in a timely manner, if at all.

In addition, the Company intends to pursue approval of Hydrogel with BfArM under the European Medical Device Regulation. Management has been advised that the BfArM testing and registration process may typically require approximately six to eight months. These timelines are general industry estimates only and are subject to significant uncertainty. Actual review times may differ materially, and there can be no assurance that approval will be obtained within these timeframes or at all. Separate regulatory submissions and approvals may also be required for each specific cancer indication for which marketing authorization is sought.

 **<u>MEDUSA</u>** 

The Company is also preparing for regulatory submission of MEDUSA, its disinfectant product, to the EPA. The process is expected to involve registration of Polyquat DMA/E 50 as a new active ingredient for non-food contact uses, along with applications for end-use products. This review requires extensive chemistry, toxicology, ecotoxicology, and environmental fate data. Based on preliminary guidance from regulatory consultants, management anticipates that the EPA review process could extend for a year or longer, but the duration is inherently uncertain and may vary depending on data requirements and the EPA's review process.

The timing and outcome of FDA, BfArM, and EPA reviews are inherently uncertain, and regulatory approvals may not be obtained in a timely manner, or at all. Delays or failures in securing approval would materially affect the Company's ability to commercialize its products. See Risk Factors—Risks Related to Regulatory Approval for a more complete discussion of these uncertainties.

**Product Launch and Manufacturing**

CSDX is preparing to scale-up production of Hydrogel as it advances toward commercialization. Management currently plans for U.S. production to commence in the first quarter of 2026, subject to obtaining necessary regulatory approvals and securing adequate financing to fund manufacturing, validation, and initial market launch activities. Activities during 2025 are expected to focus on establishing manufacturing processes, including technology transfer to a U.S.-based manufacturing site or contract manufacturer, and securing supply chain logistics. Broader trends in the medical technology industry—such as supply chain disruptions and cost inflation—may affect the Company's ability to source raw materials and sterile packaging on acceptable terms. The ability to meet production timelines by early 2026 is uncertain, and any operational hurdles or delays in facility readiness could impact the product launch schedule.

Management's decision to pursue equity financing in 2025, including the $5 million loan agreement previously disclosed, is tied to funding these manufacturing and launch activities. Investors will be able to monitor the Company's progress in late 2025 by reviewing updates provided in the Company's SEC filings regarding: (i) the status of regulatory submissions and approvals, (ii) progress in establishing U.S. manufacturing capacity, and (iii) steps taken to secure supply chain and distribution channels. See Risk Factors—Related to Business.

43 www.csdcorp.us

**Market Adoption and Competition**

Upon entering the market, Hydrogel will face competition from at least one well-established product. Boston Scientific's SpaceOAR hydrogel (acquired from Augmenix) is currently the leading tissue spacer for prostate cancer radiotherapy and has an installed base of users. While Hydrogel is positioned as a next-generation spacer with broader applications, it may initially compete directly with SpaceOAR in the prostate cancer segment. Boston Scientific's resources and relationships with hospitals could pose a competitive challenge. CSDX's strategy is to differentiate Hydrogel through its enhanced features – notably, its versatility to be used in multiple cancer types (beyond just prostate) and its ready-to-use formulation that requires no mixing or prep work in the operating room. These competitive advantages, such as eliminating contamination risk and preventing potential errors in preparation, will be key selling points to drive adoption by radiation oncologists and urologists. Market acceptance is a potential uncertainty; the medical community will need to be educated on the hydrogel's benefits, and CSDX may need to sponsor additional clinical studies or publish data demonstrating improved outcomes (e.g. reduced side effects or the ability to safely escalate radiation doses). The broader trend in oncology toward hypofractionation (fewer, higher-dose treatments) could work in the Company's favor – a spacer that reliably protects healthy tissue can enable such treatment protocols. If Hydrogel can facilitate safer hypo fractionated radiotherapy, it could accelerate adoption in modern cancer care settings**.**

**Commercial Potential vs. Risks**

The market potential for Hydrogel is significant, as indicated by the valuation references: management often notes that a predecessor product was bought for $500 million, underscoring the high value placed on effective spacer technologies in radiation oncology. Moreover, by expanding the indications to other cancers (e.g. gynecological or gastrointestinal cancers where organ spacing can prevent collateral damage), CSDX aims to tap into multiple therapy markets. If successful, Hydrogel could generate substantial revenue streams across different oncology subfields. However, this potential comes with execution risks. The Company is still small and will need to form distribution partnerships or build a salesforce to reach hospitals and clinics globally. Establishing relationships with key opinion leaders in radiation oncology is crucial for driving adoption. There is also the general risk of new entrants or technologies: for instance, other biotech companies might develop competing spacer materials or completely different solutions to protecting healthy tissue during radiotherapy. To maintain its competitive position, the Company will need to continue advancing its product strategy and strengthening clinical and commercial differentiation. CSDX benefits from its exclusive rights to market, distribute, and commercialize the Hydrogel product within defined territories, providing a protected competitive position and meaningful barriers to direct competition. This exclusivity supports early commercia traction and helps reduce the likelihood of copycat products entering the same markets in the near term. Another factor that may influence commercial adoption is reimbursement. Insurance coverage in the U.S. and internationally will play an important role in hospital utilization decisions. For example, completing products such as SpaceOAR obtained specific reimbursement codes; CSDX will need to ensure similar coverage, otherwise the out-of-pocket cost to patients could limit usage.

**Diversification and Other Products**

A notable development during the first quarter of 2025 was the launch of the MEDUSA disinfectant product. This reflects a diversification of the Company's activities to include infection control products in addition to therapeutic devices. MEDUSA's commercialization is at an early stage, and its future market acceptance, sales levels, and regulatory outcomes remain uncertain. Management has articulated internal objectives for MEDUSA that, if achieved, could expand the scale of the Company's operations; however, there can be no assurance that these objectives will be realized in whole or in part.

The Company has also explored brand-building initiatives to support MEDUSA, including preliminary discussions with a major European football club regarding potential sponsorship opportunities. Those negotiations have since been halted, and management does not intend to pursue such opportunities until the Company receives regulatory clearance in the United States to market MEDUSA.

44 www.csdcorp.us

MEDUSA presents a distinct regulatory and commercial profile compared to Hydrogel. Whereas Hydrogel is regulated as a medical device subject to FDA clearance and specialist marketing, MEDUSA requires approval by the EPA in the United States and competes in a broader consumer and institutional disinfectant market with numerous established manufacturers. The extent to which the Company can successfully balance resources between these two product lines, and the timing of any regulatory approvals, remain important uncertainties for investors to consider.

**Management and Organizational Changes**

Another development in late 2024 was changes to the Company's board and executive team. In August 2024, new directors and officers were appointed, including a Vice President/CFO and additional independent directors, while some prior directors stepped down. These changes brought in individuals with specific expertise—such as a Chief Operating Officer with medtech experience and new board members with industry connections—which may influence the Company's strategic direction and operational execution. Such changes can impact the Company's strategic direction and operational execution.

In early 2025, the Company engaged in preliminary discussions with potential investors regarding a possible private placement of its Series C Preferred Stock; these discussions were summarized in a non-binding letter of intent and did not result in a definitive agreement. Management continues to evaluate financing alternatives to support its commercialization objectives. The Company's ability to grow will also depend on hiring qualified personnel in R&D, regulatory affairs, and sales, as competition for talent in the medtech field remains high, which could increase short-term expenses.

**Macroeconomic and Market Conditions**

CSDX operates in the healthcare sector, which is generally less cyclical than other industries, but it is not immune to broader economic conditions. Inflationary pressures could increase the cost of raw materials for the hydrogel or components for packaging. Currency fluctuations may also affect the Company since part of its operations (and manufacturing or parent company support) is in Europe – the valuation of the Hydrogel was initially done in euros and then converted to USD. If the dollar/euro rate changes significantly, it could impact cost structures or the perceived value of overseas funding. Additionally, capital market conditions in 2025 will determine how easily the Company can raise further equity. Micro-cap public companies can face volatile trading and difficult financing environments if investor sentiment turns negative. The OTCQB listing provides a platform, but ultimately CSDX may seek an uplist to a national exchange to access a broader pool of investors – such ambitions would depend on meeting certain financial and governance criteria, which remain a longer-term consideration.

 **Manufacturing, Suppliers, and Supply Chain Risks** 

As the Company prepares for commercialization of its licensed products, Hydrogel and MEDUSA, its reliance on its affiliates represents a key uncertainty. The Company does not manufacture either product internally.

For Hydrogel, the Company has not yet engaged a commercial manufacturer. If FDA clearance is obtained, the Company expects to contract with a suitable U.S. based facility for production.

For MEDUSA, production is currently handled by third-party manufacturers through the Company's affiliates: Turkuaz Factory manufactures MEDUSA for the European market under CS Pharma, and Gulf Center Group manufactures MEDUSA for the Middle East market under CS Interpharm. If MEDUSA receives EPA authorization, the Company intends to contract with a U.S. based manufacturer for production and distribution in the American market.

The Company's supply chain depends on a limited number of manufacturers and suppliers. Broader industry trends, including supply chain disruptions, cost inflation, and regulatory requirements affecting third-party manufacturers, may adversely impact the availability of raw materials, packaging, and finished products. Any disruption in these relationships could delay commercialization, increase costs, or otherwise affect the Company's ability to meet projected timelines.

45 www.csdcorp.us

**Conclusion**

The path forward for CS Diagnostics Corp. presents opportunities as well as significant uncertainties. The Company is in the process of developing Hydrogel, which it believes may represent a novel approach in the medical device space, along with MEDUSA, a long-acting disinfection product. Neither product has received marketing authorization in the United States, and there can be no assurance that regulatory approval will be obtained in a timely manner, or at all.

Like many emerging growth companies, CS Diagnostics faces challenges including obtaining required regulatory approvals, scaling up manufacturing and sales, securing adequate financing, and competing with established industry participants, all while transitioning into an SEC-reporting company subject to enhanced disclosure and compliance requirements. Management has prepared forward-looking statements regarding potential future milestones, such as possible FDA approval of Hydrogel, anticipated timelines for U.S. production, and potential revenue generation. These statements reflect management's current plans and observations, but are inherently subject to numerous risks and uncertainties.

Actual results may differ materially from management's expectations due to factors such as the timing and outcome of regulatory processes, competitive dynamics, availability of capital, and the Company's ability to execute its commercialization strategy. Investors should carefully review the risk factors and uncertainties described in this filing when evaluating the Company's prospects.

**Going forward**

CS Diagnostics Corp. intends to continuously update stakeholders on its progress. The Company's management remains confident that by focusing on its core strengths –regulatory expertise, licensing and commercialization of medical technologies, and strategic partnerships – it can navigate the upcoming challenges and build a sustainable, high-growth business that delivers long-term shareholder value. Looking ahead to 2026, the Company expects to achieve key milestones, including, without limitation, FDA approval for Hydrogel, securing additional financing, and advancing initial market launches. The Company's financial health and operational results will hinge on the successful realization of these objectives. All forward-looking statements in this MD&A are made as of the current date and are subject to the safe harbor provisions; actual outcomes will be reported in future filings, and management undertakes to update its guidance as appropriate in light of new information or changes in circumstances.

**LEGAL PROCEEDINGS**

From time to time, we may become involved in various legal or administrative claims and proceedings arising in the ordinary course of business.

 **<u>U.S. District Court for the Northern District of Texas: CS Diagnostics Corp. v. Wilson, Case No. 3:25-cv-01158-N</u>**

In early 2025, following a decline in the Company's stock price from approximately $3.00 per share in late 2024 to sub-penny levels, the Company discovered that a minority shareholder had sold a significant volume of CSDX stock despite having previously indicated a long-term investment intent. Management sought to reach a voluntary arrangement with the shareholder to mitigate market disruption, but the shareholder continued selling. The Company believes these actions contributed to a loss of investor confidence and impaired relationships with potential investors and service providers.

46 www.csdcorp.us

As a result, on May 7, 2025, the Company filed a civil action in the United States District Court for the Northern District of Texas, captioned CS Diagnostics Corp. v. Wilson, Case No. 3:25-cv-01158-N, seeking damages and equitable remedies. The Texas federal court has granted jurisdictional discovery and has stayed the matter pending completion of that discovery, further authorizing CSDX to pursue related discovery in the State of Oregon, where our transfer agent is headquartered. As of the date of this Amendment, jurisdictional discovery is ongoing.

This matter has also affected the Company's ability to pursue its objective of meeting the listing standards of a national securities exchange in 2025. The Company emphasizes that it does not seek to restrict shareholders from selling their securities, but rather to promote orderly market activity and protect the interests of all investors.

 **<u>U.S. District Court for the District of Wyoming: CS Diagnostics Corp. v. Wilson, Case No. 25-cv-213-SWS</u>**

On or about July 17, 2025, the Company became aware that a third party was soliciting the sale of MEDUSA while claiming ownership rights in the product. Shortly thereafter, a potential purchaser contacted the Company regarding these claims. To protect its interests, on September 10, 2025, the Company filed a civil action in the United States District Court for the District of Wyoming, captioned CS Diagnostics Corp. v. Wilson, Case No. 25-cv-213-SWS, seeking damages, restitution, declaratory judgment, a permanent injunction, and other equitable relief to enforce its rights under the Exclusive License and Distribution Agreement. The Defendant moved to dismiss, and the Wyoming court subsequently dismissed the action and directed the Company to pursue its claims in the Texas court, where related jurisdictional proceedings remain pending.

The Company cannot predict the outcome, duration, or timing of these matters, and no provision for loss has been recorded in its financial statements as of the date of this filing.

 **SIGNATURES** 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 15, 2025 | **CS Diagnostics Corp.** | **CS Diagnostics Corp.** |
|  | By: | /s/Mohammad EsSayed |
|  |  | Mohammad EsSayed |
|  |  | Group CFO, VP |

---

47 www.csdcorp.us

**INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| **CS Diagnostics, Corp. Unaudited Interim Financial Statement (period ending September 30, 2025)** | **CS Diagnostics, Corp. Unaudited Interim Financial Statement (period ending September 30, 2025)** |
| Balance Sheets as of September 30, 2025, and December 31, 2024 | **F-1** |
| Statements of Operations for the Three months and Six months period ended September 30, 2025, and September 30, 2024 | **F-2** |
| Statements of Stockholders' Equity for Six months period ended September 30, 2025, and December 31, 2024 | **F-3** |
| Statements of Cash Flows for the Six months period ended September 30, 2025, and September 30, 2024 | **F-4** |
| Notes to the Financial Statements | **F-5** |

---

48 www.csdcorp.us

**Condensed Consolidated Balance Sheets**

---

| |
|:---|
| **CS DIAGNOSTICS CORP. CSDX** |
| **BALANCE SHEET** |
| **FOR THE PERIOD ENDED SEPTEMBER 30 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025**<br>**(Unaudited)** | **December 31, 2024**<br>**(Audited)** |
| *<u>Assets</u>* |  |  |
| **Current Assets** |  |  |
| Cash | 13 | 501 |
| Other Receivables | 31000 |  |
| **Total Current Assets** | $**31013** | $**501** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499431013** | $**499400501** |
| **<u>Liabilities and Stockholders' Deficit</u>** |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 1609 | 1428 |
| Non-current liabilities |  |  |
| **Total Liabilities** | $**1609** | $**1428** |
| **Shareholder's Equity / (Deficit)** |  |  |
| Common stock, $0.00001 par value; 250,000,000 shares authorized,137,340,200 shares issued and outstanding as of September 30, 2025 | 1373 | 1373 |
| Preferred stock Series A, $0.00001 par value;1,000,000 shares authorized, 10 shares issued and outstanding as of September 30, 2025 |  |  |
| Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of September 30, 2025 | 2000 | 2000 |
| Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2025 | 40 |  |
| Additional paid-in capital | 504161838 | 504163629 |
| Accumulated deficit | (4735847) | (4767928) |
| **Total Stockholders' Equity /(Deficit)** | $**499429404** | $**499399073** |
| **Total Liabilities and Stockholders' Equity /(Deficit)** | $**499431013** | $**499400501** |

---

*. The accompanying notes are an integral part of these financial statements*

F-1 www.csdcorp.us

**Condensed Consolidated Statement of Operations**

---

| |
|:---|
| **STATEMENT OF OPERATIONS** |
| **FOR THE PERIOD ENDED SEPTEMBER 30, 2025**<br>**(Unaudited)**<br>|

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For The Three <br> Months Ended <br> September 30 <br> 2025** | **For The Three <br> Months Ended <br> September 30 2024** | **For The nine <br> Months Ended <br> September 30 <br> 2025** | **For The nine <br> Months Ended <br> September 30 <br> 2024** |
| Revenue | 23050 | 7964 | 94200 | 106381 |
| **Revenue** | $**23050.00** | $**7964.00** | $**94200.00** | $**106381.00** |
| *Operating Expenses* |  |  |  |  |
| Professional Fee | 23162 | 7358 | 39695 | 92622 |
| Research & Development expenses | 0 |  | 0 |  |
| General & Administrative Expenses | 70 | 70 | 22424 | 311 |
| Total Operating expenses | 23232 | 7428 | 62119 | 92933 |
| **Income/loss) from Operations** | $**(182)** | $**536** | $**32081** | $**13448** |
| Other Income / (Expense) |  |  |  |  |
| Debt Written off |  |  |  |  |
| Net Income / (loss) | $(182) | $536 | $32081 | $13448 |
| Basic and diluted loss per share | 0.00 | 0.00 | 0.00 | 0.00 |
| **basic and diluted loss weighted average shares** | **137430200** | **129790200** | **137430200** | **123290200** |

---

*The accompanying notes are an integral part of these financial statements.*

F-2 www.csdcorp.us

**Condensed Consolidated Statement of Stockholders (Deficit)**

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF STOCKHOLDERS (DEFICIT)** |
| **FOR THE PERIOD ENDED SEPTEMBER 30, 2025** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock B** | **Preferred Stock B** | **Preferred Stock C** | **Preferred Stock C** | **Common Stock** | **Common Stock** | **Additional** | **Accumulated** | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Paid-in Capital** | **Deficit** | **Total** |
| Balance, January 1, 2024 | 20000000 | $2000 | $0 | $0 | 110790200 | $1018 | $504173122 | $(4798689) | $499407451 |
| Reversed Stock Split |  |  |  |  |  |  |  |  |  |
| Shares Issued/Converted | (1325) | $0 | $0 | $0 | 26500000 | $355 | $(9493) |  | $(9138) |
| Net income (loss) for the year |  |  |  |  |  |  |  | $761 | $761 |
| **Balance, December 31, 2024** | **19998675** | $**2000** | $**0** | $**0** | **137290200** | $**1373** | $**504163629** | $**(4767928)** | $**499399073** |
| Balance, June 30, 2025 | 19992575 | 2000 | 4000000 | 40 | 137340200 | 1373 | 504163629 | (4735665) | 499431181 |
| Shares Issued/Converted |  |  |  |  |  |  | $(1751) |  | $(1751) |
| Net income (loss) for the period ended September 30, 2025 |  |  |  |  |  |  |  | $(182) | $(182) |
| Shares Issued in acquisition of Assets |  |  |  |  |  |  |  |  |  |
| **Balance, September 30, 2025** | **19992575** | **2000** | **4000000** | **40** | **137340200** | **1373** | **504161838** | **(4735847)** | **499429404** |

---

*The accompanying notes are an integral part of these financial statements.*

F-3 www.csdcorp.us

**Condensed Consolidated Statement of Cash Flows**

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF CASH FLOWS** |
| **FOR THE PERIOD ENDED SEPTEMBER 30, 2025**<br> **(Unaudited)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended September 30** | **For the Nine Months Ended September 30** |
|  | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net profit/ (loss) | 32081 | 4885 |
| Adjustment to reconcile net loss to net cash used in operating activities |  |  |
| Changes in assets and liabilities |  |  |
| Other Receivables | (31000) | 26100 |
| Account payables | (1609) | 893 |
| **Net cash used in operating activities** | $**(528)** | $**31878** |
| **Cash flows from investing activities** |  |  |
| Intangible Asset |  | (499444401) |
| **Net cash provided by Investing activities** |  | $**(499444401)** |
| **Cash flows from financing activities** |  |  |
| Additional Capital Paid Up |  | 499444401 |
| Series C Shares | 40 |  |
| **Net cash provided by financing activities** | $**40** | $**499444401.00** |
| Net increase /(decrease) in cash | (488) | 31878 |
| Cash beginning of period | 501 | 9730 |
| **Cash end of period** | $**13** | $**41608** |

---

*The accompanying notes are an integral part of these financial statements.*

F-4 www.csdcorp.us

**CS Diagnostics, Corp.**

**Notes to the Financial Statements**

**September 30, 2025, and December 31, 2024**

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*<u>Basis of Presentation</u>*

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

*<u>Use of Estimates</u>*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

*<u>Concentrations of Credit Risk</u>*

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.

*<u>Cash and Cash Equivalents</u>*

The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023

*<u>Fair Value of Financial Instruments</u>*

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below:

Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates.

Level 3: Level 3 inputs are unobservable inputs.

F-5 www.csdcorp.us

The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values.

The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates.

*<u>Income Taxes</u>*

We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

*<u>Net income (loss) per common share</u>*

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended September 30, 2025 and 2024, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company.

*<u>Recent Accounting Pronouncements</u>*

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 - GOING CONCERN**

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(-4,735,847) on September 30, 2025. The continuation of the Company as a going concern through September 30, 2025, is dependent upon improving profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

F-6 www.csdcorp.us

The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

**NOTE 4 – INCOME TAXES**

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

Net deferred tax assets consist of the following components as of:

---

| | | |
|:---|:---|:---|
|  | **September**<br> **30, 2025** | **December <br> 31, 2024** |
| **Federal income tax benefit attributable to:** |  |  |
| **Current Operations** | $— | $- |
| **Less: valuation allowance** |  |  |
| **Net provision for Federal income taxes** | $— | $— |

---

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following:

---

| | | |
|:---|:---|:---|
|  | **September**<br> **30, 2025** | **December**<br> **31, 2024** |
| **Deferred tax asset attributable to:** |  |  |
| **Net operating loss carryover** | $— | $— |
| **Less: valuation allowance** |  |  |
| **Net deferred tax asset** | $— | $— |

---

On September 30, 2025, the Company had net operating loss carry forwards of approximately $(4,735,847) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported on September 30 2025, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015.

**NOTE 5 – SUBSEQUENT EVENTS**

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

F-7 www.csdcorp.us

## Exhibit 99.2

**Exhibit 99.2**

---

| | |
|:---|:---|
| Tom Wrankmore, Ahornstraße 10, 06246 Bad Lauchstädt | ![](tomwrankmore_logo.jpg) |

---

CS Diagnostics Pharma GmbH Mr. Thomas Fahrhöfer

Müller-zu-Bruck-Straße 12

83052 Bruckmühl

Date

2023-9-4

Dear Mr. Fahrhöfer,

You have asked me to evaluate the process for the production of CS Protect-Hydrogel on the basis of the future economic benefits to be achieved for the CS Diagnostics Group as of September 30, 2023. I would like to comment on this as follows:

 **Description and identification of the intangible asset** 

The CS Protect-Hydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation.

Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy.

The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months.

The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.

![](ex992_footer.jpg)

Seite 1 von 9

The CS Hydrogel was developed by CS Diagnostics Pharma GmbH and CS Interpharm LLC, both companies of the CS Diagnostics Group, in cooperation with the Rheinisch-Westfälische Technische Hochschule Aachen and the DWI - Leibniz-Institut für Interaktive Materialien e.V. The patent application was filed with the German Patent and Trademark Office in 2023. The applicant for the patent is the DWI - Leibniz Institute for Interactive Materials e.V., which has granted CS Diagnostics Pharma GmbH an exclusive right to use the invention.

 **Competitive environment** 

 <u>Competitor products</u>

In terms of tissue spacers, hydrogel-based as well as hyaluronic acid-based spacers are used in cancer treatment. However, hyaluronic acid spacers are niche products with a small market share.

In the case of hydrogel spacers, a competitor product from Boston Scientific Corporation is currently available on the market. The competitor product SpaceOAR Hydrogel System was developed in 2010 by Augmentix, Inc. The shares in Augementix, Inc. were fully acquired by Boston Scientific Corporation in 2018 for a fixed purchase price of USD 500 million plus a variable purchase price component of USD 100 million upon achievement of certain sales targets. The competitor product has been further developed, is currently marketed under the SpaceOAR Vue Hydrogel trademark, and is approved exclusively for use in prostate radiation. The product marketed by Boston Scientific Corporation consists of three components that are mixed in a predetermined sequence and drawn into a syringe by a trained and skilled person.

The molecule of the CS Protect-Hydrogel differs significantly from the molecule of the competitor product. According to research by the Rheinisch-Westfälische Technische Hochschule Aachen or the DWI - Leibniz Institute for Interactive Materials e.V. and the CS Diagnostics Group, patent infringements are not to be expected.

 <u>Unique selling proposition (USP)</u>

The CS Protect-Hydrogel is a more advanced hydrogel both from the molecular structure, chemical physical properties and medical applications. Compared to the competitor product of Boston Scientific Corporation, CS Protect-Hydrogel has the following practical, hygienic, medical and economic advantages:

Practical advantages:

- easy application of the CS Protect-Hydrogel since it is a "ready-to-use" product

- avoidance of a further work step

Seite 2 von 9

Hygienic advantages:

- immediate application of the CS Protect-Hydrogel after removal from sterile packaging

- no risk of contamination due to preparation and assembly of the product

- exclusion of another hygienic risk area within the treatment room

Medical advantages:

- no risk of wrong mixture (especially wrong sequence) and therefore no potential patient's missed appointment

- extended application range - besides prostate cancer also for cervical, esophageal, bladder and breast cancer

- hypofractionation possible - significantly fewer treatment sessions per patient

- dose escalation possible - acceleration of radiation therapy

Economic advantages:

- lower personnel costs during treatment due to the elimination of assistance for mixing the hydrogel

- lower room utilization costs per patient as there is no longer a risk of patients having to be treated again due to incorrect mixtures (higher number of patients per treatment room)

- lower cleaning costs due to the ready-to-use principle

- fewer lawsuits and/or insurance claims due to incorrectly mixed hydrogels requiring the patient to be treated again

- lower purchase price for the clinics than for the competitor product

 <u>Market entry barriers</u>

The CS Protect-Hydrogel is a medical device and requires registration or approval by the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA or the Federal Institute for Drugs and Medical Devices (BfArM) after CE testing and certification in Germany. Registration or approval is preceded by a testing procedure. The CS Diagnostics Group anticipates a period of 6 to 12 months for approval in the U.S. and 6 to 8 months for the testing procedure and registration of the CS Protect-Hydrogel in Germany.

Since a competitor product is already available on the market and is used worldwide for prostate irradiation, CS Protect-Hydrogel does not need to be re-explained or advertised for use in prostate irradiation. Extensive information and advertising is required for the treatment of other types of cancer.

Seite 3 von 9

The CS Protect-Hydrogel is a further developed substitute product for the competing product of Boston Scientific Corporation on the market. Due to the easier handling, the lower medical risks and cost risks, and the expanded scope of application, the CS Diagnostics Group expects that the respective purchasing departments of clinics (including specialty clinics) and hospitals will quickly adopt and list the CS Protect-Hydrogel in their portfolios.

 **Valuation of future economic benefits** 

 <u>Total market and market share</u>

Hydrogel spacers are used in radiotherapy for prostate, esophageal, bladder, breast and cervical cancer. The use of hydrogel spacers is contraindicated in approximately 10 % of irradiated patients. For the major markets in the USA and the European Union, the potential use is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br> new cases per <br> year <br> patients  | <br> thereof irradiation <br> in % patients  | <br> thereof irradiation <br> in % patients  | thereof <br> contra- <br> indicated <br> patients  | application <br> potential <br> hydrogel <br> patients  |
| European Union<sup>1)</sup> |  |  |  |  | <br> 209897  |
| &nbsp;&nbsp;&nbsp; Prostate Cancer | 335514 | 25.0 | 83879 | 8388 | 75491 |
| &nbsp;&nbsp;&nbsp; Breast Cancer | 355457 | 40.0 | 142183 | 14218 | 127965 |
| &nbsp;&nbsp;&nbsp; Bladder Cancer | 157484 | 3.0 | 4725 | 473 | 4252 |
| &nbsp;&nbsp;&nbsp; Cervical cancer | 30447 | 5.0 | 1522 | 152 | 1370 |
| &nbsp;&nbsp;&nbsp; Esophageal Cancer | 30327 | 3.0 | 910 | 91 | 819 |
| USA<sup>2)</sup> |  |  |  |  | 175503 |
| &nbsp;&nbsp;&nbsp; Prostate Cancer | 288300 | 25.0 | 72075 | 7208 | 64867 |
| &nbsp;&nbsp;&nbsp; Breast Cancer | 297790 | 40.0 | 119116 | 11912 | 107204 |
| &nbsp;&nbsp;&nbsp; Bladder Cancer | 82290 | 3.0 | 2469 | 247 | 2222 |
| &nbsp;&nbsp;&nbsp; Cervical cancer | 13960 | 5.0 | 698 | 70 | 628 |
| &nbsp;&nbsp;&nbsp; Esophageal Cancer | 21560 | 3.0 | 647 | 65 | 582 |
| Total |  |  |  |  | 385400 |

---

<sup>1)</sup> Data source: International Agency for Research on Cancer (Data basis: 2020); https://gco.iarc.fr/

<sup>2)</sup> Data source: American Cancer Society (Data basis: 2023); https://www.cancer.org/

Seite 4 von 9

With one application per patient, the annual sales potential of hydrogel spacers in the European Union and the USA is 385,400 units.

In addition to the CS Protect-Hydrogel, one competitor product is used worldwide. The CS Diagnostics Group believes that a market share of approximately 50 % can be achieved for the CS Protect- Hydrogel in the medium term due to its simpler handling, lower medical risks and cost risks, and expanded scope of application.

 <u>Prices and recoverable amounts</u>

The competitor product of CS Protect-Hydrogel is currently offered for sale to clinics and hospitals at market prices ranging from EUR 1,100 to EUR 1,900, with prices of around USD 2,000 in the USA and between EUR 1,100 and EUR 1,800 in the European Union.

The CS Diagnostics Group will position the CS Protect-Hydrogel as a "ready-to-use" product below these prices. The Group is expected to call selling prices between EUR 1,100 to EUR 1,300 per unit in the European Union and USD 2,000 (i.e. approx. EUR 1,900) per unit in the USA.

With an expected market share of around 50 %, annual revenues of EUR 282 million to EUR 303 million would thus be achievable.

 <u>Future economic benefits</u>

The future economic benefits from the CS Protect-Hydrogel for the CS Diagnostics Group results from the proceeds from the sale less the manufacturing costs of the hydrogel and the variable distribution costs.

In preliminary discussions of the CS Diagnostics Group with potential manufacturers of the hydrogel, manufacturing prices between EUR/unit 150 (European Union) to 180 (USA) have been promised. As variable distribution costs, the CS Diagnostics Group expects 25% of sales revenues.

The CS Diagnostics Group assumes a product life cycle of approximately 10 years from market launch. Market launch is expected after approval or registration of the product in 2025. A compound annual growth rate (CAGR) of 4.9 % p.a. is assumed for the overall market.

Seite 5 von 9

Overall, this results in the following assumptions for assessing the economic benefits of the CS hydrogel:

---

| | | | |
|:---|:---|:---|:---|
| | | EU (27) | USA |
| Selling price | EUR/unit | 1100 | 1900 |
| Production price | EUR/unit | 150 | 180 |
| Distribution costs | % | 25.0 | 25.0 |
| Compound annual growth rate (CAGR) | % p.a. | 4.9 | 4.9 |

---

According to the planning of the CS Diagnostics Group, the target values for the market share of approx. 50 % will be achieved as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Target value Share of total market (in %) | Target value Share of total market (in %) | Target value Share of total market (in %) | Target value Share of total market (in %) | Target value Share of total market (in %) |
| <br> year  | <br> Prostate Cancer  | <br> Breast Cancer  | <br> Bladder Cancer  | <br> Cervical cancer  | Esophageal <br> Cancer  |
| 2025 | 10 | 5 | 5 | 5 | 5 |
| 2026 | 20 | 10 | 10 | 10 | 10 |
| 2027 | 30 | 20 | 20 | 20 | 20 |
| 2028 | 40 | 30 | 30 | 30 | 30 |
| 2029 | 50 | 40 | 40 | 40 | 40 |
| 2030 | 50 | 50 | 50 | 50 | 50 |
| 2031 | 50 | 50 | 50 | 50 | 50 |
| 2032 | 50 | 50 | 50 | 50 | 50 |
| 2033 | 50 | 50 | 50 | 50 | 50 |
| 2034 | 50 | 50 | 50 | 50 | 50 |

---

Seite 6 von 9

Taking these assumptions into account, the following future cash flows and their present values as of September 30, 2023 (risk- and maturity-equivalent interest rate of 10 % p.a.) result from the CS Protect-Hydrogel:

---

| | | | | |
|:---|:---|:---|:---|:---|
| year | <br> Sales <br> mio. EUR  | <br> Expenses <br> mio. EUR  | Profit margin / <br> Cashflow <br> mio. EUR  | <br> Net present value <br> mio. EUR  |
| 2025 | 42 | 15 | 27 | 23 |
| 2026 | 89 | 32 | 57 | 44 |
| 2027 | 162 | 58 | 103 | 72 |
| 2028 | 241 | 87 | 154 | 98 |
| 2029 | 328 | 119 | 210 | 121 |
| 2030 | 394 | 143 | 252 | 132 |
| 2031 | 414 | 150 | 264 | 126 |
| 2032 | 434 | 157 | 277 | 120 |
| 2033 | 455 | 165 | 291 | 115 |
| 2034 | 478 | 173 | 305 | 109 |
| **Totals** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3038 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1099 | 1939 | **961** |

---

The sum of the present values and thus the future economic benefit over the expected product life cycle is therefore **EUR 961 million**.

Seite 7 von 9

 <u>Sensitivity analysis</u>

The future economic benefit of the CS Protect-Hydrogel is mainly dependent on market penetration and the achievement of market share as well as the achievable selling prices per unit. Changes in these assumptions result in the following present values of the future cash flows from CS Protect- Hydrogel for the sales markets of the European Union and the USA:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; market share <br> (%): | 20 | 30 | 40 | 50 | 60 |
| selling price (per unit): |  |  |  |  |  |
| EU (27) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 950 | 126 | 189 | 252 | 315 | 378 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1000 | 134 | 201 | 268 | 336 | 403 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1050 | 143 | 214 | 285 | 357 | 428 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1100 | 151 | 227 | 302 | 378 | 453 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1150 | 159 | 239 | 319 | 399 | 478 |
| USA |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1750 | 212 | 318 | 424 | 530 | 637 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1800 | 219 | 329 | 438 | 548 | 658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1850 | 226 | 339 | 452 | 566 | 679 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1900 | 233 | 350 | 466 | 583 | 700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1950 | 240 | 360 | 481 | 601 | 721 |
| Totals |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 950/1,750 | 338 | 507 | 676 | 845 | 1014 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,000/1,800 | 353 | 530 | 707 | 884 | 1060 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,050/1,850 | 369 | 553 | 738 | 922 | 1107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,100/1,900 | 384 | 576 | 769 | 961 | 1153 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,150/1,950 | 400 | 600 | 799 | 999 | 1199 |

---

Seite 8 von 9

 **Valuation of the intangible asset** 

The value of the CS Diagnostics Group's right to use CS Protect-Hydrogel is mainly dependent on the market penetration and the market share achieved as well as the achievable sales prices. In the most likely scenario of a market share of 50 % and sales prices of EUR/unit 1,100 (EUR (27)) and EUR/unit 1,900 (USA), the economic benefit as the net present value of future cash surpluses as of September 30, 2023 is **EUR 961 million**.

Yours sincerely,

![](wrankmore_sig.jpg)

Tom Wrankmore <br> Wirtschaftsprüfer <br> [certified public auditor]

Seite 9 von 9

## Exhibit 99.3

**Exhibit 99.3**

![](ex993-001.jpg)

New Organ Spacer Development of a new spacer to reduce side effects in radiation therapy of prostate carcinoma.

![](ex993-002.jpg)

Agenda 11.02.2022 New Organ Spacer -Souad Krüger2 ? About prostate cancer. ? Number of cases worldwide ? Treatment methods ? Radiation therapy for prostate carcinoma ? Current situation ? Target properties of the hydrogel / Innovation ? Realization ? Adaptability of the gel-system ? Gelation and flexibility ? Animal Experiments with contrast medium ? Advantages and disadvantages ? Status of the project ? Other applications ? Market launch

![](ex993-003.jpg)

11.02.2022 New Organ Spacer -Souad Krüger3 About prostate cancer ? Cancer of the prostate gland in men and formation of metastases in lymph nodes and bones. ? The Cancer grows slowly without pain and typical symptoms in the early stages. That is why prostate cancer is diagnosed very late. ? Symptoms: Urinary urgency, Burning when urinating, Blood in the urine, strong back pain etc. ? Prostate cancer is among the most commonly diagnosed malignancies in men and is the third leading cause of cancer-related deaths. ? In Germany alone, around 58,776 people were diagnosed with prostate cancer in 2016 and 14,963 died of prostate cancer. ? Affected are men in higher age (> 40 years).

![](ex993-004.jpg)

11.02.2022 New Organ Spacer -Souad Krüger4 Number of new cancer cases worldwide by cancer type in 2020 Brust Lunge Darm Prostata Magen Leber Gebärmutterhals Speiseröhre Schilddrüse Blase Non-Hodgkin-Lymphom Bauchspeicheldrüse Leukämie Niere Endometriumkarzinom 604.127 604.100 586.202 573.278 544.352 495.773 474.519 431.288 417.367 905.677 1.089.103 1.414.259 1.931.590 2.261.419 2.206.771 Shortened version Source: Statista.com The statistics show the number of new cancer cases worldwide by cancer type in 2020. According to the International Agency for Research on Cancer, the number of new cancer cases worldwide this year was estimated at about 19.3 million. ? Of these, prostate cancer accounted for about 1,414,259 new cases.

![](ex993-005.jpg)

11.02.2022 New Organ Spacer -Souad Krüger5 Number of cancer deaths worldwide by cancer type in 2020 Lunge Darm Leber Magen Brust Speiseröhre Bauchspeicheldrüse Prostata Gebärmutterhals Leukämie Non-Hodgkin-Lymphom Gehirn, zentrales Nervensystem Blase Eierstock Niere 375.304 341.831 311.594 259.793 251.329 212.536 207.252 179.368 544.076 466.003 830.180 768.793 684.996 935.173 1.796.144 Shortened version Source: Statista.com The International Agency for Research on Cancer estimates that there will be around 9.96 million cancer deaths worldwide in 2020 ? Of these, prostate cancer accounted for approximately 375,304 cancer deaths.

![](ex993-006.jpg)

11.02.2022 New Organ Spacer -Souad Krüger6 Global distribution of new cancer cases by world region in 2020 The statistics show the global distribution of new cancer cases (incidence) by WHO world region in 2020. According to the International Agency for Research on Cancer, around 19.29 million new cancer cases were registered worldwide in 2020. ? Africa accounted for around 4.4 percent of this figure. Source:Statista.com

![](ex993-007.jpg)

11.02.2022 New Organ Spacer -Souad Krüger7 Global distribution of cancer deaths by world region in 2020 The statistics show the global distribution of cancer deaths by WHO world region in 2018. According to the International Agency for Research on Cancer, around 9.96 million people died of cancer worldwide in 2020. ? Europe accounted for approximately 21.8 percent of this total. Source:Statista.com

![](ex993-008.jpg)

11.02.2022 New Organ Spacer -Souad Krüger8 Incidence rate of prostate cancer among men in selected countries in Europe in 2012 Norwegen Frankreich Schweden Irland Schweiz Island Finnland Estland Dänemark Belgien Niederlande Slowenien Lettland Luxemburg Deutschland 129,7 127,3 119 114,2 107,2 106,6 96,694,4 91,390,983,482,982,7 78,877,3 Shortened version 0 20 40 60 80 100 120 140 Source: Statista.com The statistics show the incidence rate of prostate cancer among men in selected countries in Europe in 2012. ? With an average of 77.3 new cases per 100,000 men in Germany that year.

![](ex993-009.jpg)

11.02.2022 New Organ Spacer -Souad Krüger9 Treatment methods ? To find an appropriate therapy depends on the stage of prostate cancer, previous diseases and age and lifestyle. Problemstellung ? There are several therapies to choose from for the treatment of prostate cancer: ? Controlled waiting ('watch and Wait'). ? Bad health condition and old age. Treatment are usually not successful or have too great a risk. Regular check-ups. ? Active surveillance ? Low risk profile and no complaints. At regular intervals, the prostate is always examined. ? Surgical removal of the prostate. ? Most frequently performed procedure for prostate cancer in Germany. Surgical removal of the prostate, seminal vesicle and nearby lymph nodes. ? Radiation therapy (external or internal). ? Destruction of the tumor by ionizing radiation. ? Hormone therapy. ? Chemotherapy. ? Cancer cells differ from healthy tissue in that their growth is incessant and unregulated. Chemotherapy targets precisely this point and inhibits the growth of the fast-growing cells.

![](ex993-010.jpg)

11.02.2022 New Organ Spacer -Souad Krüger10 Radiation therapy for prostate carcinoma ProstateRadiationRectal sensorRectum ? Irradiation of the tumor tissue, which destroys the malignant tumor cells. ? Patients are irradiated several times a week for seven to nine weeks with a total radiation dose of 74 - 80 Gy.

![](ex993-011.jpg)

11.02.2022 New Organ Spacer -Souad Krüger11 Radiation therapy for prostate carcinoma Problem definition ? Radiation therapy damages the rectum. Chronic side effects ? Increased tendency to bowel problems. ? Change in bladder and urethral function. ? Erectile dysfunction. Solution ? Use of a temporary spacer material between the prostate and rectum. ? Creates a distance of approx. 1 cm. ? Radiation dose is minimized to the adjacent rectum. ? Damage is reduced. ? Simultaneous possibility to apply a higher radiation dose. ? Number of treatments is reduced. . WithoutHydrogel With Hydrogel High radiation dose Organ AHydrogel Organ B

![](ex993-012.jpg)

11.02.2022 New Organ Spacer -Souad Krüger12 Current situation ¼ of prostate cancer patients are irradiated annually. ? However, only about 300 patients per year receive a spacer. Commercial 3-component gel-system: 1 Powder is dissolved & drawn into the syringe. 2 Adjust syringe volume. 3 Assembling the syringe + injection New developed 2-component gel-system: 1 Unpack syringe + injection Ready to use

![](ex993-013.jpg)

11.02.2022 New Organ Spacer -Souad Krüger13 Current situation A rectal balloon catheter as internal immobilization device for conformai radiotherapy of prostate cancer Comparison: Rectal balloon (Plastic based) Hydrogele (wasserbasiert) Approx. 8 mm distance between rectum and prostate gland approx. 10 mm distance between rectum and prostate gland Uncomfortable Soft / comfortable Surgical insertion and removal Degrades in the body within a few months

![](ex993-014.jpg)

11.02.2022 New Organ Spacer -Souad Krüger14 Target properties of the hydrogel / Innovation ? "Ready-to-use" 2-component material (liquid polymer components). ? Controlled cross-linking within a few seconds ('In situ'). ? Not too stiff: Pain. ? Not too soft: unreliable shielding of organs. ? Visualization by iodine for CT. ? Degradation stable in the body for several months. ? Complete absorption after end of therapy. ? Hydrogel & degradation products must not be toxic.

![](ex993-015.jpg)

11.02.2022 New Organ Spacer -Souad Krüger15 Realization Polymer APolymer BPolymer APolymer BpH = 7,4 37 °C Degradation Polymer BPolymer APolymer A Polymer B waterPolymer A Polymer B Polymer B Polymer A Cross-linking pH > 8.5 Liquid ? Use of liquid, special 6-arm star-shaped polyethylene glycols (sPEG) ? Development of a polymer library. ? Crosslinking by click chemistry takes place within a few seconds. ? Degradation of the hydrogel takes place by hydrolysis in the body. PPoolylymmeerr AA + Polymer B1 2

![](ex993-016.jpg)

11.02.2022 New Organ Spacer -Souad Krüger16 Adaptability of the gel-system Gelation time / mechanical properties & degradation time of the hydrogel can be tailored. By systematically varying the crosslinking parameters. Molecular weightInitiator End group of the polymerConcentra-tionCross-linking function

![](ex993-017.jpg)

11.02.2022 New Organ Spacer -Souad Krüger17 Gelation and flexibility Gelation of the hydrogel in 22 sec. Flexibility of the hydrogel after gelation. The hydrogel retains its shape despite pressure

![](ex993-018.jpg)

11.02.2022 New Organ Spacer -Souad Krüger18 Animal Experiments with contrast medium When injecting, the syringe is slowly pulled out. To fill the area of the prostate (length: 6 cm). Gelation time: approx. 20 sec. Hydrogel can be visualized on CT. Hydro-gel

![](ex993-019.jpg)

11.02.2022 New Organ Spacer -Souad Krüger19 Advantages and disadvantages Commercial 3-component gel-system ? Polymer components can only be stored as solids. ? Manual dissolution of the components leads to potential sources of error. ? Gelation times too fast. ? Visualization of the hydrogel in CT not possible. ? High prices (monopoly). ? ? Only 2% of irradiated patients receive an organ placeholder. New developed 2-component gelation system ? Simple handling ? ? Minimization of possible sources of error. ? Variable gel time ? ? Physician has more time to inject. ? Visualization of the hydrogel in the CT. ? Price reduction - competition in the market.

![](ex993-020.jpg)

11.02.2022 New Organ Spacer -Souad Krüger20 Status of the project General: ? This development project is funded by the EFRE Lead Market NRW. ? CS Diagnostics GmbH, DWI-Leibniz Institut für interaktive Materialien e.V. and Uniklinik Aachen are collaborating on the project. ? The project was launched in 2018 and will run until the end of 2021. Currently: ? Start of animal experiments in rats. ? Integration of iodine components into the hydrogel for visualization under CT. ? Patenting of the developed product. Target: ? At the end of the project a ?ready to use" spacer hydrogel will be developed, with a gelationtime of 20 seconds and degrades within 6 months. ? A suitable sterilization process should be developed. ? The polymers and the degradation products should have no toxic properties on living organisms.

![](ex993-021.jpg)

11.02.2022 New Organ Spacer -Souad Krüger21 Other applications Due to the adaptability of the gel properties, further areas of application are to arise from the already developed hydrogel in the field of: radiotherapy in men and women to separate other organs from each other. Transgender adaptation surgery. Reduction of postoperative adhesions.

![](ex993-022.jpg)

11.02.2022 New Organ Spacer -Souad Krüger22 Market launch ? Every year, 1.4 million people are diagnosed with prostate cancer worldwide. ? The most commonly used treatment method is radiation therapy. ? Until now, only about 2 % of patients received a spacer to reduce side effects. (High prices of the previous spacer). Throughournew developedproduct,weaimto improve the application of a hydrogel spacer in humans. So that the side effects during the radiotherapy will be reduced and psychological health problems caused by the therapy will be minimized. Through a good cooperation with the suppliers and producers, a faster and safer manufacturing process should be created. This will keep supply chains short and ensure that the product is developed safely, quickly and cost-effectively for patients. For a better live.

![](ex993-023.jpg)

Thank you for your attention

## Exhibit 99.4

**Exhibit 99.4**

![](ex994-001.jpg)

Cs Diagnostics Corp. 14 November 2025 1603 Capitol Avenue, Suite 413 Cheyenne, WY 82001 United States of America Confirmation Letter In reference to The CS Protect Hydrogel product, titled "Space-Gel; Spacer Hydrogel for Organ Shielding During Radiation Treatment of Prostate Carcinoma" (DWI file reference: DW-LD015), the technical/medical testing and trials was developed by the DWI Leibniz Institute for Interactive Materials, Department of Advanced Materials for Biomedicine ("DWI"). The idea of The CS Protect Hydrogel product was brought forward to DWI by Mr. Thomas Fahrhoefer, therefore, initial contracts were signed between DWI and CS Diagnostics Gmbh and La Pharm "both entities were fully owned by Mr. Thomas Fahrhoefer and now both are dissolved". Therefore, CS Group represented by its all entities sold all rights of The CS Protect Hydrogel to CS Diagnostics Corp on September 4th 2023. On March 21, 2024, to regulate the rights of The CS Protect Hydrogel product DWI, represented by RWTH Innovation GmbH, entered into an exclusive license agreement with CS Diagnostics Pharma GmbH ("CS Pharma"), granting CS Pharma the exclusive right to manufacture, market, sublicense, and commercialize products based on The CS Protect Hydrogel product for use in prostate cancer applications. Under the agreement, CS Pharma is authorized to grant sublicenses with DWI's consent and is responsible for maintaining the licensed intellectual property and obtaining the necessary regulatory approvals for commercialization. Currently, CS Diagnostics Pharma GmbH ("CS Pharma"), CS Diagnostics Corp (CSDX) and DWI are in final stages to produce a consolidated one contract that defines CSDX as the owner of The CS Protect Hydrogel and all related rights, and DWI to be the patent applicator and Royality from sales partner. This letter was issued to support CSDX application with Securities Exchange Commission "SEC". Thomas Fahrhoefer

## Exhibit 99.5

**Exhibit 99.5**

---

| | |
|:---|:---|
| Tom Wrankmore, Wirtschaftsprüfer, Ahornstraße 10, 06246 Bad Lauchstädt  | ![](wrankmore_header.jpg) |

---

CS Diagnostics Pharma GmbH<br> Mr. Thomas Fahrhöfer

Müller-zu-Bruck-Straße 12

83052 Bruckmühl

Datum <br> 2025-04-15

Dear Mr. Fahrhöfer,

you have asked me to evaluate the global distribution rights for MEDUSA on the basis of the future economic benefits to be achieved for the CS Diagnostics Group as of **April 1, 2025** (valuation date). I would like to comment on this as follows:

1. Description of the Intangible Asset: Global Distribution Rights for
 MEDUSA

The intangible asset under evaluation consists of the exclusive global distribution rights for the surface disinfectant MEDUSA. These rights grant the holder the sole authorization to market and distribute the product within the target regions of North America, Europe, the Middle East, Africa, and Asia / Pacific. The exclusivity is contractually secured for the full economic life cycle of the product, which is estimated at 20 years based on potential technological advancements and the emergence of microbial resistance.

a) Product Description and Areas of Application

MEDUSA is a non-alcohol-based surface disinfectant available in various container sizes (e.g., 30 ml, 250 ml, 500 ml, 1 liter) as well as in the form of pre-moistened wipes. The product was developed by CS Interpharm LLC, a company of the CS Diagnostics Group, and is intended for the hygienic cleaning of surfaces in professional settings, particularly in:

- Hotel operations

- Food service establishments

- Public institutions such as schools, childcare facilities, sports venues, airports, and hospitals and for use by end consumers in private households.

![](wrankmore_footer.jpg)

According to the manufacturer, the product exhibits antibacterial, antiviral, and antifungal properties. As it does not contain alcohol, MEDUSA is not classified as a hazardous substance under applicable regulations. This may offer advantages in terms of storage, transport, and handling safety, especially for frequent use by personnel without the need for specialized protective equipment.

A notable product characteristic, as reported by the provider, is the ability to analytically detect the presence of the substance on treated surfaces up to 10 days after application. It is explicitly noted, however, that this detection does not imply any proven duration of antimicrobial efficacy or protective effect during this period.

b) Intellectual Property and Development Status

MEDUSA was developed by CS Interpharm LLC. The product formulation is not protected by a patent, and according to company statements, no patent application is planned. The rationale given is that patenting would require public disclosure of the formulation. Protection of the product is therefore based on:

- Confidential knowledge (know-how) concerning its composition and manufacturing

- Regulatory approvals in selected markets (e.g., Europe and the Middle East)

- Use of the brand name "MEDUSA"

c) Scope of Distribution Rights

The distribution rights under evaluation include:

- Exclusive rights to distribute all current and future variants of the MEDUSA product

- Commercial use of the existing product name

- Utilization of existing and future regulatory approvals in the defined territories

- Exclusivity against third parties within the contractually defined regions

Utilization of the rights takes place within a regulated market environment, with varying approval processes depending on the region. Regulatory authorizations are already in place for Europe and the Middle East. According to the information provided, applications for approval in North America are currently in progress, while evaluation for the African and Asian / Pacific markets is ongoing.

2. Market Competition

a) Market Overview by Region

The surface disinfectant market in MEDUSA's target regions is characterized by internationally established suppliers whose products differ in terms of active ingredients, fields of application, and pricing. The main competing products by region are:

· **Europe**:
 Mikrozid® (Schülke & Mayr), Sagrotan® (Henkel), Domestos® (Unilever),
 Incidin® (Ecolab), Sterillium® Protect & Care (Hartmann Group)

· **North America**: Lysol® (Reckitt Benckiser), Oxivir® TB (Diversey), Peroxide Multi Surface
 Cleaner (Ecolab), Clorox® (Clorox Company)

· **Middle East / Africa**: Domestos®, Dettol® (Reckitt Benckiser), Clorox®, Oxivir®,
 Incidin®

Most of these products are based on **alcoholic, chlorine-based, or oxidative active substances**, such as ethanol, sodium hypochlorite, hydrogen peroxide, or quaternary ammonium compounds (QACs). These ingredients typically offer **rapid disinfection effects**, but they are generally **volatile**, **irritating**, or **classified as hazardous substances**. As a result, special handling and storage precautions are often required.

Application areas range from professional settings (e.g., hospitals, food processing, public institutions) to private use (e.g., Sagrotan, Sterillium).

**b)** **Price Comparison and Market Positioning** 

Compared to competing products, MEDUSA can be positioned as follows:

 **Price Overview: Competitor Products vs. MEDUSA (in USD per unit size)** 

 *(Prices converted from EUR using an exchange rate of 1 EUR = 1.08 USD)* 

 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Region** | **Product (examples)** | **250 ml** | **500 ml** | **1 Liter** |
| **Europe** | Domestos | 1.20 | 2.40 | 4.81 |
|  | Mikrozid | 3.09 | 6.19 | 12.36 |
|  | Incidin | 4.34 | 8.69 | 17.37 |
|  | Sterillium Protect & Care | 11.31 | 22.63 | 45.24 |
|  | Sagrotan | 19.03 | 38.04 | 76.08 |
| **North America** | Clorox | 1.85 | 3.69 | 7.38 |
|  | Lysol | 6.31 | 12.61 | 25.23 |
|  | Oxivir | 6.36 | 12.71 | 25.43 |
|  | Peroxide Multi Surface Cleaner | 10.44 | 20.89 | 41.76 |
| **Middle East / Africa** | Domestos | 1.20 | 2.40 | 4.81 |
|  | Clorox | 1.90 | 3.80 | 7.61 |
|  | Incidin | 4.34 | 8.69 | 17.37 |
|  | Dettol | 6.80 | 13.59 | 26.94 |
|  | Oxivir | 6.36 | 12.71 | 25.43 |
| **MEDUSA** | (Planned Sales Price) | 4.49 | 5.99 | 10.99 |

---

MEDUSA is thus positioned in the **mid-price segment** - above entry-level mass-market products (e.g., Domestos, Clorox), but **significantly below premium brands** such as Sagrotan or Sterillium. In combination with relatively low production costs, this results in an **average gross margin of approximately 72 to 74%**.

**c)** **Competitive Advantages of MEDUSA** 

In comparison to standard market products, the following distinguishing features and potential advantages of MEDUSA can be identified:

---

| | | |
|:---|:---|:---|
| **Feature** | **MEDUSA** | **Competitor Products** |
| Alcohol-based | No | Mostly yes |
| Active ingredient type | Alcohol-free, non-oxidative | Ethanol, hypochlorite, peroxide, QACs |
| Hazardous material classification | Not required | Generally required |
| Application frequency | Potentially 1 × daily | Multiple times daily |
| Detectability on surface | Up to 10 days (analytical only) | Minutes |
| Product format | Spray & wipes | Spray/liquid; wipes less common |
| Target usage | Professional/commercial and private use | Mixed (B2C and B2B) |

---

One key advantage of MEDUSA in professional settings is the **potential to reduce the frequency of application**. Since the product remains detectable on treated surfaces for up to 10 days, the number of required disinfection cycles may be significantly reduced. By contrast, conventional disinfectants typically require **multiple daily applications**, especially in high-traffic areas such as restrooms, reception zones, or communal spaces.

This results in a **substantial savings potential in terms of labor and staffing**, which are significant cost factors in professional cleaning and facility management.

**d)** **Market Entry Barriers** 

Despite its technical differentiation, various entry barriers must be considered across all target regions:

· **Regulatory hurdles**: Approval of biocidal products requires extensive documentation and testing,
 depending on regional requirements (e.g., EU BPR, U.S. EPA).

· **Brand loyalty**: Many institutional buyers maintain long-term supplier relationships and preferred
 vendor lists.

· **Established distribution and logistics structures**: Competitors benefit from mature networks, training
 programs, and service infrastructure.

· **Trust and credibility**: Market acceptance of new products depends on demonstrable efficacy,
 safety, and seamless integration into existing hygiene protocols.

MEDUSA already holds regulatory approvals in Europe and the Middle East. According to the CS Diagnostics Group, approval processes for North America are ongoing, and research is underway for entry into African and Asian / Pacific markets.

**3.** **Valuation of the Distribution Rights for MEDUSA** 

**a)** **Total Market and Target Market** 

The valuation of the exclusive global distribution rights for the surface disinfectant MEDUSA is based on an assessment of the underlying addressable market. Relevant in this context are the markets for professional surface disinfection in **Europe**, **North America**, **Middle East and Africa** and in **Asia / Pacific**, where MEDUSA's product concept is aligned with regulatory frameworks, market structures, and application profiles.

The available market data indicates steady growth in the coming years. The aggregate size of the target market is projected to increase from **USD 5.46 billion in 2023** to **USD 8.84 billion in 2030**, representing a compound annual growth rate (CAGR) of **7.1%**. In the same period, the global market is expected to grow to **USD 9.49 billion** (CAGR: **7.2%**). The regional development is summarized below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Region**  | **Market Volume<br> 2023<br> (USD million)** | **2025<br> (USD million)** | **2030<br> (USD million)** | **CAGR<br> 2023-2030<br> (%)**  | **Target<br> Market**  |
| **Europe** | 1634 | 1859 | 2565 | 6.7 | yes |
| **North America** | 1968 | 2238 | 3089 | 6.7 | yes |
| **Middle East & Africa** | 331 | 380 | 535 | 7.1 | yes |
| **Asia / Pacific** | 1528 | 1788 | 2651 | 8.2 | yes |
| **Remaining World** | 390 | 451 | 649 | 7.6 | no |
| **Global Market Total** | **5850** | **6716** | **9490** | **7.2** |  |
| **Target Market Total** | **5461** | **6265** | **8841** | **7.1** |  |

---

The addressable target market accounts for approximately 93% of the global market volume. The valuation is based exclusively on this portion of the market, as no market entry strategy is currently planned for the remaining regions.

**b)** **Volume Effect Due to Reduced Application Frequency** 

One of MEDUSA's key product features is the **long-lasting surface presence of the active ingredient**, which remains analytically detectable for up to 10 days. While this does not imply a verified antimicrobial efficacy over that period, it may support a **reduction in disinfection frequency** in operational environments - especially in standardized, high-traffic commercial facilities.

Based on the target customer segmentation, the following distribution and volume impact applies:

---

| | | |
|:---|:---|:---|
| **Segment** | **Share of Sales** | **Volume Effect** |
| Hotels | 30.0% | -50.0% |
| Food Service | 30.0% | 0.0% |
| Other | 40.0% | 0.0% |
| **Weighted Average** |  | **-15.0%** |

---

In hotel operations, a reduction in application frequency appears feasible due to standardized cleaning cycles in guest rooms. In food service and public institutions, however, disinfection is typically integrated into broader cleaning routines, meaning no significant volume effect is expected in those segments. The **overall volume effect is -15%**, which also supports MEDUSA's positioning in terms of time and cost efficiency.

**c)** **Pricing and Cost Structure** 

The economic valuation of the distribution rights is also based on MEDUSA's pricing and cost structure. The product is offered in various unit sizes and as wet wipes. MEDUSA is positioned in the **mid-price range**, while achieving an **average gross margin of 72.4%** due to its low production costs.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Unit Size** | **Sales Price<br> (USD/unit)** | **Cost of Goods<br> Sold (USD/unit)** | **Gross Margin (%)** | **Share of Sales<br> (%)** |
| 250 ml | 4.49 | 1.66 | 63.0 | 11.1 |
| 500 ml | 5.99 | 1.80 | 69.9 | 33.3 |
| 1 Liter | 10.99 | 2.58 | 76.5 | 33.3 |
| 30 ml | 2.49 | 0.56 | 77.5 | 11.1 |
| Wet Wipes | 2.99 | 0.86 | 71.2 | 11.1 |
| **Average** |  |  | **72.4** |  |

---

 **Distribution expenses** are conservatively estimated at **35% of sales**, broken down as follows:

· 20%:
 Distribution partners and wholesalers

· 8%:
 Freight and logistics

· 7%:
 Sales and marketing

These assumptions reflect a typical cost structure for an internationally expanding B2B and B2C consumer product.

**d)** **Discount Rate (Risk-Equivalent Interest Rate)** 

To determine the present value of future cash flows, a **risk-adjusted discount rate** is applied based on the Capital Asset Pricing Model (CAPM). Since the distribution right is treated as a standalone intangible asset, the cost of equity is used as the relevant rate of return:

---

| | | |
|:---|:---|:---|
| **Component** | **Value** | **Description** |
| Risk-Free Rate | 4.3% | 10-year US Treasury Bonds |
| Market Risk Premium | 5.5% | US equity market assumption |
| Beta Factor | 1.6 | Start-up / life science profile |
| Country Risk Premium | 0.8% | Weighted average of target regions |
| **Total Discount Rate** | **13.9%** | Applied as WACC for cash flow valuation |

---

This rate reflects the risk profile of an early-stage, high-margin health-related product without patent protection, but with proven differentiating product characteristics and partial regulatory approval.

**e)** **Present Value of Future Cash Flows** 

The financial value of the distribution right is based on the **discounted future free cash flows** derived from the exclusive commercialization of MEDUSA over a 20-year horizon (2025–2045). The valuation assumes a gradual market penetration, with a market share of **0.1% in 2025** (beginning 4th Quarter of 2025), increasing linearly to **3.0% from 2030 onward**, applied to the defined target market.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Year** | **Sales<br> (USD million)** | **COGS<br> (USD million)** | **Distribution<br> Costs<br> (USD million)** | **Cash Flow<br> (USD million)** | **Net present<br> value<br> (USD million)** |
| 2025 | 1 | -1 | -1 | 1 | 1 |
| 2026 | 41 | -11 | -14 | 15 | 12 |
| 2027 | 79 | -22 | -27 | 29 | 21 |
| 2028 | 122 | -34 | -43 | 45 | 28 |
| 2029 | 170 | -47 | -60 | 64 | 34 |
| 2030 | 225 | -62 | -79 | 84 | 40 |
| 2031–2045 | 5970 | -1650 | -2089 | 2230 | 377 |
| **Total (2025–2045)** |  |  |  |  | **513** |

---

The **net present value (NPV)** of the distribution rights based on expected cash flows and a discount rate of 13.9% amounts to **USD 513 million**.

**4.** **Sensitivity Analysis** 

The valuation of the global distribution rights for MEDUSA is based on a number of assumptions and future expectations, the realization of which cannot be predicted with certainty. Two key variables have a decisive impact on the resulting fair market value:

1. The **actual market share achieved** in the relevant geographical
 target markets (Europe, North America, Middle East and Africa, and Asia / Pacific)

**2.** The **efficiency gain for the end user**, resulting from
 reduced application frequency, which in turn affects the **sales volume and revenue potential** 

While market share depends on factors such as regulatory approvals, distribution reach, and customer acceptance in the professional segment, the volume effect stems from the fact that certain customer groups - particularly in the hotel industry - may significantly reduce the number of daily disinfection applications. This has an impact not only on product consumption but also on revenue generation. For this reason, a sensitivity analysis is necessary to explore various combinations of these two factors.

 **Sensitivity Matrix** 

The table below shows the resulting net present value (in USD million) based on different scenarios for the **final target market share (0.1% to 4.0%)** and the **volume reduction (0% to -30%)**:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Final Target Market<br> Share (%)** | **0%** | **-5%** | **-10%** | **-15%** | **-20%** | **-25%** | **-30%** |
| 0.10 | 20 | 19 | 18 | 17 | 16 | 15 | 14 |
| 0.50 | 101 | 95 | 90 | 85 | 80 | 75 | 70 |
| 0.75 | 151 | 143 | 136 | 128 | 121 | 113 | 106 |
| 1.00 | 201 | 191 | 181 | 171 | 161 | 151 | 141 |
| 1.50 | 302 | 286 | 271 | 256 | 241 | 226 | 211 |
| 2.00 | 402 | 382 | 362 | 342 | 322 | 302 | 281 |
| 2.50 | 503 | 477 | 452 | 427 | 402 | 377 | 352 |
| 3.00 | 603 | 573 | 543 | 513 | 482 | 452 | 422 |
| 3.50 | 704 | 668 | 633 | 598 | 563 | 528 | 492 |
| 4.00 | 804 | 764 | 724 | 683 | 643 | 603 | 563 |

---

 **Interpretation of Results**

· **Base case**: The current valuation of **USD 513 million** is based on achieving a **3.0% market share** and a **weighted volume reduction of -15%**.

· A market
 share 0.5 percentage points lower (i.e., 2.5%) under the same volume effect would result
 in a valuation of **USD 427 million** (-17%).

· Conversely,
 if MEDUSA achieved a 4.0% market share with no volume reduction, the valuation would increase
 to **USD 804 million** (+57% compared to the base case).

· A stronger
 efficiency effect (e.g., -25%) would further reduce revenues and result in a valuation of **USD 452 million** (at 3.0% market share).

This analysis highlights the **significant sensitivity of the valuation to changes in market share and product usage efficiency**.

**5.** **Conclusion on the Fair Market Value of the Distribution Rights for MEDUSA** 

Based on the available market analyses, product characteristics, financial forecasts, and the discounted cash flow (DCF) valuation approach, an indicative valuation has been determined for the exclusive global distribution rights to the surface disinfectant MEDUSA.

The net present value of the projected cash flows over the economic useful life of 20 years (2025-2045), assuming a **target market share of 3.0%** from the year 2030 and a **weighted volume effect of -15%**, amounts to **USD 513 million**. The calculation is based on a **risk-adjusted discount rate of 13.9%**, derived using the CAPM methodology and reflecting the product- and market-specific risk profile.

The valuation is primarily influenced by the following factors:

· the
 actual development of market share in the defined target regions (Europe, North America,
 Middle East & Africa, Asia / Pacific)

· the
 achievable efficiency gains for end users (e.g., reduced consumption due to less frequent
 application)

· the
 pricing and margin structure across the different product variants

· the
 duration and stability of regulatory approvals in the respective regions

The sensitivity analysis presented in Section 4 illustrates the potential range of valuation outcomes under varying assumptions. Depending on the realized market penetration and consumption efficiency, the fair market value may range from approximately **USD 281 million** (2% market share with a 30% volume reduction) to **over USD 700 million** (3-4% market share with lower volume loss or additional growth potential).

Under the assumptions applied in this report, the **fair market value of the distribution rights is estimated at approximately USD 513 million**.

Yours sincerely,

![](wrankmore_sig.jpg)

Tom Wrankmore<br> Wirtschaftsprüfer<br> [certified public auditor]

## Exhibit 99.6

**Exhibit 99.6**

![](ex996-001.jpg)

+:- -'1tit :::;Consignor: Safapac Ltd. 4 Stapledon Road, Orton Southgate Peterborough, Cambridgeshire PE2 6TB United Kingdom : J- ..,11 1 M 3 4 3 4 7 6 ORIGINAL Consignor's ref: 4 : ":!,f l J.,.._,11 2 ".?. ,,?, ?, e .a...iI t ,,?, CS INTERPHARM GENERAL TRADING CO. LLC Bay Square, BB2, Office no. 809 Business Bay, Dubai United Arab Emirates CERTIFICATE OF ORIGIN Originated in: United Kingdom : LaW. ....... 5 Method of Transport: By Air 3 Remarks : 11 Marks and Numbers: : .:.WW!., r11..,'ll "AS ADDRESSED" Quantity and Kind of Packages: : -w,l,Jlt,u½-S MEDUSA MP-003 (Surface sanitizer (biocide)) Description of Goods: : 4&. I .::.la..t.,. Weight (gross & net): 6 : (._,l 'lll.,1.j t-1 1) .:,:,,II Total Gross: 34.2 KG 30 litres packed into 3 boxes, each containing 10 x lL plastic jerricans s per Invoice Number 203235116-2 dated 23/05/2024 Goods Manufactured by: SAFAPAC LTD, 4 STAPLEDON ROAD, ORTON SOUTHGATE, PETERBOROUGH, CAMBRIDGESHIRE, PE2 6TB, UNITED KINGDOM Total Net: 30 KG r., t;. -:,1..., L:J. ,?.. L:J , .. b, "' "f.1-io-::,.,.j},rj-. l;.'.'r l!JII!: - .... UK-CAM54472-4684192-A ece rt.sgs.com .>-;-Jl-p,0o _.liJI t i IIUJ,,-i ARAB-BRITISH CHAMBER OF COMMERCE Issuing Authority 861 Arab-British Chamber of Commerce Tate Freight Forms Tel:+44 (0)203 926 6200 Web: www.tatefreightforms.co.uk

![](ex996-002.jpg)

Safapac COMMERCl/l:i. l NV lCE Invoice Date: 23/05/2024 Invoice Number: 203235116 -2 Page: 1 of 1 Order No: 203235116-2 Seller /Exporter Buyer/Importer Delivery Address Safapac Limited . 4 Sta pledon Road Orton Southgate Peterborough PE2 6TB UK . VATNo: GB676996353 EORINo:676996353000 Tel: +44 (0) 1733 367650 Name: Katarzyna Szulc CS INTERPHARM GENERAL TRADING CO. LLC Bay Square, 882, Office no. 809 Business Bay, Dubai, United Arab Emirates VAT No: 100292175500003 Tel: +971 4 559 6268 Name: Mohammad Essayed CS INTERP HARM GENERAL TRADING CO. LLC Bay Sq u are, BB2, Office no. 809 Business Bay, Dubai, United Arab Emirates VAT No : 100292175500003 Te l: +971 4 559 6268 Name: Mohammad Essayed Email Katarzyna.szulc@safapac.co.uk Email: Mohammad.Essayed@csinterpharm.ae Em ai l: M ohammad .Essa yed@csin t erpharm .ae lncoter ms: DDP, CS I NTERP HARM GENERAL TRAD ING CO. LLC, Bay Square, 882, Office no. 809, Business Bay, Dubai, United Arab Emirates, ln cot erm s 2020 -- -- - ---- Description ---Number of Boxes ----Number of units/bags/boxes - Unit price (Eur) . - Net Weight (legs) Gross Weight (legs) Total Amount (Eur) Product: MEDUSA MP-003 Commodity Code: 3808941000 3 10 x lL bottle (each box) 0.50 10 (each box) 11.4 (each b ox) 15 - -- - - - - --- - Tota l invoice va lue: 15 Euro To tal gross weight (l

![](ex996-003.jpg)

861 Arab-British Chamber of Commerce Tate Freight Forms Tel:+44 (0)203 926 6200 Web: www.tatefreig hlforms.co.uk IConsignor: Safapac Ltd. I' 4 Stapledon Road,' Orton·southgate Peterborough, Cambridgeshire· PE.2 6'):'B ' ' :J-)1 ,, . I,? /? M t !, f 3 4 3 4 7 6 · , ,. ,, ORIGINAL- .. '1..., I IL(United Kingdom Te(Jmi r\efil 367 650 ' : ' J. ,11 II.: ': ... Ii' 'I(,, CS INTERPHARM GENERAL TRADING CO. Bay Square, BB2; Office no. 809 Business Bay, , Dubai'? LLC \('I I , f ,1 CERTIFICA'' TE OF ORIGIN I (,;. ,. I l ?? ,· , , h ? I ! . I !l ('(l,t (' United Arab Emirates f, ' 'I 1 II !.11\1? ! " , , , (II l ' , , . ,. , Originated in: ' 1 I ' i ,. r 11 : 1.aW.... ii 5 I: ' .,. ' ,? United Kingdom ,, Method of Transport: I ... By Air ? I .. I , ?,,.a.:_;. 3 Remarks: ..' ?,. (?,1 , I I ?1 1. I I ' I' 1' '' '" ? I !, ' Marks and Numbers: : ol.:llall, rli_,\'1 1 Quantity and Kind of Packages: ' I : luu Description of Goods: ., : · .:.La..!,. Weight (gross & net): 6 : (J "'-'._,it...! .:u,11 "AS ADDRESSED" MEDUSA MP-003 .. , , (Surface saniti er (biocide)) ,.' 30 litres packed into 3 boxes, each containing 10 x 11 plastic jerricans l .? t ?'1· Total Gross: 34.2 KG , Total Net: 30 KG ' ,. s per Invoice Number 20323511-62 dated 23/05/2024 Goods Manufactured by: SAFAPAC LTD, 4 STAPLEDON ROAD, ORTON SOUTHGATE, PETERBOROUGH, CAMBRIDGESHIRE. PE2 6TB, UNITED KINGDOM HE UNDERSIGNED AUTHORITY CERTIFIES THAT THE GOODS DESCRIBED ABOVE ORIGINATE IN THE COUNTRY SHOWN IN BOX 5 o r-,i.J Ji,,.Jf i,j ? ? I l.£'L.!.,j.. i i i..i,Sill e:,1....... 11 ..:,i ?liJi u..i_,1.1 I L..Ja..i)-+Jl liJI ,, I IIUJ,,,o,,,,,l ARAB-BRITISH CHAMBER OF COMMERCE Issuing Authority ,. </p

![](ex996-004.jpg)

861 Arab-British Chamber of Com merce , t . ::; Consignor: Safapac Ltd. 4 Stapledon Road, Orton Southgate Peterboroug,h Cambridgeshire PE2 6TB United Kingdom CS INTERPHARM GENERAL TRADING CO. LLC Bay Square, BB2, Office no. 809 Business Bay, Dubai United Arab Emirates : J-.)1 1 M 2 CERTIFICATE ORIGIN 3 4 3 4 7 6 CONTROL COPY Consignor's ref: 4 4 ,,, ?, e i .J1-., .... ?.,., CERTIFICATE OF ORIGIN Originated in: United Kingdom :LAW. ........ 5 Method of Transport: By Air 3 Remarks: 11 Marks and Numbers: : ,:,ldall, i-U}J/1 "AS ADDRESSED" Quantity and Kind of Packages: : -u.,lJI t MEDUSA MP-003 Description of Goods: : i.c. I .:.la.."6 Weight (gross & net): 6 : (._,l lll_, ._,.it...11) . u,11 Total Gross: 34.2 KG (Surface sanitizer (biocide)) 30 litres packed into 3 boxes, each containing 10 x lL plastic jerricans Total Net: 30 KG r=1G;, - · :1 1jil l.:J? I ? ? :? -l.:J .. ":Jri:. ':-.". [!],;.t_...r:?.: .. + UK-CAM54472-4684192-A ecert.sgs.com The Consignor whose name (name of firm) is shown above (1) or the Undersignedwhose name (name of firm) is also shown below (7) APPLIES for the issue of a Certific ate of Origin for the goods detailed herein whose origin is declared above. AND DECLARES that the particulars given in this application and the supporting documents, and information furnished to the Arab-British Chamber of Commerce with a view to the issue of this Certificate; are correct, that the goods to which such documents and information relateare those in respect of which the application is made for the Certificate. that the goods fulfil the conditions laid down by the rules concerning the common definition of the concept of the origin of goods, AND UNDERTAKES to furnish, at the request of the Arab -British Chamber of commerce, such additional information and supporting documents as may be required for the issue of the Certificate. Applicant's name and address, if other than consignor: 7 CAM0054472/004684192/A Place &date: Peterborough 24 May Sig . As per Invoice Number 203235116-2 dated 2310§/.2024 Goods Manufactured by: SAFAPAC LTD, 4 ST LEDON ROAD, ORTON SOUTHGATE CAMBRIDGESHIRE, PE 6TB ITED KINGDOM

![](ex996-005.jpg)

turkuaf ! Turkuaz Sagltk Hizmetleri Dezenfektan Aktivite Test Raporu (Disinfectant Activity Test Report) DokiimanNo: (Document No) Yaym Tarihi: (Date of Published) Revizyon Tarihi: (Date of Revision) Revizyon No: (Revision No) RP.07.05.01 23.08.2017 00 Turkuaz Saghk Mikrobiyoloji Laboratuvari (Turkuaz Sagltk Microbiology laboratory) iSTANBUL/Tiirkiye(TurkeyJ Tel : +90 212 428 6848 Fax : +90 212 428 6853 E-mail : mik robiyoloji@ turkuazsaglik.com.tr TEST REPORT Dezenfektan Hakkmda TammlayICI Bilgiler (Identification of the disinfectant-sample) Uriin Adi (Name of the product) Lot Numaras1 (Batch number) Uretici (Manufacturer) Saklama Ko ullari (Storage conditions) Urtintin tireticisi tarafmdan tavsiye edilen sulandirma s1v1s1 (Product diluent recommended by the manufacturer for use) Aktifii;erik ve Konsantrasyonu (Active substance(s) and its (their) concentration(s)) Dates of test (Test Tarihi) : Medusa : None :None : 5-30 C : Direct use : Klar based : 18.09.2024 Sonu (Results) : Effective / Etkili EN 13727 standardma gore Pseu domonas aeruginosa, Staphylococcus aureus, Medusa ilrilnil, direkt kullamm ile 20 C de 5 dakika temiz (0,3 g/1 bovine albumin) ortam ko ullarmda bakterisidal aktivitesi c;:a h 1lm1 tlr. Test sonuc;:lanna gore Medusa ilrUnii istenilen siirelerde ad1 gec;:en bakterilere kar t etkili bulunmu tur. (According to EN I 3727 standard, the bactericidal activity of Medusa product was studied under clean (0.3 g// bovine albumin) conditions for 5 minutes at 20 ° C with direct use against Pseudomonas aeruginosa, Staphylococcus aureus. According to the test results, Medusa product was found to be effective against the mentioned bacteria for the desired periods.)

![](ex996-006.jpg)

Logaritmic Reduction>Slog5 min I 8 %90 Temas Soresi (dakika) Contact time (min) Vc2 Yc1 Dron Konsantrasyonu%(Cone. of the product%) Staphylococcus aureus turkuaf Turkuaz Sagllk Hizmetleri Dezenfektan Aktivite Test Rapor,i (Disinfectant Activity Test Report) DoktimanNo: (Document No) RP.07.05.01Yaym Tarihi: (Date of Published) 23.08.2017 Revizyon Tarihi: (Date of Revision) Revizyon No: (Revision No) 00 Standart : EN 13727 (Standarl) Uriin Adi : Medusa Uretiei Adi : None (Name of the product) (Manufacturer) Uriin Lotu : None Uriin Giiriiniimii : Liquid (Batch numbe,) (Appearance of the product) Saklama Ko ullari : 5-30 C (Storage conditions) Diliisyon Niitralizan Method : DE Neutralizing Broth Mcmbran Filtrasyon Metodu : X (Dilution neutralization method) (Membrane filtration method) Yayma Mctodu (Spread plate) Diikme Mctodu Y1kama (:iizcltisi (Rinsing liquid) ; X (Pour plate) ; X Petri Saym : 2 Niitralizan : DE Neutralizing Broth (Number of plates) (Neutralize,) Test S1cakhg1 : 20C inkiibasyon S1cakhg1 : 32,SC (fest temperature) (Incubation temperature) Mikroorganizma : ATCC 6538 S. a11re11s inkiibasyon Ortam1 : ETV-006 (Jest organism) ATCC 9027 P. aemginosa (Incubation substances) Test Tarihi : 18.09.2024 (Date of Test) Sorum Ju Pcrsonel : Esra Kahraman imza (Responsible Person) (Signature) t1lVt Test Siispansiyonu ve Test (Jest Suspension and Test) Pseudomonas aeruginosa Test Siispansiyonu ([est-suspension) (N and NO): N Vea Vo ' . 10-6 133 141 10-1 17 15 Staphylococcus aureus Test Silspansiyonu ([est-suspension) (N and NO): N Vea Vo ', 10-6 144 148 10-1 11 16 Pseudomonas aeruginosa UrOn Konsantrasyonu%(Cone. of the product%) Yc1 Vc2 Temas Sorcsi (dakika) Contact time (min) Logaritmic Reduction %90 4 5 5min >Slog:

![](ex996-007.jpg)

turkuaf Turkuaz Sagltk Hizmetleri Dezenfektan Aktivite Test Raporu (Disinfectant Activity Test Report) DoktimanNo: (Document No) RP.07.05.01Yaym Tarihi: (Date of Published) 23.08.2017 Revizyon Tarihi: (Date of Revision) Revizyon No: (Revision No) 00 Turkuaz Saghk Mikrobiyoloji Laboratuvan (Furkuaz Saglik Microbiology Laboratory) i ST ANBV LIT il rkiye (TurkeyJ Tel : +90 212 428 6848 Fax : +90 212 428 6853 E-mail : mik robiyoloji@turkuazsaglik. com.tr TEST REPORT Dezenfektan Hakkmda Tammlay1C1 Bilgiler (Identification of the disinfectant-sample) Uriln Adi (Name of the product) Lot Numaras1 (Batch numbe,) Uretici (Manufacture,) Saklama Ko ullan (Storage conditions) Urilniln ilreticisi tarafmdan tavsiye edilen sulandirma s1v1s1 (Product diluent recommended by the manufacturer for use) Aktif i erik ve Konsantrasyonu (Active substance(s) and its (their) concentration(s)) Dates of test (Test Tarihi) : Medusa :None : None : 5-30 C : Direct use : Klorbased : 18.09.2024 Sonu (Results) : Effective I Etkili EN 13624 standardma gore Candida albicans, Medusa Uri.inti direkt kullamm ile 20 °C de 5 dakika temiz (0,3 g/1 bovine albumin) ortam ko ullannda yeastsidal aktivitesi r;:ah ilm1 t1r. Test sonur;:larma gore Medusa Uri.inti istenilen si.irelerde adt ger;:en yeastsidal bulunmu tur. EN 13624 standardma gore Aspergillus brasiliensis, Medusa Uri.inti direkt kullamm ile 20 °C de 30 dakika temiz (0,3 g/1 bovine albumin) ortam ko ullarmda fungusidal aktivitesi r;:alt 1lm1 t1r. Test sonur;:lanna gore Medusa i.irlini.i istenilen slirelerde ad1 ger;:en fungusidal bulunmu tur. (According to EN 13624 standard, Candida a/bicans, Medusa product was studied for yeast cidal activity with direct use al 20 ° C for 5 minutes in clean (0.3 git bovine albumin) environmental conditions. According to the test results, Medusa product was found to be yeastcidal for the desired periods of time. According lo EN 13624 standard, Aspergi//us brasiliensis, Medusa product was studied for fungicidal activity with direct use at 20 ° C for 30 minutes in clean (0.3 git bovine albumin) environmental conditions. According to the test results, Medusa product was found to be fungicidal for the desired periods of time.)

![](ex996-008.jpg)

turkuatr'- Turkuaz Sagltk Hizmetleri Dezenfektan Aktivite Test Raporu (Disinfectant Activity Test Report) Doktiman No: (Document No) RP.07.05.01Yaym Tarihi: (Date of Published) 23.08.2017 Revizyon Tarihi: (Date of Revision) Revizyon No: (Revision No) 00 , Standart · - (Standart) Uriin Adi : . (Name of the product) Uriin Lotu (Batch number) Saklama Ko ullan (Storage conditions) Diliisyon Niitralizan Method (Dilution neutralization method) Yayma Metodu (Spread plate) Diikme Metodu (Pour plate) Petri SaylSI (Number of plates) Test S1cakhg1 (Test temperature) Mikroorganizma (Test organism) Test Tarihi (Date of Test) Sorumlu Personel (Responsible Person) : EN 13624 : Medusa : None : 5-30 C : DE Neutralizing Broth : : X : 2 : 20C : ATCC 10231 C albicans ATCC 16404 A. brasiliensis : 18.09.2024 : Esra Kahraman Uretici Adi (Manufacturer) Uriin Giiriiniimii (Appearance of the product) Mcmbran Filtrasyon Metodu (Membrane filtration method) Y1kama <;:ozeltisi (Rinsing liquid) Niitralizan (Neutralize,) inkiibasyon S1cakhg1 (Incubation temperature) inkiibasyon Ortam1 (Incubation substances) imza (Signature) : None : Liquid :x :x : DE Neutralizing Broth : 22,SC : ETV-004 !AA Candida a/bicans Oriin Konsantrasyonu%(Cone. of the product %) Ve1 Ve2 Temas Siiresi (dakika) Contact time (min) Logaritmic Reduction %90 2 1 5 min >4log Aspergillus brasi/iensis Oriin Konsantrasyonu%(Cone. of the product%) Ve1 Ve2 Temas Siiresi (dakika) Contact time (min) Logaritmic Reduction %90 2 5 30min >4logTest Siispansiyonu ve Test (Test Suspension and Test) Ca111/id11 albica11s Test Siispansiyonu rrest-susoension) (N and NO): N Ve, Vo - 1 . 10-5 120 133 10-6 14 IO Aspergill11s brasilie11sis Test Siispansiyonu (Iest-susoension) (N and NO): N Vc1 Vc2 10-5 123 110 10·6 11 13

![](ex996-009.jpg)

Machine Translated by Google FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOPROCESSING IGB Interim report Experiment on surface disinfection without mechanics ? Work package 1 Innovation field: virus-based technologies Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB Nobelstrasse 12 70569 Stuttgart Projektpartner: CS Interpharm L.L.C. and CS Diagnostics Created on 30.03.2022

![](ex996-010.jpg)

Machine Translated by Google Contents 1 Introduction .................................................................................................................. 1 2 Experimental procedure .................................................................................................. 1 Results .................................................................................................................................. 3 Work package 1 ............................................................................................................... 3 3 3.1 3.1.1 3.1.2 3.1.3 3.1.4 Staphylococcus aureus .................................................................................................. 3 Pseudomonas aeruginosa .............................................................................................. 4 Candida albicans ........................................................................................................... 5 Phi6 ............................................................................................................................... 6 4 Summary ...................................................................................................................... 8 5 Source reference ............................................................................................................ 9 Fraunhofer IGB , I \| I

![](ex996-011.jpg)

Machine Translated by Google Fraunhofer IGB 1 \| 9 Introduction 1 Introduction To verify the effectiveness of the test provided by CS Interpharm LLC and CS Diagnostics A surface disinfection test (EN 14476:2019) based on the VAH (Association for Applied Hygiene) was carried out on the surface disinfectant "Medusa". This test took place at the Fraunhofer Institute for Interfacial Engineering and Biotechnology, one of over 80 research institutes of the Fraunhofer Society, which has more than 40 locations throughout Germany. Various accredited test laboratories are available for this purpose in different institutes of the Fraunhofer Society. In this specific case, the disinfecting properties of "Medusa" were tested on four different organisms: a gram-positive bacterium (Staphylococcus aureus), a gram-negative bacterium (Pseudomonas aeruginosa), an enveloped virus (Phi6) and a yeast fungus (Candida albicans). This interim report presents the results from Work Package 1 (WP1, 5-min incubation), in which the bactericidal, fungicidal and virucidal efficacy of two different formulations in five concentrations each was determined. Experimental procedure Stainless steel plates, Ø 15 mm, served as model surfaces. In preparation, the test surfaces were cleaned with universal cleaner and placed in isopropanol (70 vol.%). Finally, the platelets were washed in ultrapure water and dried at 70 °C. The pathogens used were cultivated in liquid culture according to the optimal growth conditions. To simulate a contaminated surface, 0.05 ml of the test suspension was applied to the center of each test area (see Figure 1). The area was dried under the safety cabinet for 120 minutes. After the test suspension had dried, the test areas were covered with 0.1 ml of product test solution. After 5 minutes, the exposure time of the test solution was stopped by adding 5 ml of neutralization buffer. Dilutions were then made in phosphate buffered saline (PBS) and 10 µl each was dropped in triplicate onto TSA plates. Figure 1: Test setup AP1 Stainless steel plate with 50 µL pathogen suspension

![](ex996-012.jpg)

Machine Translated by Google Fraunhofer IGB 2 \| 9 The culture media for determining pathogen growth were incubated for 24 hours at 37 °C ± 1 °C (P. syringae 25 °C ± 1 °C). The disinfecting effect was determined based on the reduction in colony forming units (CFU) for bacteria and fungi or plaque forming units (PFU) for viruses compared to the untreated sample. To check the experiments carried out, four controls were carried out to confirm the effectiveness of the test solution and to exclude interfering influences from the neutralization buffer. Experimental procedure Table 1: Controls Number Designation K0 K1 K2A K2B K3 Control (CFU/PFU) of the originally used pathogen culture Control 1 ? Test solution was replaced by PBS Control 2A ? Test solution 1 (formulation 1) was mixed with 5 ml of neutralization buffer and incubated for 5 minutes ? then 50 µL of pathogen suspension were added - determines the successful neutralization of the test solution by the Neutralization buffer Control 2B - Test solution 6 (formulation 2) was mixed with 5 ml of neutralization buffer and incubated for 5 minutes - then 50 µL of pathogen suspension were added - determines the successful neutralization of the test solution by the Neutralization buffer Control 3 ? 50 µL pathogen suspension was incubated with 5 ml neutralization buffer for at least 30 minutes to exclude any influence of the neutralization buffer K4 Control 4 ? Test solution and neutralization buffer were replaced by PBS ? determines the loss of CFU/PFU through the test itself For evaluation, the number of remaining CFU for bacteria and fungi respectively was used. PFU for viruses are counted in at least three biological replicates and compared to an untreated control. If a reduction of at least 5 log levels for bacteria or a reduction of at least 4 log levels for viruses and fungi can be demonstrated for the selected test concentration and test time, the surface disinfectant can be described as bactericidal, virucidal or fungicidal under the set parameters. Table 2: Neutralization solution Neutralization solution Polysorbat 80 30 g/l Lecithin 3 g/lL-Cystein 1 g/l,H20 ad 1000 ml

![](ex996-013.jpg)

Machine Translated by Google Fraunhofer IGB 3 \| 9 2 Results Results 2.1 Work Package 1 In work package 1, the bactericidal, fungicidal and virucidal effects of the disinfectant "Medusa" were investigated in two formulations (A ? "Medusa alcohol based" and B ? "Medusa alcohol free") using five different concentrations (1-5) with an exposure time of 5 minutes. 2.1.1 Staphylococcus aureus Staphylococci are widespread as commensal colonizers of the skin and the mucous membranes of the oropharynx in humans and animals, and are facultatively pathogenic as infectious agents. The most pathogenic of the known staphylococcal species is Staphylococcus (S.) aureus [1]. Infections with S. aureus are difficult to treat due to resistance to various groups of antibiotics. The control: Control 0 shows the initial CFU of the pathogen culture used. In control 1, the disinfectant was replaced by pH-stabilized saline solution (PBS) and shows the remaining CFU (the reduction) by the test setup itself. In controls 2A, the disinfectant was added to neutralization solution before the start of the test, thus showing the effectiveness of the neutralization. In control 3, pathogens were added to neutralization buffer and then plated, which shows a possible Influence (reduction) of CFU by the neutralization buffer. The result of the controls carried out is that the test resulted in a reduction in the CFU of around 1.5 log levels. This is mainly due to the drying of the bacteria on the surface and was expected. The other controls show no significant reduction in the CFU, which suggests that a reduction in the germs due to the buffers used can be ruled out and is instead due to the disinfectant. Testing solutions: For test solutions A1 - A5, a reduction in CFU of at least 5 log levels was determined, so these solutions can be described as bactericidal.

![](ex996-014.jpg)

Machine Translated by Google Fraunhofer IGB 4 \| 9 Staphylococcus aureus 1010 109 108 107 106 KBE 105 104 103 102 101 A1A2A3A4A5B1B2B3B4B5 Results Control 0 above sea level Control 1 Control 2A Control 3 Control 4 Figure 2: Proof of efficacy for the test organism S. aureus (5 min incubation time) Total number of CFU counted (Y-axis) for each test solution and controls (X-axis). The distance between the dotted lines corresponds to the required reduction by 5 log levels. 2.1.2 Pseudomonas aeruginosa Pseudomonas aeruginosa is one of the most common causes of nosocomial pneumonia worldwide in the case of ventilation, wound and urinary tract infections. Infection with these bacteria can lead to sepsis. Immunocompromised patients are primarily affected. Nosocomial pneumonia and sepsis are associated with high mortality. The natural reservoir of P. aeruginosa is moist habitats in the environment, where many sufferers first become infected with the pathogen. Transmission from patient to patient (e.g. via the hands of nursing staff) also occurs within hospitals. Most P. aeruginosa strains are naturally resistant to a variety of antibiotics [²] and are therefore difficult to treat. The control: The controls were carried out according to Table 1 for the gram-negative pathogen Pseudomonas aeruginosa and correspond in type and severity to the Results of S. aureus (see section 3.1.1). A disinfectant effect can therefore be attributed to the effect of the test substance.

![](ex996-015.jpg)

Machine Translated by Google Fraunhofer IGB 5 \| 9 Results Pseudomonas aeruginosa 1010 109 108 107 106 KBE 105 104 103 102 101 A1A2A3A4A5B1B2B3B4B5 Control 0 Control 1 Control 2A Control 3 Control 4 Figure 3: Evidence of efficacy for the test organism P. aeruginosa (5 min incubation time) Total number of CFU counted (y-axis) for each test solution and controls (x-axis). The distance between the dotted lines corresponds to the required reduction by 5 log levels. Testing solutions: For test solutions A2 - A5, a reduction in CFU of at least 5 log levels was determined, so these solutions can be described as bactericidal. 2.1.3 Candida albicans Candida albicans is a fungus of the genus Candida, which belongs to the yeast family. In humans, it occurs mainly as a saprophyte, but also occurs as a facultative pathogen that can cause so-called candidiasis as an opportunistic pathogen [3]. The control: The controls were carried out according to Table 1 for the pathogen Candida albicans and correspond in type and severity to the results for S. aureus (see section 3.1.1) and Pseudomonas aeruginosa (see section 3.1.2). A disinfectant effect can therefore be attributed to the effect of the test substance.

![](ex996-016.jpg)

Machine Translated by Google Fraunhofer IGB 6 \| 9 Candida albicans 1010 109 108 107 106 KBE 105 104 103 102 101 A1A2A3A4A5B1B2B3B4B5 Results Control 0 above sea level Control 1 Control 2A Control 3 Control 4 Figure 4: Evidence of efficacy for the test organism C. albicans (5 min incubation time) Total number of CFU counted (y-axis) for each test solution and controls (x-axis). The distance between the dotted lines corresponds to the required reduction by 4 log levels. Testing solutions: For test solutions A2 - A5, a reduction of the CFU of at least 4 log levels was determined, which means that these could be described as yeasticidal (fungicidal agent that also kills yeast fungi). 2.1.4 Phi6 Phi6 is an enveloped RNA virus with a segmented double-stranded genome. Phi6 is very similar to SARS-CoV-2 or influenza viruses in terms of particle size, external structure and type of genome. Phi6 is therefore an ideal model virus for virological studies. Unlike other surrogate viruses, Phi6 is a bacteriophage that can only infect bacteria and poses no danger to humans, animals or plants. Despite repeated testing, the drying of the viruses led to fluctuations in the plaque-forming units, which prevented reliable counting. The experiment was repeated with non-dried viruses. Stable measurement results were achieved here. The following results show the experiment with non-dried viruses.

![](ex996-017.jpg)

Machine Translated by Google Fraunhofer IGB 7 \| 9 The control: Results The controls were carried out for the Phi6 virus as shown in Table 1 for formulations A and B and correspond in type and severity to the results of Formulation A for S. aureus (see section 3.1.1) and Pseudomonas aeruginosa (see section 3.1.2) or Candida albicans (see section 3.1.3). A disinfecting effect can therefore be attributed to the effect of the test substance. Phi6 without drying out PFU 1010 109 108 107 106 105 104 103 102 101 A1A2A3A4A5B1B2B3B4B5 Control 0 above sea level Control 1 Control 2A Control 3 Control 4 Figure 5: Proof of efficacy for the test organism Phi6 (5 min incubation time) Total number of PFU counted (y-axis) for each test solution and controls (x-axis). The distance between the dotted lines corresponds to the required reduction by 4 log levels. Testing solutions: For test solutions A1 to B5, a reduction of the CFU of more than 4 log levels was determined, all test solutions can therefore be considered as limited virucidal (disinfectants that only inactivate enveloped viruses).

![](ex996-018.jpg)

Machine Translated by Google Fraunhofer IGB 8 \| 9 3 Summary Summary The disinfectant "Medusa" was tested using four test organisms, representing different pathogens. Two formulations were used: "Medusa alcohol based" (formulation A) and "Medusa alcohol free" (formulation B), each in five concentrations. The disinfectant showed disinfecting properties within a contact time of 5 minutes. Formulation A achieved a significant reduction in the bacteria S. aureus and P. aeruginosa, the yeast Candida albicans and the surrogate virus Phi6, which kills enveloped viruses such as the influenza virus is simulated. Formulations A2 to A5 (Medusa Alcohol based)can therefore be classified as bactericidal, yeasticidal and limited virucidal. Formulation B (Medusa Alcohol free), sufficient to be described as limited virucidal (effective against enveloped viruses). Prof. Dr. Susanne M. Bailer Head of Virus-based Technologies Head of Virus-Based Therapies Branch Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB Institute of Interfacial Process Engineering and Plasma Technology IGVP the University of Stuttgart Nobelstrasse 12 70569 Stuttgart, Germany

![](ex996-019.jpg)

Machine Translated by Google Fraunhofer IGB 9 \| 9 4 Source reference Source reference [1] RKI Guide - Staphylococcal diseases, especially infections caused by MRSA[https://www.rki.de/DE/ Content/Infekt/EpidBull/Merkblaetter/Ratgeber_St aphylokokken_MRSA.html;jsessionid=5BD3D0C5405FC570A47E43E03DCB4A 7C.internet092#doc2373986bodyText2 [2] [https://www.rki.de/DE/Content/Infekt/Antibiotikaresistenz/nosokomiale_Errege r/Pseudomonas.html] [3] https://flexikon.doccheck.com/de/Candida_albicans

![](ex996-020.jpg)

0C (/) '.5-3g :g;. ffi CD@ - [:(l ro - ,:: MEDUSA is a Surface Disinfectant Product (SDP) kills 99.999% of Bacteria and Enveloped Viruses including I me® Restaurants @ Bars0 Aircrafts @ Public transport® Stadiums. Directions for use:0 Turn the green Q. :;::- nozzle to the open position8 Lightly mist desired surface at a distance of 20 cm O Wipe surface with a clean Q.- _l- [ cloth and allow MEDUSA to dry completely.0 After applying, use tap water to clean spillages and dirt. C, For ""Tl ll> 3 ..... proven lasting use the MEDUSA" Test Kit to check surfaces every 3 to 5 days. Suitable for use on Tables; :? g-rn Q Seating; Door handles; Touchscreens; Toilet seats; Baths and Taps; Refrigerators; Changing mats; Highchairs; 8 3 ro s= Desks ; Windows ; Mirrors; Fabrics; Bins; Food contact surfaces; Painted or Varnished surfaces. Storage: Keep 0 C - ;} £; out of reach of children. Store at room temperature, keep out of direct sunlight and away from food and drink. 'C C Keep only in the original container. Warnings and Precautions: Avoid inhalation and eye contact. Causes skin 95 and serious eye irritation. First Aid: ? If inhaled, move person to a well-ventilated area. ? If contact with the (/) eyes, rinse cautiously with water for several minutes. Remove contact lenses if present. If eye irritation persists, ?>-a.CO seek medical advice ? If swallowed, rinse mouth with water. Do not induce vomiting. Seek immediate medical)> ocw advice/attention ? If skin contact, wash immediately with plenty of water and soap. If skin irritation or rash : occurs , seek medical advice/attention. 7J\* Ingredients include: Water (Ultra clean), Oidecyldimethylammonium Chloride, Benzalkonium Chloride and 8 "0. Polyquat DMNE. Manufactured in United Kingdom. C')o

![](ex996-021.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? PRODUCT INFORMATION SHEET MEDUSA - Alcohol Free Surface Disinfectant Solution Version_1

![](ex996-022.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? 1 Description: MEDUSA offers top-tier disinfectant solutions tailored for diverse environments, including homes, offices, hospitality venues, general public spaces, and healthcare facilities. MEDUSA alcohol-free formula ensures powerful antimicrobial protection tailored to provide 99.99% results. The product is available in various pack sizes: 30ml, 100 ml, 500 ml, 750 ml, 1000 ml, as well as available to be supplied in bulk starts with 5 litre pack. Key Features: ? Bactericidal, fungicidal, virucidal ? Direct application on different surfaces ? Alcohol-free formulation, Non-Dangerous and Non-Inflammable ? Advanced formula with optimum pH 5 to 7 ? European quality manufacturing. ? Check presence of MEDUSA using MEDUSA strips. ? Recyclable bottle and trigger Active Ingredients: 1. Di-decyl di-methyl Ammonium Chloride: It is a fungicide, an antiseptic for wood and other surface and disinfectant for cleaning. 2. Benzalkonium Chloride: It is quaternary ammonium compound used in the pharmaceutical and chemical industry as an antimicrobial preservative, antiseptic, and disinfectant. 3. Polyquat DMA/E 50: The non-irritating ingredient enduring biocidal properties and effectively removing both organic and inorganic residues. Physical Properties: Property/ Parameter DescriptionState LiquidColour Colourless/ TransparentOdour MildpH 5.00 ?7.00 Shelf Life: The expiry date is 24 months. The shelf life was defined according to the stability and primary packaging (compatibility) test results and the knowledge and experience on the product and/or similar formulas.

![](ex996-023.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? 2 Quality Assurance: Every batch of MEDUSA undergoes rigorous testing to verify its effectiveness and safety, complying with the latest EU standards for biocidal products. Handling Instructions: Precautions for use: Safety data sheet available on request. Read label before use. Keep out of reach and sight of children. If medical advice is needed, have the product container or the label handy. Wash hands thoroughly after handling. Do not swallow. Dispose of content/container according to national regulation. Use biocides safely and sustainably. It is illegal to use this product for uses or in a manner other than prescribed in this document. Do not apply soap application after spraying MEDUSA. For more information: For information, you can contact CS Interpharm General Trading Co LLC, +971 4 559 6268. Disinfection Performance: This product starts killing microorganism (Bacteria, Yeast, Fungi and Virus) in 5 minutes which last more than ten days. Bacteria: Test Method Test DurationTest Organism EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Staphylococcus aureus ATCC 6538 EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Escherichia coli ATCC 10536 EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Pseudomonas aeruginosa ATCC 15442 EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Enterococcus hirae ATCC 10541 Fungi: Test Method Test DurationTest Organism EN 1650: Yeasticidal activity for food, industrial, domestic and institutional areas 5 Minutes Candida albicans

![](ex996-024.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? 3 Virus: (Proven Virucidal efficacy against SARS COV 2 Like virus even after 10 days of application) Test Method Test DurationTest Organism EN 14476: (Virucidal, all enveloped viruses such as Influenza virus) 5 Minutes Influenza virus EN 14476: (Limited Virucidal, all enveloped viruses such as Coronavirus, HIV, Herpes virus, Hepatitis virus). 5 Minutes Phi 6, surrogate SARS-CoV-2 Storage: Temperature Conditions: Store the containers in a cool, dry place with a storage temperature not exceeding +30°C (86°F). Shelf Life of strip: When stored correctly, MEDUSA test strips remain effective until the expiry date marked on the package. Keep MEDUSA test strips shielded from direct sunlight and moisture to preserve their integrity. Method of Use: Product usage: The product is an alcohol-free ready-to-use multipurpose spray for surface disinfection. The spray is intended for use by professionals in commercial areas (offices, retail, airports, bus stations, supermarkets, etc.), food service and industrial areas (manufacturing and transport/maintenance) as well as home and other hospitality venues. Instruction of use: Turn the nozzle to the ON position. Keeping the bottle upright, spray from 20?25 cm away. Leave for up to five minutes, wipe clean. For professional use you must wear gloves. For surfaces that come in contact with food: use only on hard non-porous surfaces and rinse thoroughly with water. Test Method to check working efficiency of MEDUSA even after days of application. Step 1: Activation of test strips by dipping strip into water and shake off excess water from the test strip. Step 2: Apply this strip to the MEDUSA treated area and wait for few minutes. Step 3: Observe the colour change on the strip to check the presence of MEDUSA.

![](ex996-025.jpg)

7/25/2024 (Issue date) GB - en1/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Issue date: 7/25/2024 Version: 1.0 Product form : Mixture Name : Medusa Alcohol-Free Product code : MED03B100 Type of product : Biocidal products (e.g. Disinfectants, pest control) 1.2. Relevant identified uses of the substance or mixture and uses advised against Relevant identified uses Intended for general public Main use category : Consumer use,Professional use,Industrial use Use of the substance/mixture : Bactericide Disinfectant 1.3. Details of the supplier of the safety data sheet Supplier CS INTERPHARM GENERAL TRADING CO., LLC Bay Square, BB2, Office no. 809-816 Buisness Bay Dubai United Arab Emirates T +971 4 559 6268 info@csinterpharm.ae, www.csinterpharm.ae 1.4. Emergency telephone number Emergency number : +971528611930 (Office Hours) Country/Area Organisation/Company Address Emergency number Comment United Kingdom National Poisons Information Service (Birmingham Centre) City Hospital Dudley Road B18 7QH 0344 892 0111 Classification according to Regulation (EC) No. 1272/2008 [CLP] Hazardous to the aquatic environment ? Chronic Hazard, Category 3 Full text of H and EUH statements: see section 16 H412 Adverse physicochemical, human health and environmental effects Harmful to aquatic life with long lasting effects. 2.2. Label elements Labelling according to Regulation (EC) No. 1272/2008 [CLP] Signal word (CLP) : - Hazard statements (CLP) : H412 - Harmful to aquatic life with long lasting effects. Precautionary statements (CLP) : P102 - Keep out of reach of children. P273 - Avoid release to the environment. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation. SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier SECTION 2: Hazards identification 2.1. Classification of the substance or mixture

![](ex996-026.jpg)

7/25/2024 (Issue date) GB - en2/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 2.3. Other hazards Contains no PBT/vPvB substances ? 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 Name Product identifier Conc. (% w/w) Classification according to Regulation (EC) No. 1272/2008 [CLP] BENZALKONIUM CHLORIDE CAS-No.: 68424-85-1 EC-No.: 270-325-2 REACH-no: 01-2119965180- 41 < 1 Acute Tox. 4 (Oral), H302 Skin Corr. 1B, H314 Eye Dam. 1, H318 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 1, H410 didecyldimethylammonium chloride CAS-No.: 7173-51-5 EC-No.: 230-525-2 EC Index-No.: 612-131-00-6 REACH-no: 01-2119945987- 15 < 1 Acute Tox. 4 (Oral), H302 Acute Tox. 4 (Dermal), H312 Skin Corr. 1B, H314 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 2, H411 Methanamine, N-Methyl-, polymer with 2- (chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy- 1,3-propanoldiylchloride CAS-No.: 25988-97-0 < 1 Acute Tox. 4 (Oral), H302 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 1, H410 Full text of H and EUH statements: see section 16 First-aid measures general : If you feel unwell, seek medical advice. First-aid measures after inhalation : Remove person to fresh air and keep comfortable for breathing. First-aid measures after skin contact : Wash skin with plenty of water. First-aid measures after eye contact : Rinse eyes with water as a precaution. First-aid measures after ingestion : Call a poison center or a doctor if you feel unwell. 4.2. Most important symptoms and effects, both acute and delayed Symptoms/effects after inhalation : None under normal use. Symptoms/effects after skin contact : None under normal conditions. Symptoms/effects after eye contact : None under normal conditions. Symptoms/effects after ingestion : None under normal conditions. 4.3. Indication of any immediate medical attention and special treatment needed Treat symptomatically. Suitable extinguishing media : Water spray. Dry powder. Foam. Carbon dioxide. Unsuitable extinguishing media : Do not use a heavy water stream. SECTION 3: Composition/information on ingredients 3.2. Mixtures SECTION 4: First aid measures 4.1. Description of first aid measures SECTION 5: Firefighting measures 5.1. Extinguishing media

![](ex996-027.jpg)

7/25/2024 (Issue date) GB - en3/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 5.2. Special hazards arising from the substance or mixture Fire hazard : No fire hazard. Explosion hazard : No direct explosion hazard. Hazardous decomposition products in case of fire : Toxic fumes may be released. 5.3. Advice for firefighters Firefighting instructions : Fight fire from safe distance and protected location. Do not enter fire area without proper protective equipment, including respiratory protection. Protection during firefighting : Do not attempt to take action without suitable protective equipment. Self-contained breathing apparatus. Complete protective clothing. General measures : Stop leak if safe to do so. Notify authorities if product enters sewers or public waters. Absorb spillage to prevent material damage. For non-emergency personnel Protective equipment : Wear recommended personal protective equipment. Emergency procedures : Ventilate spillage area. For emergency responders Protective equipment : Do not attempt to take action without suitable protective equipment. For further information refer to section 8: "Exposure controls/personal protection". Emergency procedures : Evacuate unnecessary personnel. Stop leak if safe to do so. 6.2. Environmental precautions Avoid release to the environment. 6.3. Methods and material for containment and cleaning up For containment : Absorb spilled material with sand or earth. Contain any spills with dikes or absorbents to prevent migration and entry into sewers or streams. Stop leak without risks if possible. Methods for cleaning up : Take up liquid spill into absorbent material. Other information : Dispose of materials or solid residues at an authorized site. 6.4. Reference to other sections For further information refer to section 13. Additional hazards when processed : Not expected to present a significant hazard under anticipated conditions of normal use. Precautions for safe handling : Ensure good ventilation of the work station. Wear personal protective equipment. Hygiene measures : Do not eat, drink or smoke when using this product. Always wash hands after handling the product. 7.2. Conditions for safe storage, including any incompatibilities Technical measures : Keep in a cool, well-ventilated place away from heat. Storage conditions : Keep cool. Protect from sunlight. Packaging materials : Store always product in container of same material as original container. 7.3. Specific end use(s) No additional information available SECTION 6: Accidental release measures 6.1. Personal precautions, protective equipment and emergency procedures SECTION 7: Handling and storage 7.1. Precautions for safe handling

![](ex996-028.jpg)

7/25/2024 (Issue date) GB - en4/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 No additional information available 8.2. Exposure controls Appropriate engineering controls Appropriate engineering controls: Ensure good ventilation of the work station. Personal protection equipment Personal protective equipment: Wear recommended personal protective equipment. Personal protective equipment symbol(s): Eye and face protection Eye protection: Safety glasses Skin protection Skin and body protection: Wear suitable protective clothing Hand protection: Protective gloves Respiratory protection Respiratory protection: In case of insufficient ventilation, wear suitable respiratory equipment Environmental exposure controls Environmental exposure controls: Avoid release to the environment. Physical state : Liquid Colour : Colourless. Odour : characteristic. Odour threshold : Not available Melting point : Not applicable Freezing point : 0 °C Boiling point : 100 °C Flammability : Not flammable Lower explosion limit : Not available Upper explosion limit : Not available Flash point : > 100 °C Auto-ignition temperature : Not available Decomposition temperature : Not available pH : 5 ? 7 PH solution concentration : 100 % Viscosity, kinematic : Not available Solubility : Soluble in water. Partition coefficient n-octanol/water (Log Kow) : Not available SECTION 8: Exposure controls/personal protection 8.1. Control parameters SECTION 9: Physical and chemical properties 9.1. Information on basic physical and chemical properties

![](ex996-029.jpg)

7/25/2024 (Issue date) GB - en5/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Vapour pressure : Not available Vapour pressure at 50 °C : Not available Density : Not available Relative density : 0.95 ? 1.05 Relative vapour density at 20 °C : Not available Particle characteristics : Not applicable 9.2. Other information No additional information available The product is non-reactive under normal conditions of use, storage and transport. 10.2. Chemical stability Stable under normal conditions. 10.3. Possibility of hazardous reactions No dangerous reactions known under normal conditions of use. 10.4. Conditions to avoid None under recommended storage and handling conditions (see section 7). 10.5. Incompatible materials Oxidizing agent. Strong acids. 10.6. Hazardous decomposition products Under normal conditions of storage and use, hazardous decomposition products should not be produced. Acute toxicity (oral) : Not classified Acute toxicity (dermal) : Not classified Acute toxicity (inhalation) : Not classified didecyldimethylammonium chloride (7173-51-5) LD50 oral rat 329 mg/kg bodyweight Animal: rat, Guideline: OECD Guideline 401 (Acute Oral Toxicity) LD50 dermal rat > 1000 mg/kg bodyweight Animal: rat, Guideline: OECD Guideline 402 (Acute Dermal Toxicity), Guideline: EU Method B.3 (Acute Toxicity (Dermal)) Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) LD50 oral rat 1672 mg/kg OECD 401 LD50 dermal rat > 2000 mg/kg OECD 402 Skin corrosion/irritation : Not classified pH: 5 ? 7 Serious eye damage/irritation : Not classified pH: 5 ? 7 Respiratory or skin sensitisation : Not classified Germ cell mutagenicity : Not classified Carcinogenicity : Not classified Reproductive toxicity : Not classified SECTION 10: Stability and reactivity 10.1. Reactivity SECTION 11: Toxicological information 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

![](ex996-030.jpg)

7/25/2024 (Issue date) GB - en6/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 STOT-single exposure : Not classified STOT-repeated exposure : Not classified Aspiration hazard : Not classified didecyldimethylammonium chloride (7173-51-5) Viscosity, kinematic 24.5 mm²/s Temp.: '20°C' Parameter: 'kinematic viscosity (in mm²/s)' 11.2. Information on other hazards No additional information available SECTION 12: Ecological information 12.1. Toxicity Ecology - general : Harmful to aquatic life with long lasting effects. Hazardous to the aquatic environment, short-term (acute) Hazardous to the aquatic environment, long-term (chronic) : Not classified : Harmful to aquatic life with long lasting effects. BENZALKONIUM CHLORIDE (68424-85-1) LC50 - Fish [1] 0.85 mg/l Rainbow trout EC50 - Crustacea [1] 0.016 mg/l EC50 72h - Algae [1] 0.02 mg/l Selenastrum capricornutum didecyldimethylammonium chloride (7173-51-5) LC50 - Fish [1] 0.19 mg/l Pimephales promelas (fathead minnow) EC50 - Crustacea [1] 0.062 mg/l Daphnia magna (Water flea) EC50 96h - Algae [1] 0.026 mg/l Pseudokirchneriella subcapitata (green algae) LOEC (chronic) 0.047 mg/l Test organisms (species): Daphnia magna Duration: '21 d' NOEC (chronic) 0.021 mg/l Test organisms (species): Daphnia magna Duration: '21 d' NOEC chronic fish 0.032 mg/l Danio rerio (zebra fish) NOEC chronic crustacea 0.014 mg/l Daphnia magna (Water flea) Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) LC50 - Fish [1] 0.077 mg/l oncornhynchus mykiss (rainbow trout) OECD 203 EC50 - Crustacea [1] 0.08 mg/l daphina magna (big water flea)OECD 202 ErC50 algae 0.13 mg/l scenedesmus subspicatus OECD 201 NOEC chronic fish 0.024 mg/l oncornhynchus mykiss (rainbow trout) NOEC chronic crustacea 0.026 mg/l daphina magna (big water flea) 12.2. Persistence and degradability Medusa Alcohol-Free Persistence and degradability Not rapidly degradable BENZALKONIUM CHLORIDE (68424-85-1) Persistence and degradability Not rapidly degradable

![](ex996-031.jpg)

7/25/2024 (Issue date) GB - en7/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 didecyldimethylammonium chloride (7173-51-5) Persistence and degradability Not rapidly degradable Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) Persistence and degradability Not rapidly degradable Biodegradation > 80 % 12.3. Bioaccumulative potential Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) Partition coefficient n-octanol/water (Log Pow) < 1 12.4. Mobility in soil No additional information available 12.5. Results of PBT and vPvB assessment No additional information available 12.6. Endocrine disrupting properties No additional information available 12.7. Other adverse effects No additional information available SECTION 13: Disposal considerations 13.1. Waste treatment methods Regional legislation (waste) : Disposal must be done according to official regulations. Waste treatment methods : Dispose of contents/container in accordance with licensed collector's sorting instructions. Sewage disposal recommendations : Disposal must be done according to official regulations. Product/Packaging disposal recommendations : Disposal must be done according to official regulations. Additional information : Do not re-use empty containers. HP Code : HP14 - "Ecotoxic:" waste which presents or may present immediate or delayed risks for one or more sectors of the environment SECTION 14: Transport information In accordance with ADR / IMDG / IATA / ADN / RID ADR IMDG IATA ADN RID 14.1. UN number or ID number Not regulated for transport 14.2. UN proper shipping name Not regulated Not regulated Not regulated Not regulated Not regulated 14.3. Transport hazard class(es) Not regulated Not regulated Not regulated Not regulated Not regulated 14.4. Packing group Not regulated Not regulated Not regulated Not regulated Not regulated

![](ex996-032.jpg)

7/25/2024 (Issue date) GB - en8/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 ADR IMDG IATA ADN RID 14.5. Environmental hazards Not regulated Not regulated Not regulated Not regulated Not regulated No supplementary information available 14.6. Special precautions for user Overland transport Not regulated Transport by sea Not regulated Air transport Not regulated Inland waterway transport Not regulated Rail transport Not regulated 14.7. Maritime transport in bulk according to IMO instruments Not applicable SECTION 15: Regulatory information 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture EU-Regulations REACH Annex XVII (Restriction List) Contains no REACH substances with Annex XVII restrictions REACH Annex XIV (Authorisation List) Contains no REACH Annex XIV substances REACH Candidate List (SVHC) Contains no substance on the REACH candidate list PIC Regulation (Prior Informed Consent) Substances subject to Regulation (EU) No 649/2012 of the European Parliament and of the Council of 4 july 2012 concerning the export and import of hazardous chemicals: Didecyldimethylammonium chloride (7173-51-5) POP Regulation (Persistent Organic Pollutants) Contains no substance subject to Regulation (EU) No 2019/1021 of the European Parliament and of the Council of 20 June 2019 on persistent organic pollutants Ozone Regulation (1005/2009) Contains no substance subject to REGULATION (EU) No 1005/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 September 2009 on substances that deplete the ozone layer. Dual-Use Regulation (428/2009) Contains no substance subject to the COUNCIL REGULATION (EC) No 428/2009 of 5 May 2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items. Explosives Precursors Regulation (2019/1148) Contains no substance subject to Regulation (EU) 2019/1148 of the European Parliament and of the Council of 20 June 2019 on the marketing and use of explosives precursors.

![](ex996-033.jpg)

7/25/2024 (Issue date) GB - en9/10 Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Drug Precursors Regulation (273/2004) Contains no substance subject to Regulation (EC) 273/2004 of the European Parliament and of the Council of 11 February 2004 on the manufacture and the placing on market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances. 15.2. Chemical safety assessment No chemical safety assessment has been carried out SECTION 16: Other information Abbreviations and acronyms: ADN European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways ADR European Agreement concerning the International Carriage of Dangerous Goods by Road ATE Acute Toxicity Estimate BCF Bioconcentration factor BLV Biological limit value BOD Biochemical oxygen demand (BOD) COD Chemical oxygen demand (COD) DMEL Derived Minimal Effect level DNEL Derived-No Effect Level EC-No. European Community number EC50 Median effective concentration EN European Standard IARC International Agency for Research on Cancer IATA International Air Transport Association IMDG International Maritime Dangerous Goods LC50 Median lethal concentration LD50 Median lethal dose LOAEL Lowest Observed Adverse Effect Level NOAEC No-Observed Adverse Effect Concentration NOAEL No-Observed Adverse Effect Level NOEC No-Observed Effect Concentration OECD Organisation for Economic Co-operation and Development OEL Occupational Exposure Limit PBT Persistent Bioaccumulative Toxic PNEC Predicted No-Effect Concentration RID Regulations concerning the International Carriage of Dangerous Goods by Rail SDS Safety Data Sheet STP Sewage treatment plant ThOD Theoretical oxygen demand (ThOD) TLM Median Tolerance Limit VOC Volatile Organic Compounds CAS-No. Chemical Abstract Service number

![](ex996-034.jpg)

7/25/2024 (Issue date) GB - en10/10Medusa Alcohol-Free Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Abbreviations and acronyms: N.O.S. Not Otherwise Specified vPvB Very Persistent and Very Bioaccumulative ED Endocrine disruptor Full text of H- and EUH-statements: Acute Tox. 4 (Dermal) Acute toxicity (dermal), Category 4 Acute Tox. 4 (Oral) Acute toxicity (oral), Category 4 Aquatic Acute 1 Hazardous to the aquatic environment ? Acute Hazard, Category 1 Aquatic Chronic 1 Hazardous to the aquatic environment ? Chronic Hazard, Category 1 Aquatic Chronic 2 Hazardous to the aquatic environment ? Chronic Hazard, Category 2 Eye Dam. 1 Serious eye damage/eye irritation, Category 1 H302 Harmful if swallowed. H312 Harmful in contact with skin. H314 Causes severe skin burns and eye damage. H318 Causes serious eye damage. H400 Very toxic to aquatic life. H410 Very toxic to aquatic life with long lasting effects. H411 Toxic to aquatic life with long lasting effects. H412 Harmful to aquatic life with long lasting effects. Skin Corr. 1B Skin corrosion/irritation, Category 1, Sub-Category 1B Safety Data Sheet (SDS), EU This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

![](ex996-035.jpg)

. Our Vision: Creating an excellent city that provides the essence of success and comfort of sustainable living. +97142246666: u.iS , +97142215555: ? , 67 . P.O.Box: 67 DUBAI, UAE, Tel.: +971 4 221 5555, Fax.: +971 4 224 6666E-mail: info@dm.gov.ae Website: www.dm.gov.ae Public Health & Safety Department Consumer Products Safety Section Consumer Products Registration Certificate Biocides Reference Number: CPRE-2023-026266 : >Registration Status: Approved : Registration Date: 18/05/2023 : Category: Disinfectant Sanitizers : Brand Name: MEDUSA : Company Name: HEXAMET GENERAL TRADING L.L.C : >..! Country of Origin: United Kingdom : L..! J..4 Product Details Product Name MEDUSA - Surface Disinfectant Important Notes Registration Certificate is valid for 5 years from date of issue & any alteration or deletion in any way will invalid it. Registration Certificate is granted upon company's request and the above listed product is freely distributed in the local market & Dubai Municipality will not be responsible for any consequences of variations in the product. Registration Certificate is issued upon the currently enforced regulations and subjected for modification according to the requirements of concerned department. All the imported & marketed products will be subjected to inspection and conformity with the currently enforced regulations This certificate has been electronically generated and approved by Dubai Municipality and does not need signature or Stamp . Consumer Products Safty Section 5 . .'. " ?

![](ex996-036.jpg)

. Our Vision: Creating an excellent city that provides the essence of success and comfort of sustainable living. +97142246666: u.iS , +97142215555: ? , 67 . P.O.Box: 67 DUBAI, UAE, Tel.: +971 4 221 5555, Fax.: +971 4 224 6666E-mail: info@dm.gov.ae Website: www.dm.gov.ae Variants Information MEDUSA - Surface Disinfectant International Barcode: 5065014477007 Scent / Flavor: NONE Product Color / Shade: NONE Size / Weight / Volume: 500 mL

![](ex996-037.jpg)

Produktdatenblatt Datenblatt: Meldung eines Biozid-Produktes nach ChemBiozidMeldeV Unter Zugrundelegung der von Ihnen gemachten Angaben wurde Ihnen eine mit "N" beginnende Registriernummer zugewiesen. Alle in dem Biozid-Produkt "Medusa Alcohol- free" enthaltenen Wirkstoffe sind für die gewählte/n Produktart/en in Anhang II der Delegierten Verordnung (EU) Nr. 1062/2014 gelistet. Ohne vorherige Zulassung darf dieses Biozid-Produkt gemäß § 28 Absatz 8 des Chemikaliengesetzes, sofern die weiteren Voraussetzungen ebenfalls erfüllt sind, bis zur Entscheidung der Genehmigung des/ der Wirkstoff/e auf dem Markt bereitgestellt werden, längstens jedoch bis zum 31. Dezember 2024. GEMELDETES BIOZID-PRODUKT Handelsname (Trad e name) Medusa Alcohol-free RegistriernummerN- 114739 Meldedatum24.09.20 24 Letztes Bestätigung sdatum 24.09.2024 Bestätigung der zu- geschriebenen Wirk ung Im Rahmen der Meldung wurde die zugeschriebene Wirkung des Biozid-Produkts bestätigt. Bitte beachten Sie, dass weder Wirksa mkeit noch Unbedenklichkeit von Biozid-Produkten unter den Üb ergangsregelungen behördlich geprüft sind.

![](ex996-038.jpg)

Hinweis Das Biozidprodukt kann für die Dauer des Genehmigungsverfa hrens des Wirkstoffs bzw. des letzten zu genehmigenden Wirks toffs ohne Zulassung auf dem Markt bereitgestellt werden. Aktiv Wirksto?e (Anhang II) Wirkstoffname Polymer aus N-Methylmethanamin (Einecs 204-697-4) mit (C hlormethyl)oxiran (Einecs 203-439-8)/Polymeres quaternäres Ammoniumchlorid (PQ Polymer) CAS-Nr.25988-97-0 EC-Nr. PT2 ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 0.5 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Polymer of N-Methylmethanamine (EINECS 204-697-4 wit h (chloromethyl)oxirane (EINECS 203-439-8) / Polymeric q uaternary ammonium chloride (PQ Polymer) - Verdant Spe- cialty Solutions GMBH Hinweis Phase-out Datum Aktiv Wirkstoffname Alkyl(C12-16)dimethylbenzylammoniumchlorid (ADBAC/BK C (C12-16)) CAS-Nr.68424-85-1 EC-Nr.270-325-2 PT2

![](ex996-039.jpg)

ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 0.5 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBA C/BKC (C12-16)) - Thor GmbH (Acting for Thor Specialities (UK) Ltd) Hinweis Phase-out Datum Aktiv Wirkstoffname Didecyldimethylammoniumchlorid (DDAC) CAS-Nr.7173-51-5 EC-Nr.230-525-2 PT2 ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 0.5 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Didecyldimethylammonium chloride (DDAC) - THOR ESPE CIALIDADES, S.A. Hinweis Phase-out Datum Aktiv ANGABEN ZUM INVERKEHRBRINGER/HERSTELLER/IMPORTEUR Firmenname CS Diagnostics Pharma GmbH

![](ex996-040.jpg)

Anschrift83052 Bruck mühl, Müller-zu-Bruck-Str. 12 LandDeutschland BundeslandBayern E-Mail Adresseheidi.becker@the-force.org AnsprechpartnerHerrThomas Migotsch Telefon+49 8062 728 0880 Telefax Hinweis Änderungshistorie Datum Änderung 25.09.2024 10:08:44 Produktname: Der Name wurde von Medusa MP-003 in Medusa Alcohol-free geändert.

## Exhibit 99.7

**Exhibit 99.7**

![](ex997-001.jpg)

1 Statement issued by the Health and Safety Executive (For a biocidal product only for export) Statement Number: BIO973 Export of biocides to United Arab Emirates This is to confirm that biocidal products intended to be freely made available on the market in Great Britain require authorisation under Regulation (EU) No 528/2012 as it has effect in Great Britain (hereafter referred to as the GB Biocidal Products Regulation or GB BPR). Biocidal products intended solely for export do not require such authorisation under the GB Biocidal Products Regulation. The product listed below on this statement has not been authorised to be made available on the market in Great Britain. Product name: Medusa MP 001-ALC Active substance(s): Didecyldimethylammonium chloride (CAS# 7173-51-5) Certificate supplied to: Medusa SDP Holdings (United Kingdom) Limited 207 Regent Street London W1B 3HH United Kingdom Signed: R Bankes / S Carey / K Kenyon / C Brockbank (authorised signatories) Date: 13 September 2022 On behalf of the Health and Safety Executive Chemicals Regulation Division, Redgrave Court, Merton Road, Bootle, Merseyside, L20 7HS, United Kingdom Email address: biocidesenquiries@hse.gov.uk Additional information 1. The Health and Safety Executive, on behalf of the Secretary of State (as regards England), the Scottish Ministers (as regards Scotland) and the Welsh Ministers (as regards Wales), pursuant to agency agreements coming into force on 1 January 2021 authorises specifically formulated biocidal products for specific uses in Great Britain. 2. This product does not have authorisation under the GB Biocidal Products Regulation. . 3. This product cannot be made available on the market in Great Britain.

![](ex997-002.jpg)

2 4. The Health and Safety Executive makes no representation as to the legal rights or obligations of whatever nature attaching to the above product, or, concerning the right of the Company to manufacture it. 5. The signatory is authorised by the Health and Safety Executive. Details may be verified with the Legalisation Section, Foreign and Commonwealth Office. Please visit https://www.gov.uk/get-document-legalised for further information. 6. The following information has been supplied by the applicant and has not been verified by the Health and Safety Executive: Product name for export: Medusa MP 001-ALC Manufacturer: Safapac Limited 4 Stapledon Road Orton Southgate Peterborough PE2 6TB United Kingdom Consignor (manufacturer / exporter): Medusa SDP Holdings (United Kingdom) Limited 207 Regent Street London W1B 3HH United Kingdom Consignee (importer / distributor): Elegant Services Office 201 Al Qaizi Building Salah al Deen Road Deira Dubai United Arab Emirates

![](ex997-003.jpg)

THE U N DE RS IGNE D AUT H ORITY C E R TIF I ES TH AT T H E GO O DS D ESCR IBE D AB OV E O RI GI N ATE I N THE CO U NTRY SHOWN IN BOX 3 WEST & NORTH YORKSHIRE CHAMBER OF COMMERCE West & North Yorkshire Chamber of Commerce ELECTRONIC CERTIFYING STAMP 25 Oct 2022 Certificate Number: FJ1411980 Authorised by H M Government ? 1 Consignor Medusa SDP Holdings (United Kingdom) Limited 3rd Floor Office 207 Regent Street London lflB 3HH United Kin dom 2 Con s ignee BEXANBT GENERAL TRADING L.L.C. Office 201, Al Qaizi Building !alah al Deen Road Deira Dubai United Arab Emirates No. FJ 1411980ORIGINAL 640927UAE UNITED KINGDOM CERTIFICATE OF ORIGIN 3 Country of Origin United Kingdom (England). 4 Tran s port details (OptionaQ 5 Remarks 6 It em num ber; mark s; num bers, number and kind of packages;description of goods MEDUSA MP. 001-ALC MEDUSA surface disinfectant (Custom Tariff Code: 3808 94 10 00) 6000 As per Invoice Number MED131721 dated 10/10/2022bottles of Medusa Surface Disinfcetant. 7 Quantity Quantity if not N ight: 500ml Bottles x 6,000 Units= 3,000Ltrs Place anddate of ,ssue: name, s,gnature and stamp of competent authority DTVXP 13026 Tamires Souza-Cichorz AUTHORISED SIGNATORY I!) ?.. UK-CMS50984-4235587·E Mercury Print &Packaging Ltd, Leeds West & North Yorkshire Chamber of Commerce uses the trading name Chamber International for dellvenng trading services

![](ex997-004.jpg)

P.O. Box 67 Dubai, Tel. No.: 00971-4-3027007, Fax: 00971-4-3362696 E-mail: info@dm.gov.ae Website: www.dm.gov.ae Organization: ? ??? ? ? ? ??? ? ? ? ? ? ?? ?? ? Dubai Central Laboratory Department ????????? ??????: Document Title: TEST REPORT ??????? ? ????: Doc Ref. DM-DCLD-F-CP-2154 ??????? ??? : Request No. CPTR-2022-0009725 Report No.538967 Test Start 22.12.2022 Request Date 19/12/2022 12:03PM Report Date28/12/2022 Test Completion 28.12.2022 Customer Information Name: HEXAMET GENERAL TRADING L.L.C E-mail : eserve@eim.ae Contact no. 971568328155 Ref. No. CPRE-2022-065740 Service Type BUSINESS Product Information Name MEDUSA - Surface Disinfectant Brand MEDUSA Manufacturer others Date of Manufacturer 28/04/2022 Country of Origin United Kingdom Batch / Lot. SL280422A Barcode 5065014477007 Quantity 1 Volume 100 ml Active Ingredients Propan-2-ol Dilution condition Direct Condition of use - Laboratory Information Name: Dubai Central Laboratory Department Address & Contact Al Karama area, Dubai, United Arab Emirates, Tel. No.: 00971-4-3027007, E-mail: LABS@dm.gov.ae Website: www.dm.gov.ae, Important Links Service Information Laboratory LocationReport Authentication Date of Issue : 23/09/2022Rev No:. 1Open Data / ??? ?? ? ???? ?? Level of confidentiality / ?????? ????Page 1 of 3

![](ex997-005.jpg)

P.O. Box 67 Dubai, Tel. No.: 00971-4-3027007, Fax: 00971-4-3362696 E-mail: info@dm.gov.ae Website: www.dm.gov.aeDocument ref. DM-DCLD-F-CP-2154Report number. 538967 Microbiology tests Experimental conditions Product diluent Not Applicable Contact time 5 Minutes Test temperature 20 Deg C Interfering substance 3 % Bovine Albumin Incubation temperature 37 Deg C Neutralizer Dey-Engley Neutralizing Broth S/N Test Method Test Parameters Test Suspension Final Count (CFU/ml) Bactericidal Effect (Log Reduction) Specification Limit Bactericidal Efficacy (%)1 Quantitative Suspension Test for Evaluation of Bactericidal Activity of Chemical Disinfectants and antiseptics (BS EN 1276/2019) Staphylococcus aureus ATCC 65387.39 2.15 5.24 ? 5 99.99943 Escherichia coli ATCC 105367.36 2.15 5.21 ? 5 99.99939 Pseudomonas aeruginosa ATCC 15442 7.35 2.15 5.20 ? 5 99.99938 Enterococcus hirae ATCC 105417.40 2.15 5.25 ? 5 99.99945 Report summary Test requested ConclusionObservation Quantitative Suspension Test for Evaluation of Bactericidal Activity of Chemical Disinfectants and antiseptics (BS EN 1276/2019) COMPLIED Based on EN1276:2019 the tested product possesses bactericidal activity in 5 minutes at 20 deg C under dirty condition Date of Issue : 23/09/2022Rev No:. 1Open Data / ??? ?? ? ???? ?? Level of confidentiality / ?????? ????Page 2 of 3

![](ex997-006.jpg)

P.O. Box 67 Dubai, Tel. No.: 00971-4-3027007, Fax: 00971-4-3362696 E-mail: info@dm.gov.ae Website: www.dm.gov.aeDocument ref. DM-DCLD-F-CP-2154Report number. 538967 NOTE: ? The results contained herein apply only to the sample submitted and to the specific tests carried out and to the product information provided by the customer. ? Customer and Product information are provided by the customer and the Laboratory is not responsible for it . ? (\*) Indicates that the test is not accredited by EIAC. ? (\*\*) Indicates Halal Tests accredited by EIAC (EIAC Certification HBN-TEST-001). ? Labeling and shelf life requirements of food products are not part of the test. ? For microbiological results in consumer products, the data on the performance of the method used, which includes information about the variability associated with the reported result is available upon request. ? The expanded uncertainty is based on a coverage factor k=2, at a confidence level of 95%. ? Abbreviation indications: SN = Serial Number, DM= Dubai Municipality, DCLD = Dubai Central Laboratory Department, NA = Not Applicable, NC = Not Conducted, ND = Not Detected, NS=No Standard, , LOD= Limit of Detection, LOQ= Limit of Quantitation, LOR = Limit of Reporting, Uexp % = Expanded Uncertainty Percent. ? For report authentication do not hesitate to contact LABS@dm.gov.ae for any clarification. ? This report cannot be used for advertisement, campaign, and legal purpose without our permission. ? This report shall not be reproduced except in full and with the written approval of the laboratory . The Uexp% (log10 CFU) for Microbiology parameters = 0.026602. Remarks: NIL This is a system generated and electronically approved report by Consumer Products and Commodities Laboratory Section Manager -END OF REPORT- Date of Issue : 23/09/2022Rev No:. 1Open Data / ??? ?? ? ???? ?? Level of confidentiality / ?????? ????Page 3 of 3

![](ex997-007.jpg)

FRAUNHOFER INSTITUTE FOR INTERFACE AND BIOPROCESS ENGINEERING IGB Progress Report Experiment on surface disinfection without mechanics - work package 2 (10 days) Innovation field virus-based technologies Fraunhofer Institute for Interfacial and Biochemical Engineering IGB Nobelstrasse 12 70569 Stuttgart Project partners: CS Diagnostics GmbH CS Interpharm LLC 19. Mai 2022

![](ex997-008.jpg)

Contents 1 Introduction. .......................................................................................................... 1 2 Experimental procedure ........................................................................................ 1 3 3.1 Results. ................................................................................................................... 3 Work package 2....................................................................................................... 3 Sample preparation. ................................................................................................. 3 3.2 Phi6. ......................................................................................................................... 5 4 Summary. ............................................................................................................... 6 5 Sources. .................................................................................................................. 7 Fraunhofer IGB , 2 \| 7

![](ex997-009.jpg)

Fraunhofer IGB 3 \| 7 Introduction 1 Introduction To check the effectiveness of a surface disinfectant developed by CS Diagnostics, a surface disinfection test based on the VAH (Association for Applied Hygiene) was carried out. Representative test organisms were used per test, an enveloped virus (Phi6) . In this interim report the results from work package 2 (WP2, 10 days incubation) are presented, in which a possible virucidal effect was tested on two formulations, each in one concentration. 2 Experimental procedure Small stainless steel plates, Ø 15 mm, served as model surfaces. In preparation, the test surfaces were cleaned with a universal cleaner and placed in isopropanol (70% by volume). Finally, the plates were washed in ultrapure water and dried at 70 °C. The pathogens used were cultivated according to the optimum growth conditions. To simulate a surface impregnated with the newly developed disinfectant, the test areas were standardized sprayed perpendicularly to the surface at a distance of 20 cm with one pump at a time. The amount of disinfectant applied was 5.9 µl/cm² (SD 2.9 µl). As a control, phosphate-buffered saline (PBS) was sprayed onto the slides. After the stainless steel plates had been coated, the plates were stored in sterile 12-well plates at room temperature for ten days until further use. A total of 12 slides were prepared for each organism: Three plates each with test solution A4 (MEDUSA with alcohol) and B4 (MEDUSA without alcohol), another six plaques were treated with control solution (PBS) as reference. 20 cm Figure 1: Schematic representation of the standardized spraying process.

![](ex997-010.jpg)

Fraunhofer IGB 4 \| 7 In order to test the virucidal effect of test solution A4 or B4, after ten days on a metal surface, 50 ÿl of the test organisms were dropped onto the plates and incubated for 15 minutes at room temperature. Disinfection was stopped by adding 1 ml of neutralization buffer, serially diluted and plated. The culture media for determining pathogen growth were incubated for 24 h at 37 °C ± 1 °C (P. syringae 25 °C ± 1 °C). The disinfecting effect was determined based on the reduction of the plaque forming units (PFU) for viruses, compared to the untreated sample. Neutralization buffer controls were performed to evaluate the effectiveness of neutralization and to rule out possible influences of the buffer on the samples. These results can be found in the report on work package I. For the evaluation, the number of remaining PFU for viruses in at least three biological replicates were counted and compared to an untreated control (PBS). If at least four log reductions for viruses could be demonstrated for the selected test concentration and test time, the surface disinfectant can be designated as virucidal under the set parameters. Experimental procedure Table 2: Neutralization solution neutralization solution polysorbate 80 30 g/l lecithin L-cysteine 3 g/l 1 g/l H20 ad 1000 ml

![](ex997-011.jpg)

Fraunhofer IGB 5 \| 7 3 Results Work package 2 In work package 2, the virucidal effect of a surface sprayed with disinfectant was examined after ten days. 3.1 Sample preparation Test solution A4 (MEDUSA with alcohol) required 12 minutes and test solution B4 (MEDUSA without alcohol) 30 minutes to dry. In the case of test solution B4 foam formation was observed after the spraying process. 3.2 Phi6 Phi6 belongs to the enveloped RNA viruses with a segmented double-stranded genome. Phi6 is very similar to SARS-CoV-2 in terms of particle size, external structure and type of genome. Phi6 is therefore an ideal model virus for virological studies. Compared to other surrogate viruses, Phi6 is a bacteriophage which can only infect bacteria and poses no danger to humans, animals or plants. Results

![](ex997-012.jpg)

Fraunhofer IGB 6 \| 7 Test solutions: For the test solutions A4 and B4, more than four log reduction could be determined after ten days, therefore surfaces that were sprayed with the test solution A4 or B4 can be designated as limited virucidal (disinfectants that only inactivate enveloped viruses). Summary Phi6 107 106 105 PFU 104 103 102 101 100 A4 B4 A4 control B4 control Figure 5: Proof of efficacy for the test organism Phi6 (10 days incubation period). Total number of CFU counted (Y-axis) for each test solution and controls (X-axis). 4 Summary In summary, a disinfecting effect on the SARS-CoV-2 surrogate virus Phi6 could be determined after ten days for an impregnated, metallic surface with test solution A4 or B4. The log reduction in PFU compared to the untreated control was more than six log levels and therefore met the required reduction for the designation "limited virucidal".

![](ex997-013.jpg)

Fraunhofer IGB 7 \| 7 Sources 5 Sources [1] RKI guide - Staphylococcal diseases, especially infections caused by MRSA [https://www.rki.de/DE/ Content/ Infekt/EpidBull/Merkblaetter/Ratgeber_Staphyl okokken_MRSA.html;jsessionid=5BD3D0C5405FC570A47E43E03DCB4A7C.in ternet092#doc2373986bodyText2] [2] [https://www.rki.de/DE/Content/Infekt/Antibiotikaresistenz/nosokomiale_Errege r/Pseudomonas.html] [3] https://flexikon.doccheck.com/de/Candida_albicans

![](ex997-014.jpg)

> ia 1' Lo"' >J , ... '"!'· · · ua Middle East Testing Services L.L.C. ?I I k TEST REPORT Report No: METS-R 13135/2022 Sample ID Sample Receiving Date Reporting Date Date of Analysis Tested by Issue No Sample Information: Sample Description Brand Production Date Expiry Date Batch No Country of Origin : METS-S22-13135 : 16/12/2022 : 09/02/2023 : 16/12/2022-03/02/2023 :AV : 01 (Re-Issue Date: NG) : Medusa-Surface Disinfectant : Medusa : 28/04/2022 : 04/09/2024 : SL280422A :UK Details of present study and findings Objective: To study the anti-viral activity of submittedsampleinaccordance with BS EN 14476:2019. Conclusion:On the basis of the resultsit can be concludedthat the test specimen has Virucidal activity 4.31 log reduction against Influenza Virus (VR-1469) (Refer Page No. 2 and 3 for more details) Prepared by Mier Biological ScienceDivision(BSD) EmployeeCode: METS AJ EC 229 Verified by Team Head' Biological Science Division (BSD) EmployeeCode: METS AJ EC 200 N z0 Q) ::, (/) .!!2 0 --=:t' LL 0::: E 0 LL Page 1 of 3 AJMAN.U.A.E. ABU DHABI.uA.E. DOHA. QATAR +911 s 744 5538 +9112 444 2353 +974 77525010 E-mail: lab@metslab.com ClientI Establishment : M/s. Medusa Sdp Holding (UnitedKingdom) Limited

![](ex997-015.jpg)

... "'!' J-:!- · ·'.) uo > ;. " Lo ;J ,Middle East Testing Services L.L.C.?AJ MAN . U. A.E I ABU DHABI.U.A.E.I DOHA. QATAR+ 974 77825070+911s 744 5538 E-mail: lab@ metslab .com + 9 71 2 44 4 2353 E Result of Virucidal Efficiency Testing: Report No.: METS-R 1313520/ 22 Date of Analysis: 16/12/2022-03/02/2023 Reference culture Influenza Virus (VR-1469)Clean condition 0.3 Q/L: Bovine SerumAlbuminProduct TestConcentration NeatIncubation temoerature 36°Clnterferinasubstance Albumin Bovine 0.3a/I (clean conditions)Neutralization method Dilution methodGrowth medium MEM 10% FCSMaintenance medium MEM 2% FCSTest Temperature 20°cActive substance AlcoholContacttime: 2 minutes N z0 -.:t" LL 0::: 0 LL Page 2 of 3 Test Contact Time Dilution (Log10) LogTCIDso/mL 1 2 3 4 5 6 7 8 Virus Control (No) 2 minuet s 4444 44444444444444444444444444444333433330003300000000000000 0000 5.81 Product 2 minutes tttt t t t t 0000000000000000000000000000000000000000000000000000 0000 1.50 Cytotoxic Effect - t t t t t t t t 0000000000000000000000000000000000000000000000000000 0000 1.50 Clean Condition Time of Exposure-2minutesTest Microorganism Test Method LogTCIDso/mL Control (Log No) LogTCIDso/mL Product (Log Na) Virucidal Activity (L ogRdn) Specification limit(BS EN 14476: 2019)Influenza Virus (VR-1469) BS EN 14476 5.81 1.50 4.31 ;::4

![](ex997-016.jpg)

AJMAN ? U.A.E. I ABU DHABI ? U.A.E.I DOHA. QATAR+9 74 11825010?+911 s7 4 4 5538 +9112 444 2353 E-mail: lab@ metsl ab. com '- ?P·P· uA > .i U L-4 > ;.J ,... ua1f J-.:! Middle East Testing Services L.L.C. Report No.: METS?R 13135/2022 Image of the tested sample The above test results are only applicable to the sample (s) referred above. This report shall not be reproduecd except in full,without the written approval of METS laboratory. For further clarification of reports, pleasecontactqc@metslab.com -End Report- N z0 a., ::, C) "

![](ex997-017.jpg)

?3[;e?$(· area. ? If contact with the eyes, rinse cautiously with water for several minutes. Remove contact lenses if ;: MEDUSA \* is a Surface Disinfectant Product (SOP) kills 99.999% of Bacteria and Enveloped Viruses including)>C.11 ;...i.v!) m 0 m e ::,:C Cll a -: SARS-CoV-2-like and Influenza viruses. MEDUSA? can be used in CD Homes @ Offices® Schools© Hotels® Restaurants® Bars0 Aircrafts® Public transport® Stadiums. Directions for use:0 Turn the red nozzle to the open position8 Lightly mist desired surface at a distance of 20 cm8 Wipe surface with a clean cloth noOO :::,-3 Q.- '° ro and allow MEDUSA to dry completely.0 After applying, use tap water to clean spillages and dirt.0 For OJ u, 3: 8 m 8 C ::::-. ro ='-m ? CD OJ Ul (") [ x ro 5. proven lasting use the MEDUSA! Test Kit to check surfaces every 3 to 5 days. Suitable for use on Tables; Seating; Door handles; Touchscreens; Toilet seats; Baths and Taps; Refrigerators; Changing mats; Highchairs; Desks; Windows; Mirrors; Fabrics; Bins; Food contact surfaces; Painted or Varnished surfaces. Storage: Keep out of reach of children. Store at room temperature, keep out of direct sunlight and away from food and drink. a, en CD Cl. C HU Keep only in the original container. Warnings and Precautions: Flammable liquid and vapour. Do not store or iwf 'i< (/) a.g ()a. ;;; ffiO @ use near heat, open flame, sparks, and other ignition sources. Use in a well-ventilated space. Avoid inhalation and eye contact. Causes skin and serious eye irritation. First Aid: ? lf inhaled, move person to a well-ventilated Oc &!!Gro -0 §: 0. present. If eye irritation persists, seek medical advice ? If swallowed , rinse mouth with water. Do not induce vomiting. Seek immediate medical advice/attention ? If skin contact, wash immediately with plenty of water and soap. If skin irritation or rash occurs, seek medical advice/attention. Ingredients include: Propan-2-ol, Didecyldimethylammonium Chloride, Benzalkonium Chloride, Polyquat DMNE and Water (Ultra clean). Manufactured in United Kingdom. </p

![](ex997-018.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? PRODUCT INFORMATION SHEET MEDUSA - Alcohol Based Surface Disinfectant Solution Version_1

![](ex997-019.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? 1 Description: MEDUSA offers top-tier disinfectant solutions tailored for diverse environments, including homes, offices, hospitality venues, general public spaces, and healthcare facilities. MEDUSA alcohol-based formula ensures powerful antimicrobial protection tailored to provide 99.99% results. The product is available in various pack sizes: 30ml, 100 ml, 500 ml, 750 ml, 1000 ml, as well as available to be supplied in bulk starts with 5 litre pack. Key Features: ? Bactericidal, Fungicidal, Virucidal ? Direct application on different surfaces ? Alcohol based formulation for quick killing of bacteria and viruses ? Advanced formula with optimum pH 5 to 7 ? European quality manufacturing ? Check presence of MEDUSA using MEDUSA strips ? Recyclable bottle and trigger Active Ingredients: Propane -2-ol (Propanol): Propanol is colourless, highly volatile, and flammable liquid. Propanol is rapidly effective against various pathogens. It is also well tolerated by humans when applied to the skin. Di-decyl di-methyl Ammonium Chloride: It is a fungicide, an antiseptic for wood and other surfaces and disinfectant for cleaning. 1. Benzalkonium Chloride: It is quaternary ammonium compound used in the pharmaceutical and chemical industry as an antimicrobial preservative, antiseptic, and disinfectant. 2. Polyquat DMA/E 50: The non-irritating ingredient enduring biocidal properties, and effectively removing both organic and inorganic residues. Physical Properties: Property/ Parameter DescriptionState Liquid Colour Colourless/ TransparentOdour Mild pH 5.00 ? 7.00 Shelf Life: The expiry date is 24 months. The shelf life was defined according to the stability and primary packaging (compatibility) test results and the knowledge and experience on the product and/or similar formulas.

![](ex997-020.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? 2 Quality Assurance: Every batch of MEDUSA undergoes rigorous testing to verify its effectiveness and safety, complying with the latest EU standards for biocidal products. Handling Instructions: Precautions for use: Safety data sheet available on request. Read label before use. Inflammable liquid, keep away from direct heat and sunlight. Keep out of reach and sight of children. If medical advice is needed, have the product container or the label handy. Wash hands thoroughly after handling. Do not swallow. Dispose of content/container according to national regulation. Use biocides safely and sustainably. It is illegal to use this product for uses or in a manner other than prescribed in this document. Do not apply soap application after spraying MEDUSA. For more information: For information, you can contact CS Interpharm General Trading Co LLC, +971 4 559 6268. Disinfection Performance: This product starts killing microorganism (Bacteria, Yeast, Fungi and Virus) in 5 minutes which last more than ten days. Bacteria: Test Method Test DurationTest Organism EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Staphylococcus aureus ATCC 6538 EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Escherichia coli ATCC 10536 EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Pseudomonas aeruginosa ATCC 15442 EN 1276: Bactericidal activity for food, industrial, domestic and institutional areas 5 Minutes Enterococcus hirae ATCC 10541 Fungi: Test Method Test DurationTest Organism EN 1650: Yeasticidal activity for food, industrial, domestic and institutional areas 5 Minutes Candida albicans

![](ex997-021.jpg)

CS INTERPHARM GENERAL TRADING CO. L.L.C.www.csinterpharm.ae Bay Square, B2, Office No. 809, Business Bay, P.O. Box 9354, Dubai, UAE Tel. No. +971 4 559 6268, Fax No. +971 4 513 6018 ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ??? ? ?? ?. ?. ? ? ? ? ? ? ?? ? ? ? ? ??? ? ?? ? ? ?? ? ? ?809 ? ? ? ? ?? ? ?2 ? ? ? ? ?? ? ? ? ?? ? ? ?? ? ?? ?? ? ? ? ? ??? ? ? ? ? ??045136018 : ? ??? 045596268 : ? ? ?? 3 Virus: (Proven Virucidal efficacy against SARS COV 2 Like virus even after 10 days of application) Test Method Test DurationTest Organism EN 14476: (Limited Virucidal, all enveloped viruses such as Coronavirus, HIV, Herpes virus, Hepatitis virus). 5 Minutes Phi 6, surrogate SARS-CoV-2 Storage: Temperature Conditions: Store the containers in a cool, dry place with a storage temperature not exceeding +30°C (86°F). Keep away from the direct heat. Shelf Life of strip: When stored correctly, MEDUSA test strips remain effective until the expiry date marked on the package. Keep MEDUSA test strips shielded from direct sunlight and moisture to preserve their integrity. Method of Use: Product usage: The product is an alcohol-based ready-to-use multipurpose spray for surface disinfection. The spray is intended for use by professionals in commercial areas (offices, retail, airports, bus stations, supermarkets, etc.), food service and industrial areas (manufacturing and transport/maintenance) as well as home and other hospitality venues. Instruction of use: Turn the nozzle to the ON position. Keeping the bottle upright, spray from 20?25 cm away. Leave for up to five minutes, wipe clean. For professional use you must wear gloves. For surfaces that come in contact with food: use only on hard non-porous surfaces and rinse thoroughly with water. Test Method to check working efficiency of MEDUSA even after days of application. Step 1: Activation of test strips by dipping strip into water and shake off excess water from the test strip. Step 2: Apply this strip to the MEDUSA treated area and wait for few minutes. Step 3: Observe the colour change on the strip to check the presence of MEDUSA.

![](ex997-022.jpg)

7/25/2024 (Issue date) GB - en1/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Issue date: 7/25/2024 Version: 1.0 Product form : Mixture Name : Medusa Alcohol-Based Product code : MED03B101 Type of product : Biocidal products (e.g. Disinfectants, pest control) 1.2. Relevant identified uses of the substance or mixture and uses advised against Relevant identified uses Intended for general public Main use category : Consumer use,Professional use,Industrial use Use of the substance/mixture : Bactericide Disinfectant 1.3. Details of the supplier of the safety data sheet Supplier CS INTERPHARM GENERAL TRADING CO., LLC Bay Square, BB2, Office no. 809-816 Buisness Bay Dubai United Arab Emirates T +971 4 559 6268 info@csinterpharm.ae, www.csinterpharm.ae 1.4. Emergency telephone number Emergency number : +971528611930 (Office Hours) Country/Area Organisation/Company Address Emergency number Comment United Kingdom National Poisons Information Service (Birmingham Centre) City Hospital Dudley Road B18 7QH 0344 892 0111 Classification according to Regulation (EC) No. 1272/2008 [CLP] Flammable liquids, Category 3 H226 Serious eye damage/eye irritation, Category 2 H319 Specific target organ toxicity ? Single exposure, Category 3, Narcosis Hazardous to the aquatic environment ? Chronic Hazard, Category 3 Full text of H and EUH statements: see section 16 H336 H412 Adverse physicochemical, human health and environmental effects Flammable liquid and vapour. May cause drowsiness or dizziness. Causes serious eye irritation. Harmful to aquatic life with long lasting effects. SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier SECTION 2: Hazards identification 2.1. Classification of the substance or mixture

![](ex997-023.jpg)

7/25/2024 (Issue date) GB - en2/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 2.2. Label elements Labelling according to Regulation (EC) No. 1272/2008 [CLP] Hazard pictograms (CLP) : GHS02 GHS07 Signal word (CLP) : Warning Contains : propan-2-ol; isopropyl alcohol; isopropanol Hazard statements (CLP) : H226 - Flammable liquid and vapour. H319 - Causes serious eye irritation. H336 - May cause drowsiness or dizziness. H412 - Harmful to aquatic life with long lasting effects. Precautionary statements (CLP) : P102 - Keep out of reach of children. P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P261 - Avoid breathing fume, vapours. P280 - Wear protective clothing, eye protection, face protection. P303+P361+P353 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water . P304+P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation. 2.3. Other hazards Contains no PBT/vPvB substances ? 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 SECTION 3: Composition/information on ingredients 3.2. Mixtures Name Product identifier Conc. (% w/w) Classification according to Regulation (EC) No. 1272/2008 [CLP] propan-2-ol; isopropyl alcohol; isopropanol CAS-No.: 67-63-0 30 ? 50 Flam. Liq. 2, H225 EC-No.: 200-661-7 Eye Irrit. 2, H319 EC Index-No.: 603-117-00-0 STOT SE 3, H336 REACH-no: 01-2119457558- 25 BENZALKONIUM CHLORIDE CAS-No.: 68424-85-1 < 1 Acute Tox. 4 (Oral), H302 EC-No.: 270-325-2 Skin Corr. 1B, H314 REACH-no: 01-2119965180- Eye Dam. 1, H318 41 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 1, H410 didecyldimethylammonium chloride CAS-No.: 7173-51-5 < 1 Acute Tox. 4 (Oral), H302 EC-No.: 230-525-2 Acute Tox. 4 (Dermal), H312 EC Index-No.: 612-131-00-6 Skin Corr. 1B, H314 REACH-no: 01-2119945987- Aquatic Acute 1, H400 (M=10) 15 Aquatic Chronic 2, H411

![](ex997-024.jpg)

7/25/2024 (Issue date) GB - en3/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Name Product identifier Conc. (% w/w) Classification according to Regulation (EC) No. 1272/2008 [CLP] Methanamine, N-Methyl-, polymer with 2- (chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy- 1,3-propanoldiylchloride CAS-No.: 25988-97-0 < 1 Acute Tox. 4 (Oral), H302 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 1, H410 Full text of H and EUH statements: see section 16 First-aid measures general : If you feel unwell, seek medical advice. First-aid measures after inhalation : Remove person to fresh air and keep comfortable for breathing. First-aid measures after skin contact : Rinse skin with water/shower. Take off immediately all contaminated clothing. First-aid measures after eye contact : Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. First-aid measures after ingestion : Get medical advice/attention if you feel unwell. 4.2. Most important symptoms and effects, both acute and delayed Symptoms/effects : May cause drowsiness or dizziness. Symptoms/effects after inhalation : May cause shortness of breath, tightness of the chest, a sore throat and cough. Symptoms/effects after skin contact : None under normal conditions. Symptoms/effects after eye contact : Eye irritation. Symptoms/effects after ingestion : None under normal conditions. 4.3. Indication of any immediate medical attention and special treatment needed Treat symptomatically. Suitable extinguishing media : Water spray. Dry powder. Foam. Carbon dioxide. Unsuitable extinguishing media : Do not use a heavy water stream. 5.2. Special hazards arising from the substance or mixture Fire hazard : Flammable liquid and vapour. Explosion hazard : No direct explosion hazard. Hazardous decomposition products in case of fire : Toxic fumes may be released. 5.3. Advice for firefighters Firefighting instructions : Fight fire from safe distance and protected location. Do not enter fire area without proper protective equipment, including respiratory protection. Protection during firefighting : Do not attempt to take action without suitable protective equipment. Self-contained breathing apparatus. Complete protective clothing. General measures : Stop leak if safe to do so. Notify authorities if product enters sewers or public waters. Absorb spillage to prevent material damage. For non-emergency personnel Protective equipment : Wear recommended personal protective equipment. SECTION 4: First aid measures 4.1. Description of first aid measures SECTION 5: Firefighting measures 5.1. Extinguishing media SECTION 6: Accidental release measures 6.1. Personal precautions, protective equipment and emergency procedures

![](ex997-025.jpg)

7/25/2024 (Issue date) GB - en4/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Emergency procedures : Ventilate spillage area. No open flames, no sparks, and no smoking. Avoid breathing fume, vapours. Avoid contact with skin and eyes. For emergency responders Protective equipment : Do not attempt to take action without suitable protective equipment. For further information refer to section 8: "Exposure controls/personal protection". Emergency procedures : Evacuate unnecessary personnel. Stop leak if safe to do so. 6.2. Environmental precautions Avoid release to the environment. 6.3. Methods and material for containment and cleaning up For containment : Absorb spilled material with sand or earth. Contain any spills with dikes or absorbents to prevent migration and entry into sewers or streams. Stop leak without risks if possible. Methods for cleaning up : Take up liquid spill into absorbent material. Notify authorities if product enters sewers or public waters. Other information : Dispose of materials or solid residues at an authorized site. 6.4. Reference to other sections For further information refer to section 13. Additional hazards when processed : Not expected to present a significant hazard under anticipated conditions of normal use. Precautions for safe handling : Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Ground/bond container and receiving equipment. Use only non-sparking tools. Take precautionary measures against static discharge. Flammable vapours may accumulate in the container. Use explosion-proof equipment. Wear personal protective equipment. Use only outdoors or in a well-ventilated area. Avoid breathing fume, spray. Avoid contact with skin and eyes. Hygiene measures : Do not eat, drink or smoke when using this product. Always wash hands after handling the product. 7.2. Conditions for safe storage, including any incompatibilities Technical measures : Ground/bond container and receiving equipment. Storage conditions : Store in a well-ventilated place. Keep cool. Keep container tightly closed. Store locked up. Storage area : Store away from heat. Special rules on packaging : Keep only in original container. Packaging materials : Store always product in container of same material as original container. 7.3. Specific end use(s) No additional information available National occupational exposure and biological limit values propan-2-ol; isopropyl alcohol; isopropanol (67-63-0) United Kingdom - Occupational Exposure Limits Local name Propan-2-ol WEL TWA (OEL TWA) 999 mg/m³ 400 ppm SECTION 7: Handling and storage 7.1. Precautions for safe handling SECTION 8: Exposure controls/personal protection 8.1. Control parameters

![](ex997-026.jpg)

7/25/2024 (Issue date) GB - en5/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 propan-2-ol; isopropyl alcohol; isopropanol (67-63-0) WEL STEL (OEL STEL) 1250 mg/m³ 500 ppm Regulatory reference EH40/2005 (Fourth edition, 2020). HSE 8.2. Exposure controls Appropriate engineering controls Appropriate engineering controls: Ensure good ventilation of the work station. Personal protection equipment Personal protective equipment: Wear recommended personal protective equipment. Personal protective equipment symbol(s): Eye and face protection Eye protection: Safety glasses Skin protection Skin and body protection: Wear suitable protective clothing Hand protection: Protective gloves Respiratory protection Respiratory protection: In case of insufficient ventilation, wear suitable respiratory equipment Environmental exposure controls Environmental exposure controls: Avoid release to the environment. SECTION 9: Physical and chemical properties 9.1. Information on basic physical and chemical properties Physical state : Liquid Colour : Colourless. Odour : Alcoholic. Odour threshold : Not available Melting point : Not applicable Freezing point : < 0 °C Boiling point : Not available Flammability : Flammable liquid and vapour. Lower explosion limit : Not available Upper explosion limit : Not available Flash point : 25 °C Auto-ignition temperature : Not available Decomposition temperature : Not available pH : 5.5 ? 7.5 PH solution concentration : 100 % Viscosity, kinematic : Not available Solubility : Soluble in water.

![](ex997-027.jpg)

7/25/2024 (Issue date) GB - en6/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Partition coefficient n-octanol/water (Log Kow) : Not available Vapour pressure : Not available Vapour pressure at 50 °C : Not available Density : Not available Relative density : 0.9 ? 1 Relative vapour density at 20 °C : Not available Particle characteristics : Not applicable 9.2. Other information No additional information available Flammable liquid and vapour. 10.2. Chemical stability Stable under normal conditions. 10.3. Possibility of hazardous reactions No dangerous reactions known under normal conditions of use. 10.4. Conditions to avoid Avoid contact with hot surfaces. Heat. No flames, no sparks. Eliminate all sources of ignition. 10.5. Incompatible materials Oxidizing agent. Strong acids. 10.6. Hazardous decomposition products Under normal conditions of storage and use, hazardous decomposition products should not be produced. Acute toxicity (oral) : Not classified Acute toxicity (dermal) : Not classified Acute toxicity (inhalation) : Not classified propan-2-ol; isopropyl alcohol; isopropanol (67-63-0) LD50 oral rat 5840 mg/kg bodyweight Animal: rat, Guideline: OECD Guideline 401 (Acute Oral Toxicity) didecyldimethylammonium chloride (7173-51-5) LD50 oral rat 329 mg/kg bodyweight Animal: rat, Guideline: OECD Guideline 401 (Acute Oral Toxicity) LD50 dermal rat > 1000 mg/kg bodyweight Animal: rat, Guideline: OECD Guideline 402 (Acute Dermal Toxicity), Guideline: EU Method B.3 (Acute Toxicity (Dermal)) Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) LD50 oral rat 1672 mg/kg OECD 401 LD50 dermal rat > 2000 mg/kg OECD 402 Skin corrosion/irritation : Not classified pH: 5.5 ? 7.5 Serious eye damage/irritation : Causes serious eye irritation. pH: 5.5 ? 7.5 SECTION 10: Stability and reactivity 10.1. Reactivity SECTION 11: Toxicological information 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

![](ex997-028.jpg)

7/25/2024 (Issue date) GB - en7/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Respiratory or skin sensitisation : Not classified Germ cell mutagenicity : Not classified Carcinogenicity : Not classified Reproductive toxicity : Not classified STOT-single exposure : May cause drowsiness or dizziness. propan-2-ol; isopropyl alcohol; isopropanol (67-63-0) STOT-single exposure May cause drowsiness or dizziness. STOT-repeated exposure : Not classified Aspiration hazard : Not classified didecyldimethylammonium chloride (7173-51-5) Viscosity, kinematic 24.5 mm²/s Temp.: '20°C' Parameter: 'kinematic viscosity (in mm²/s)' 11.2. Information on other hazards No additional information available SECTION 12: Ecological information 12.1. Toxicity Ecology - general : Harmful to aquatic life with long lasting effects. Hazardous to the aquatic environment, short-term (acute) Hazardous to the aquatic environment, long-term (chronic) : Not classified : Harmful to aquatic life with long lasting effects. propan-2-ol; isopropyl alcohol; isopropanol (67-63-0) LC50 - Fish [1] 10000 mg/l Test organisms (species): Pimephales promelas LC50 - Fish [2] 9640 mg/l Test organisms (species): Pimephales promelas BENZALKONIUM CHLORIDE (68424-85-1) LC50 - Fish [1] 0.85 mg/l Rainbow trout EC50 - Crustacea [1] 0.016 mg/l EC50 72h - Algae [1] 0.02 mg/l Selenastrum capricornutum didecyldimethylammonium chloride (7173-51-5) LC50 - Fish [1] 0.19 mg/l Pimephales promelas (fathead minnow) EC50 - Crustacea [1] 0.062 mg/l Daphnia magna (Water flea) EC50 96h - Algae [1] 0.026 mg/l Pseudokirchneriella subcapitata (green algae) LOEC (chronic) 0.047 mg/l Test organisms (species): Daphnia magna Duration: '21 d' NOEC (chronic) 0.021 mg/l Test organisms (species): Daphnia magna Duration: '21 d' NOEC chronic fish 0.032 mg/l Danio rerio (zebra fish) NOEC chronic crustacea 0.014 mg/l Daphnia magna (Water flea) Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) LC50 - Fish [1] 0.077 mg/l oncornhynchus mykiss (rainbow trout) OECD 203 EC50 - Crustacea [1] 0.08 mg/l daphina magna (big water flea)OECD 202 ErC50 algae 0.13 mg/l scenedesmus subspicatus OECD 201 NOEC chronic fish 0.024 mg/l oncornhynchus mykiss (rainbow trout)

![](ex997-029.jpg)

7/25/2024 (Issue date) GB - en8/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) NOEC chronic crustacea 0.026 mg/l daphina magna (big water flea) 12.2. Persistence and degradability Medusa Alcohol-Based Persistence and degradability Not rapidly degradable propan-2-ol; isopropyl alcohol; isopropanol (67-63-0) Persistence and degradability Not rapidly degradable BENZALKONIUM CHLORIDE (68424-85-1) Persistence and degradability Not rapidly degradable didecyldimethylammonium chloride (7173-51-5) Persistence and degradability Not rapidly degradable Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) Persistence and degradability Not rapidly degradable Biodegradation > 80 % 12.3. Bioaccumulative potential Methanamine, N-Methyl-, polymer with 2-(chloromethyl)oxirane, Poly(dimethylimino)-2-hydroxy-1,3-propanoldiylchloride (25988-97-0) Partition coefficient n-octanol/water (Log Pow) < 1 12.4. Mobility in soil No additional information available 12.5. Results of PBT and vPvB assessment No additional information available 12.6. Endocrine disrupting properties No additional information available 12.7. Other adverse effects No additional information available SECTION 13: Disposal considerations 13.1. Waste treatment methods Regional legislation (waste) : Disposal must be done according to official regulations. Waste treatment methods : Dispose of contents/container in accordance with licensed collector's sorting instructions. Sewage disposal recommendations : Disposal must be done according to official regulations. Product/Packaging disposal recommendations : Disposal must be done according to official regulations. Additional information : Flammable vapours may accumulate in the container. Do not re-use empty containers.

![](ex997-030.jpg)

7/25/2024 (Issue date) GB - en9/13 Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 HP Code : HP3 - "Flammable:" ? flammable liquid waste: liquid waste having a flash point below 60 °C or waste gas oil, diesel and light heating oils having a flash point > 55 °C and ? 75 °C; ? flammable pyrophoric liquid and solid waste: solid or liquid waste which, even in small quantities, is liable to ignite within five minutes after coming into contact with air; ? flammable solid waste: solid waste which is readily combustible or may cause or contribute to fire through friction; ? flammable gaseous waste: gaseous waste which is flammable in air at 20 °C and a standard pressure of 101.3 kPa; ? water reactive waste: waste which, in contact with water, emits flammable gases in dangerous quantities; ? other flammable waste: flammable aerosols, flammable self-heating waste, flammable organic peroxides and flammable self-reactive waste. HP4 - "Irritant ? skin irritation and eye damage:" waste which on application can cause skin irritation or damage to the eye. HP14 - "Ecotoxic:" waste which presents or may present immediate or delayed risks for one or more sectors of the environment SECTION 14: Transport information In accordance with ADR / IMDG / IATA / ADN / RID ADR IMDG IATA ADN RID 14.1. UN number or ID number UN 1993 UN 1993 UN 1993 UN 1993 UN 1993 14.2. UN proper shipping name FLAMMABLE LIQUID, FLAMMABLE LIQUID, Flammable liquid, n.o.s. FLAMMABLE LIQUID, FLAMMABLE LIQUID, N.O.S. (CONTAINS : N.O.S. (CONTAINS : (CONTAINS : propan-2-ol; N.O.S. (CONTAINS : N.O.S. (CONTAINS : propan-2-ol; isopropyl propan-2-ol; isopropyl isopropyl alcohol; propan-2-ol; isopropyl propan-2-ol; isopropyl alcohol; isopropanol) alcohol; isopropanol) isopropanol) alcohol; isopropanol) alcohol; isopropanol) Transport document description UN 1993 FLAMMABLE UN 1993 FLAMMABLE UN 1993 Flammable liquid,UN 1993 FLAMMABLE UN 1993 FLAMMABLE LIQUID, N.O.S. LIQUID, N.O.S. n.o.s. (CONTAINS : LIQUID, N.O.S. LIQUID, N.O.S. (CONTAINS : propan-2-ol; (CONTAINS : propan-2-ol; propan-2-ol; isopropyl (CONTAINS : propan-2-ol; (CONTAINS : propan-2-ol; isopropyl alcohol; isopropyl alcohol; alcohol; isopropanol), 3, III isopropyl alcohol; isopropyl alcohol; isopropanol), 3, III, (D/E) isopropanol), 3, III isopropanol), 3, III isopropanol), 3, III 14.3. Transport hazard class(es) 3 3 3 3 3 14.4. Packing group III III III III III 14.5. Environmental hazards Dangerous for the Dangerous for the Dangerous for the Dangerous for the Dangerous for the environment: No environment: No environment: No environment: No environment: No Marine pollutant: No EmS-No. (Fire): F-E EmS-No. (Spillage): S-E No supplementary information available

![](ex997-031.jpg)

7/25/2024 (Issue date) GB - en10/13Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 14.6. Special precautions for user Overland transport Classification code (ADR) : F1 Special provisions (ADR) : 274, 601 Limited quantities (ADR) : 5l Excepted quantities (ADR) : E1 Packing instructions (ADR) : P001, IBC03, LP01, R001 Mixed packing provisions (ADR) : MP19 Portable tank and bulk container instructions (ADR) : T4 Portable tank and bulk container special provisions (ADR) : TP1, TP29 Tank code (ADR) : LGBF Vehicle for tank carriage : FL Transport category (ADR) : 3 Special provisions for carriage - Packages (ADR) : V12 Special provisions for carriage - Operation (ADR) : S2 Hazard identification number (Kemler No.) : 30 Orange plates : Tunnel restriction code (ADR) : D/E EAC code : ?3YE Transport by sea Special provisions (IMDG) : 223, 274, 955 Limited quantities (IMDG) : 5 L Excepted quantities (IMDG) : E1 Packing instructions (IMDG) : LP01, P001 IBC packing instructions (IMDG) : IBC03 Tank instructions (IMDG) : T4 Tank special provisions (IMDG) : TP1, TP29 Stowage category (IMDG) : A Air transport PCA Excepted quantities (IATA) : E1 PCA Limited quantities (IATA) : Y344 PCA limited quantity max net quantity (IATA) : 10L PCA packing instructions (IATA) : 355 PCA max net quantity (IATA) : 60L CAO packing instructions (IATA) : 366 CAO max net quantity (IATA) : 220L Special provisions (IATA) : A3 ERG code (IATA) : 3L Inland waterway transport Classification code (ADN) : F1 Special provisions (ADN) : 274, 601 Limited quantities (ADN) : 5 L Excepted quantities (ADN) : E1 Carriage permitted (ADN) : T Equipment required (ADN) : PP, EX, A Ventilation (ADN) : VE01 Number of blue cones/lights (ADN) : 0 Rail transport Classification code (RID) : F1 Special provisions (RID) : 274, 601 Limited quantities (RID) : 5L Excepted quantities (RID) : E1 Packing instructions (RID) : P001, IBC03, LP01, R001

![](ex997-032.jpg)

7/25/2024 (Issue date) GB - en11/13Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Mixed packing provisions (RID) : MP19 Portable tank and bulk container instructions (RID) : T4 Portable tank and bulk container special provisions (RID) : TP1, TP29 Tank codes for RID tanks (RID) : LGBF Transport category (RID) : 3 Special provisions for carriage ? Packages (RID) : W12 Colis express (express parcels) (RID) : CE4 Hazard identification number (RID) : 30 14.7. Maritime transport in bulk according to IMO instruments Not applicable SECTION 15: Regulatory information 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture EU-Regulations REACH Annex XVII (Restriction List) Contains no REACH substances with Annex XVII restrictions REACH Annex XIV (Authorisation List) Contains no REACH Annex XIV substances REACH Candidate List (SVHC) Contains no substance on the REACH candidate list PIC Regulation (Prior Informed Consent) Substances subject to Regulation (EU) No 649/2012 of the European Parliament and of the Council of 4 july 2012 concerning the export and import of hazardous chemicals: Didecyldimethylammonium chloride (7173-51-5) POP Regulation (Persistent Organic Pollutants) Contains no substance subject to Regulation (EU) No 2019/1021 of the European Parliament and of the Council of 20 June 2019 on persistent organic pollutants Ozone Regulation (1005/2009) Contains no substance subject to REGULATION (EU) No 1005/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 September 2009 on substances that deplete the ozone layer. Dual-Use Regulation (428/2009) Contains no substance subject to the COUNCIL REGULATION (EC) No 428/2009 of 5 May 2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items. Explosives Precursors Regulation (2019/1148) Contains no substance subject to Regulation (EU) 2019/1148 of the European Parliament and of the Council of 20 June 2019 on the marketing and use of explosives precursors. Drug Precursors Regulation (273/2004) Contains no substance subject to Regulation (EC) 273/2004 of the European Parliament and of the Council of 11 February 2004 on the manufacture and the placing on market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances. 15.2. Chemical safety assessment No chemical safety assessment has been carried out SECTION 16: Other information Abbreviations and acronyms: ADN European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways ADR European Agreement concerning the International Carriage of Dangerous Goods by Road

![](ex997-033.jpg)

7/25/2024 (Issue date) GB - en12/13Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Abbreviations and acronyms: ATE Acute Toxicity Estimate BCF Bioconcentration factor BLV Biological limit value BOD Biochemical oxygen demand (BOD) COD Chemical oxygen demand (COD) DMEL Derived Minimal Effect level DNEL Derived-No Effect Level EC-No. European Community number EC50 Median effective concentration EN European Standard IARC International Agency for Research on Cancer IATA International Air Transport Association IMDG International Maritime Dangerous Goods LC50 Median lethal concentration LD50 Median lethal dose LOAEL Lowest Observed Adverse Effect Level NOAEC No-Observed Adverse Effect Concentration NOAEL No-Observed Adverse Effect Level NOEC No-Observed Effect Concentration OECD Organisation for Economic Co-operation and Development OEL Occupational Exposure Limit PBT Persistent Bioaccumulative Toxic PNEC Predicted No-Effect Concentration RID Regulations concerning the International Carriage of Dangerous Goods by Rail SDS Safety Data Sheet STP Sewage treatment plant ThOD Theoretical oxygen demand (ThOD) TLM Median Tolerance Limit VOC Volatile Organic Compounds CAS-No. Chemical Abstract Service number N.O.S. Not Otherwise Specified vPvB Very Persistent and Very Bioaccumulative ED Endocrine disruptor Full text of H- and EUH-statements: Acute Tox. 4 (Dermal) Acute toxicity (dermal), Category 4 Acute Tox. 4 (Oral) Acute toxicity (oral), Category 4 Aquatic Acute 1 Hazardous to the aquatic environment ? Acute Hazard, Category 1 Aquatic Chronic 1 Hazardous to the aquatic environment ? Chronic Hazard, Category 1

![](ex997-034.jpg)

7/25/2024 (Issue date) GB - en13/13Medusa Alcohol-Based Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Full text of H- and EUH-statements: Aquatic Chronic 2 Hazardous to the aquatic environment ? Chronic Hazard, Category 2 Eye Dam. 1 Serious eye damage/eye irritation, Category 1 Eye Irrit. 2 Serious eye damage/eye irritation, Category 2 Flam. Liq. 2 Flammable liquids, Category 2 H225 Highly flammable liquid and vapour. H226 Flammable liquid and vapour. H302 Harmful if swallowed. H312 Harmful in contact with skin. H314 Causes severe skin burns and eye damage. H318 Causes serious eye damage. H319 Causes serious eye irritation. H336 May cause drowsiness or dizziness. H400 Very toxic to aquatic life. H410 Very toxic to aquatic life with long lasting effects. H411 Toxic to aquatic life with long lasting effects. H412 Harmful to aquatic life with long lasting effects. Skin Corr. 1B Skin corrosion/irritation, Category 1, Sub-Category 1B STOT SE 3 Specific target organ toxicity ? Single exposure, Category 3, Narcosis Safety Data Sheet (SDS), EU This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

![](ex997-035.jpg)

. Our Vision: Creating an excellent city that provides the essence of success and comfort of sustainable living. +97142246666: u.iS , +97142215555: ? , 67 . P.O.Box: 67 DUBAI, UAE, Tel.: +971 4 221 5555, Fax.: +971 4 224 6666E-mail: info@dm.gov.ae Website: www.dm.gov.ae Public Health & Safety Department Consumer Products Safety Section Consumer Products Registration Certificate Biocides Reference Number: CPRE-2023-026266 : >Registration Status: Approved : Registration Date: 18/05/2023 : Category: Disinfectant Sanitizers : Brand Name: MEDUSA : Company Name: HEXAMET GENERAL TRADING L.L.C : >..! Country of Origin: United Kingdom : L..! J..4 Product Details Product Name MEDUSA - Surface Disinfectant Important Notes Registration Certificate is valid for 5 years from date of issue & any alteration or deletion in any way will invalid it. Registration Certificate is granted upon company's request and the above listed product is freely distributed in the local market & Dubai Municipality will not be responsible for any consequences of variations in the product. Registration Certificate is issued upon the currently enforced regulations and subjected for modification according to the requirements of concerned department. All the imported & marketed products will be subjected to inspection and conformity with the currently enforced regulations This certificate has been electronically generated and approved by Dubai Municipality and does not need signature or Stamp . Consumer Products Safty Section 5 . .'. " ?

![](ex997-036.jpg)

. Our Vision: Creating an excellent city that provides the essence of success and comfort of sustainable living. +97142246666: u.iS , +97142215555: ? , 67 . P.O.Box: 67 DUBAI, UAE, Tel.: +971 4 221 5555, Fax.: +971 4 224 6666E-mail: info@dm.gov.ae Website: www.dm.gov.ae Variants Information MEDUSA - Surface Disinfectant International Barcode: 5065014477007 Scent / Flavor: NONE Product Color / Shade: NONE Size / Weight / Volume: 500 mL

![](ex997-037.jpg)

Produktdatenblatt Datenblatt: Meldung eines Biozid-Produktes nach ChemBiozidMeldeV Unter Zugrundelegung der von Ihnen gemachten Angaben wurde Ihnen eine mit "N" beginnende Registriernummer zugewiesen. Alle in dem Biozid-Produkt "MEDUSA Alcohol- based " enthaltenen Wirkstoffe sind für die gewählte/n Produktart/en in Anhang II der Delegierten Verordnung (EU) Nr. 1062/2014 gelistet. Ohne vorherige Zulassung darf dieses Biozid-Produkt gemäß § 28 Absatz 8 des Chemikaliengesetzes, sofern die weiteren Voraussetzungen ebenfalls erfüllt sind, bis zur Entscheidung der Genehmigung des/ der Wirkstoff/e auf dem Markt bereitgestellt werden, längstens jedoch bis zum 31. Dezember 2024. GEMELDETES BIOZID-PRODUKT 2 Wirksto?e (Anhang II) Wirkstoffname Propan-2-ol CAS-Nr.67-63-0 Handelsname (Trad e name) MEDUSA Alcohol-based RegistriernummerN- 114740 Meldedatum24.09.20 4 Letztes Bestätigung sdatum 24.09.2024 Bestätigung der zu- geschriebenen Wirk ung Im Rahmen der Meldung wurde die zugeschriebene Wirkung desBiozid-Produkts bestätigt. Bitte beachten Sie, dass weder Wirksamkeit noch Unbedenklichkeit von Biozid-Produkten unter den Übergangsregelungen behördlich geprüft sind. Hinweis Das Biozidprodukt kann für die Dauer des Genehmigungsverfa hrens des Wirkstoffs bzw. des letzten zu genehmigenden Wirks toffs ohne Zulassung auf dem Markt bereitgestellt werden. Aktiv

![](ex997-038.jpg)

EC-Nr.200-661-7 PT2 ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 33.12 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Propan-2-ol - Shell Chemicals Europe B.V. Hinweis Phase-out Datum Aktiv Wirkstoffname Polymer aus N-Methylmethanamin (Einecs 204-697-4) mit (C hlormethyl)oxiran (Einecs 203-439-8)/Polymeres quaternäres Ammoniumchlorid (PQ Polymer) CAS-Nr.25988-97-0 EC-Nr. PT2 ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 0.5 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Polymer of N-Methylmethanamine (EINECS 204-697-4 wit h (chloromethyl)oxirane (EINECS 203-439-8) / Polymeric q uaternary ammonium chloride (PQ Polymer) - Innovative W ater Care Europe SAS Hinweis Phase-out Datum Aktiv

![](ex997-039.jpg)

Wirkstoffname Didecyldimethylammoniumchlorid (DDAC) CAS-Nr.7173-51-5 EC-Nr.230-525-2 PT2 ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 0.5 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Didecyldimethylammonium chloride (DDAC) - THOR ESPE CIALIDADES, S.A. Hinweis Phase-out Datum Aktiv Wirkstoffname Alkyl(C12-16)dimethylbenzylammoniumchlorid (ADBAC/BK C (C12-16)) CAS-Nr.68424-85-1 EC-Nr.270-325-2 PT2 ProduktartDesinfektionsmittel und Algenbekämpfungsmittel, die nicht für ei- ne direkte Anwendung bei Menschen und Tieren bestimmt sind WirkstoffartNormal Wirkstoffkonzentrat ion: 0.5 Einheit der Wirkstof fkonzentration: % Artikel95-Quellen ? Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBA C/BKC (C12-16)) - Thor GmbH (Acting for Thor Specialities (UK) Ltd) Hinweis

![](ex997-040.jpg)

Phase-out Datum Aktiv ANGABEN ZUM INVERKEHRBRINGER/HERSTELLER/IMPORTEUR Firmenname CS Diagnostics Pharma GmbH Anschrift83052 Bruck mühl, Müller-zu-Bruck-Str. 12 LandDeutschland BundeslandBayern E-Mail Adresseheidi.becker@the-force.org AnsprechpartnerHerrThomas Migotsch Telefon+49 8062 728 0880 Telefax Hinweis Änderungshistorie Datum Änderung 25.09.2024 10:08:14 Produktname: Der Name wurde von Medusa MP 001-ALC in MEDUSA Alc ohol-based geändert.